



ESCMID Global

European Congress of Clinical Microbiology & Infectious Diseases

Preliminary Programme

Vienna, Austria

11-15 April 2025



<http://www.escmid.org/congress-events/escmid-global>

ESCMID Global 2025 - Programme

Friday, 11 April 2025

4478 08:30 - 10:30 Hall 9

08:30 - 10:30

Hall 9

2-hour Educational Session

PHEI PRO

Vaccine hesitancy: from issues to solutions through developing communication skills

Chairs Monia Chemais (Soignies, Belgium)
Petar Velikov (Sofia, Bulgaria)

4478-1 08:30 Vaccine hesitancy and its consequences Noni Macdonald (Halifax, Canada)

4478-2 08:50 Why are patients and parents hesitant about vaccination? Eve Dube (Quebec City, Canada)

4478-3 09:10 Using social media to deal with vaccine hesitancy Muge Cevik (St Andrews, United Kingdom)

4478-4 09:30 Strengthening vaccine confidence in patients and parents Tba

Co-organised with: ESCMID Vaccine Study Group (EVASG)

4773 08:30 - 10:30 Hall 0

08:30 - 10:30

Hall 0

Special Session

CLN

Antimicrobial Stewardship in Different Scenarios

Chairs Murat Akova (Ankara, Türkiye)
Andre Fuchs (Augsburg, Germany)
Maddalena Giannella (Bologna, Italy)
Angela Huttner (Geneva, Switzerland)
Benedikt Huttner (Geneva, Switzerland)
Jose Ramon Pano-Pardo (Zaragoza, Spain)
Galadriel Pellejero (Zaragoza, Spain)
Holger Rohde (Hamburg, Germany)
Oana Sandulescu (Bucharest, Romania)
Jeroen Schouten (Nijmegen, Netherlands)
Valentijn Schweitzer (Utrecht, Netherlands)
Thomas Tängdén (Uppsala, Sweden)
Suzanne Van Asten (Nijmegen, Netherlands)
Dafna Yahav (Ramat-Gan, Israel)

Co-organised with: ESCMID Education Subcommittee

4723 08:30 - 10:30 Hall 2

08:30 - 10:30

Hall 2

2-hour Educational Session

CLN DX IPC

A hard nut to crack in HIV

Chairs Yoav Keynan (Winnipeg, Canada)
Justyna Kowalska (Warsaw, Poland)

4723-1 08:30 Viral reservoir: what a physician should know Ivailo Alexiev (Sofia, Bulgaria)

4723-2 08:50 Non-suppressible viraemia during HIV-1 therapy: a challenge for clinicians Jose Arribas (Madrid, Spain)

4723-3 09:10 Chronic vascular and pulmonary disease and HIV: what can we do about it? Susanne Dam Poulsen (Copenhagen, Denmark)

4723-4 09:30 Opportunistic infections: most common and most deadly Milena Stevanovikj (Sopje, North Macedonia, Republic of)

Co-organised with: Euroguidelines in Central and Eastern Europe Network Group

4709 08:30 - 10:30 Hall 3

08:30 - 10:30

Hall 3

2-hour Educational Session

DX

Challenges in identification and relevance of slow-growing pathogens

Chairs Kerrie Davies (Leeds, United Kingdom)
Yann Dumont (Vandoeuvre Les Nancy, France)

4709-1 08:30 Sampling and culturing anaerobes Hugo Cruz (Porto, Portugal)

4709-2 08:50 I have an anaerobe: what is it and does it matter? Kathleen Boiten (Groningen, Netherlands)

4709-3 09:10 Actinomyces in clinical samples: when is it worth the trouble? Eija Inkeri Könönen (Turku, Finland)

4709-4 09:30 Nocardiosis: when to test and how to manage results? David Lebeaux (Paris, France)

Co-organised with: ESCMID Study Group for Anaerobic Infections (ESGAI), ESCMID Study Group for Clostridioides difficile (ESGCD)

4488 08:30 - 10:30 Hall 4

08:30 - 10:30

Hall 4

2-hour Educational Session

CLN IPC

Surgical site infections: principles and practice in the era of multidrug resistance

Chairs Gabriel Birgand (Nantes, France)
Efthymia Giannitsioti (Athens, Greece)

4488-1 08:30 Evolving antimicrobial resistance: do we need a change in surgical antimicrobial prophylaxis? Camilla Rodrigues (Mumbai, India)

4488-2 08:50 Role of decolonisation and bowel decontamination in regions of overwhelming multidrug resistance Prasannakumar Palanikumar (Vellore, India)

4488-3 09:10 Screening for MDR GNR colonisation: is there evidence for prophylaxis Elisabeth Presterl (Vienna, Austria)

4488-4 09:30 Perioperative prophylaxis in special populations in the era of MDR Divyashree Shantamurthy (Mumbai, India)

4383 08:30 - 10:30 Hall 5

08:30 - 10:30

Hall 5

2-hour Educational Session

DX

Diagnostic parasitology in the XXIst century: is microscopy "+" still useful?

Chairs Miriam J. Álvarez-Martínez (Barcelona, Spain)
Caroline Rönnberg (Stockholm, Sweden)

4383-1 08:30 Artificial Intelligence for the diagnosis of parasitic infections Bobbi Pritt (Rochester, United States)

4383-2 08:50 Histopathology of parasitic infections Richard Bradbury (Townsville, Australia)

4383-3 09:10 Molecular diagnosis vs. microscopy in the diagnosis of parasitic infections Sitara Sr Ajampur (Vellore, India)

4383-4 09:30 Paleoparasitology: what diagnostic tools? Ayman El-Badry (Cairo, Egypt)

Co-organised with: ESCMID Study Group for Clinical Parasitology (ESGCP)

4269 08:30 - 10:30 Hall 6

08:30 - 10:30

Hall 6

2-hour Educational Session

ANT

Demystifying pharmacokinetics and population pharmacokinetics: a toolkit for non-experts

Chairs Shampa Das (Liverpool, United Kingdom)
João Paulo Telles (Sao Paulo, Brazil)

4269-1 08:30 Pharmacokinetics 101: navigating the basics for optimal dosing Linda Aulin (Leiden, Netherlands)

4269-2 08:50 The ABCs of population pharmacokinetic models Erwin Dreesen (Leuven, Belgium)

4269-3 09:10 Looking into the crystal ball: exploring the fabulous world of PK-PD simulations Vincent Aranzana-Climent (Poitiers, France)

4269-4 09:30 Decoding population pharmacokinetic papers:

ESCMID Global 2025 - Programme

Interpreting, comparing and discussing results *Iris K. Minichmayr (Vienna, Austria)*

Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG)

4775 **11:00 – 12:00** **Hall 0**
Special Session

PRO

Principles of systematic reviews (with and without meta-analysis)

Chairs
Chiara Iaria (Palermo, Italy)
Miranda Langendam (Amsterdam, Netherlands)
Blin Nagavci (Gjakove, Kosovo)
Mical Paul (Haifa, Israel)
Luigia Scudeller (Pavia, Italy)

Co-organised with: ESCMID Education Subcommittee

4357 **11:00 – 12:00** **Hall 2**
Meet-the-Expert

PHEI

Can we stop vertical transmission of syphilis, HIV and hepatitis? Regional experience

4357-1 **11:00** *Ecaterina Noroc (Chisinau, Moldova, Republic of)*
4357-2 **23:12** *Fakhriddin Nizamov (Almaty, Kazakhstan)*

Co-organised with: Euroguidelines in Central and Eastern Europe Network Group, United Nations International Children's Emergency Fund (UNICEF)

4619 **11:00 – 12:00** **Hall 3**
Meet-the-Expert

IPC

How to practise WHO Guidelines for the prevention of bloodstream infections and other intravascular catheter infections

4619-1 **11:00** *Kushlani Jayathilake (Battaramulla, Sri Lanka)*
4619-2 **23:12** *Walter Zingg (Zurich, Switzerland)*

4313 **11:00 – 12:00** **Hall 4**
Meet-the-Expert

DX AMR

How to interpret resistance patterns from antibiograms

4313-1 **23:00** *Tommaso Giani (Florence, Italy)*
4313-2 **23:12** *Diaz Lorena (Santiago, Chile)*

4517 **11:00 – 12:00** **Hall 5**
Meet-the-Expert

CLN

Biofilm-related nontuberculous mycobacterial infections: ongoing nightmare

4517-1 **23:00** *Jaime Esteban (Madrid, Spain)*
4517-2 **23:12** *Philippe Morand (Paris, France)*

Co-organised with: ESCMID Study Group for Implant-associated Infections (ESGIAI), ESCMID Study Group for Mycobacterial Infections (ESGMYC)

4700 **11:00 – 12:00** **Hall 6**
Meet-the-Expert

CLN

Children are not just small adults: interactive paediatric cases

4700-1 **23:00** *Julie Toubiana (Paris, France)*
4700-2 **23:12** *Sanjay Patel (Winchester, United Kingdom)*

4303 **11:00 – 12:00** **Hall 9**
Meet-the-Expert

PHEI

How to understand infectious disease risks in changing climates

4303-1 **11:00** *Kimberly Fornace (Singapore, Singapore)*
4303-2 **23:12** *Rachel Lowe (Barcelona, Spain)*

4605 **13:30 – 14:30** **Hall 5**
Meet-the-Expert

PHEI PRO

How to navigate Risk Communication in Public Health

4605-1 **13:30** *Christina Rolfheim-Bye (Oslo, Norway)*
4605-2 **13:42** *Marius Gilbert (Brussels, Belgium)*

Co-organised with: ESCMID Study Group for Public Health Microbiology (ESGPHM)

4713 **13:30 – 14:30** **Hall 9**
Meet-the-Expert

VAX

Do we need antiviral stewardship in immunocompromised hosts? role of cell-mediated immunity

4713-1 **13:30** *Michelle Yong (Melbourne, Australia)*
4713-2 **13:42** *Genovefa Papanicolaou (New York, United States)*

4774 **13:30 – 14:30** **Hall 0**
Special Session

IPC

Top five mistakes in Infection prevention and control

Chairs
Maeve Doyle (Waterford, Ireland)
Barbara Juliane Holzkecht (Copenhagen, Denmark)
David Ong (Zoetermeer, Netherlands)
Arjana Tambic Andrasevic (Zagreb, Croatia)

Co-organised with: ESCMID Education Subcommittee

4395 **13:30 – 14:30** **Hall 2**
Meet-the-Expert

CLN

Short regimens for treating drug-susceptible and drug-resistant tuberculosis: Insights from guidelines

4395-1 **13:30** *Daria Podlekareva (Copenhagen, Denmark)*
4395-2 **13:42** *Raquel Duarte (Porto, Portugal)*

Co-organised with: European Respiratory Society (ERS)

4228 **13:30 – 14:30** **Hall 3**
Meet-the-Expert

CLN

PrEP in Europe: Current gaps and solutions

4228-1 **13:30** *Teymur Noori (Stockholm, Sweden)*
4228-2 **13:42** *Milosz Parczewski (Szczecin, Poland)*

ESCMID Global 2025 - Programme

Co-organised with: European AIDS Clinical Society (EACS)

4484 13:30 - 14:30 Hall 4
Meet-the-Expert
CLN TRN

Orthopaedic Implant Infections: new approaches for improved outcomes

4484-1 13:30 *Marjan Wouthuyzen-Bakker (Groningen, Netherlands)*

4484-2 13:42 *Trisha Peel (Melbourne, Australia)*

Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG), ESCMID Study Group for Implant-associated Infections (ESGIAI), ESCMID Study Group for Infectious Diseases of the Brain (ESGIB)

4246 13:30 - 14:30 Hall 6
Meet-the-Expert
CLN

Timing of antimicrobials in sepsis and septic shock - the sooner the better?

4246-1 13:30 *Laura Evans (Seattle, United States)*

4246-2 13:42 *Evangelos Giamarellos-Bourboulis (Athens, Greece)*

Co-organised with: ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES), ESCMID Study Group for Staphylococci and Staphylococcal Diseases (ESGS)

4415 14:45 - 15:45 Hall 3
Meet-the-Expert
PRO

How to make sense out of guidelines and scientific evidence

4415-1 14:45 *Luigia Scudeller (Pavia, Italy)*

4415-2 14:57 *Blin Nagavci (Gjakove, Kosovo)*

Co-organised with: ESCMID Guidelines Subcommittee

4776 14:45 - 15:45 Hall 0
Special Session
PRO

Science Slam - How to Communicate Science with Clarity

Chairs
Mary Horgan (Dublin, Ireland)
Jaroslav Hrabak (Plzen, Czech Republic)
Nina Khanna (Basel, Switzerland)
Preeti Malani (Ann Arbor, United States)
Emily McDonald (Montreal, Canada)
Joshua Nosanchuk (Bronx, United States)
Jesús Rodríguez-Baño (Seville, Spain)

Co-organised with: ESCMID Education Subcommittee

4680 14:45 - 15:45 Hall 2
Meet-the-Expert
CLN

Multidisciplinary management of bone and joint infections: Is there a recipe for success?

4680-1 14:45 *Natividad Benito (Barcelona, Spain)*

4680-2 14:57 *Tiziana Ascione (Naples, Italy)*

Co-organised with: ESCMID Study Group for Lyme Borrellosis (ESGBOR)

4343 14:45 - 15:45 Hall 4
Meet-the-Expert
CLN DX

Healthcare-associated CNS infections

4343-1 14:45 *Diederik Van De Beek (Amsterdam, Netherlands)*

4343-2 14:57 *Alexandra Mailles (Paris, France)*

Co-organised with: ESCMID Study Group for Infectious Diseases of the Brain (ESGIB)

4743 14:45 - 15:45 Hall 5
Meet-the-Expert
PHEI

How to manage and prevent travellers' diarrhoea

4743-1 14:45 *Tinja Laaveri (Helsinki, Finland)*

4743-2 14:57 *Tba*

4634 14:45 - 15:45 Hall 6
Meet-the-Expert
TRN

Translation of gut microbiome data to clinical practice: a guide for clinicians

4634-1 14:45 *Aycan Gundogdu (Kayseri, Türkiye)*

4634-2 14:57 *Niranjan Nagarajan (Singapore, Singapore)*

Co-organised with: ESCMID Study Group for Host and Microbiota Interaction (ESGHAMI)

4262 14:45 - 15:45 Hall 9
Meet-the-Expert
CLN DX IPC

How to diagnose and treat infectious complications in critically ill patients receiving ECMO support

4262-1 14:45 *Jordi Riera (Barcelona, Spain)*

4262-2 14:57 *Giacomo Grasselli (Besana In Brianza, Italy)*

Co-organised with: European Extracorporeal Life Support Organization (EuroELSO)

4770 15:00 - 16:45 Hall 1
Special Session
PHEI

UNGA political declaration on AMR: moving from commitments to action - Science to inform policy: Implementing UNGA targets on AMR

INT17 15:00 **Welcome and opening remarks**

INT18 15:15 **The overall impact of currently known AMR interventions.** *Joseph Lewnard (Berkeley, United States)*

INT19 15:30 **Reducing AMR-related mortality: monitoring and achieving the 10% reduction by 2030** *Tba*

INT20 15:37 **Monitoring and achieving meaningful reductions in antimicrobial use in the animal health sector** *Tba*

INT21 15:44 **Global antibiotic policy: achieving the global 70 per cent access target** *Mike Sharland (London, United Kingdom)*

INT22 15:51 **TBA** *Tba*

INT23 16:00 **Setting and implementation targets at the country level** *Tochi Okwor (Jabi Abuja, Nigeria)*

INT24 16:15 **Q&A/Panel discussion** *Tba*

4710 16:15 - 18:15 Hall 2
2-hour Educational Session
CLN VAX

ESCMID Global 2025 - Programme

Addressing infection challenges in immunocompromised patients: a case-based exploration

Chairs *Maddalena Giannella (Bologna, Italy)*
Asma Nasim (Karachi, Pakistan)

4710-1 16:15 **Challenges in managing gastrointestinal infections in patients with primary immunodeficiency***Effrossyni Gkrania-Klotsas (Cambridge, United Kingdom)*

4710-3 16:35 **Mycobacterial infections in patients with HIV infection***Tba*

4710-4 16:55 **Breakthrough fungal infections in haematopoietic cancer and in stem cell transplantation***Dimitrios P. Kontoyiannis (Houston, United States)*

Co-organised with: ESCMID Study Group for Respiratory Viruses (ESGREV), International Immunocompromised Host Society (ICHS)

4777 16:15 – 18:15 Hall 0

CLN

Special Session

Multidisciplinary approach to early sepsis management

Chairs *Markus Bald (Lüdenscheid, Germany)*
Dokos Charalambos (Athens, Greece)
Aleksandra Davidovic (Lüdenscheid, Germany)

Co-organised with: ESCMID Education Subcommittee

4448 16:15 – 18:15 Hall 3

CLN TRN ANT

2-hour Educational Session

Going Viral! Phage Therapy Clinical rounds

Chairs *Gregory German (Maple, Canada)*
Ameneh Khatami (Sydney, Australia)

4448-1 16:15 **Clinical cases and lessons from the STAMP protocol***Holly Sinclair (Nsw, Australia)*

4448-2 16:35 **Difficult cases treated with phages***Ghady Haidar (Pittsburgh, United States)*

4448-3 16:55 **Challenging osteoarticular cases treated with phages***Tristan Ferry (Lyon, France)*

4448-4 17:15 **Treating urinary tract infections with phages: dream or reality?***Saima Aslam (San Diego, United States)*

Co-organised with: ESCMID Study Group for Non-traditional Antibacterial Therapy (ESGNTA)

4720 16:15 – 18:15 Hall 4

DX AMR

2-hour Educational Session

AMR surveillance: current challenges and new perspectives

Chairs *Lina Cavaco (Copenhagen, Denmark)*
Tomislav Mestrovic (Zagreb, Croatia)

4720-1 16:15 **The essentials of GRAM project: data sources, methodology and challenges in estimating AMR burden***Authia Gray (Washington, United States)*

4720-2 16:35 **Networks for surveillance of AMR in animal pathogens***Lucie Collineau (Lyon, France)*

4720-3 16:55 **Transition to genomic-based methodology for surveillance and outbreak detection to effectively combat AMR***Camilla Wiuff Coia (Copenhagen, Denmark)*

4720-4 17:15 **Implementing and running hospital-wide genomic surveillance of pathogens***Alexander Mellmann (Münster, Germany)*

Co-organised with: ESCMID Education Subcommittee, ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS), ESCMID Study Group for Veterinary Microbiology (ESGVM)

4374 16:15 – 18:15 Hall 5

2-hour Educational Session

TRN

Impact of diabetes on infectious diseases: what should we know?

Chairs *Irene Andia Biraro (Kampala, Uganda)*
Suzanne Van Asten (Nijmegen, Netherlands)

4374-1 16:15 **The Impact of diabetes and host-pathogen interaction and gut microbiome***Reinout Van Crevel (Nijmegen, Netherlands)*

4374-2 16:35 **Diabetes and invasive fungal infections***Tba*

4374-3 16:55 **Viral infections and diabetes: Is there a connection?***Malin Flodström-Tullberg (Stockholm, Sweden)*

4374-4 17:15 **Pathogenesis of diabetic wound infection***Tba*

4741 16:15 – 18:15 Hall 6

2-hour Educational Session

AMR

New insights into antifungal agents and resistance

Chairs *Anuradha Chowdhary (New Delhi, India)*
Jon Salmanton-Garcia (Cologne, Germany)

4741-1 16:15 **Emerging resistance in *Candida tropicalis****Sharon Chen (Sydney, Australia)*

4741-2 16:35 **Mechanisms of resistance in *Candida glabrata****David Perlin (Nutley, United States)*

4741-3 16:55 **Surveillance of resistance in *Aspergillus* species***Maiken Cavling Arendrup (Copenhagen, Denmark)*

4741-4 17:15 **Environmental surveillance for antifungal resistance***Eveline Snelders (Wageningen, Netherlands)*

4730 16:15 – 18:15 Hall 9

2-hour Educational Session

DX IPC

Primer on infection prevention and control: the crucial support by clinical microbiology

Chairs *Nico Tom Muters (Bonn, Germany)*
Margreet C. Vos (Rotterdam, Netherlands)

4730-1 16:15 **Microbial fundamentals: building blocks of infection prevention and control***Laurence Armand-Lefevre (Paris, France)*

4730-2 16:35 **Optimising environmental sampling in infection control: rational use of the microbiology laboratory***John E. Coia (Esbjerg, Denmark)*

4730-3 16:55 **The crucial role of molecular typing in infection control***Stefanie Kampmeier (Würzburg, Germany)*

4730-4 17:15 **How can we link diagnostic and antibiotic stewardship?***Constantinos Tsioutsis (Nicosia, Cyprus)*

Co-organised with: ESCMID Study Group for Nosocomial Infections (ESGNI), EUCIC Steering Committee

4770-1 17:00 – 18:30 Hall 1

Special Session

UNGA political declaration on AMR: moving from commitments to action - Policy to drive action: establishing the independent panel on evidence for action on AMR and updating the Global Action Plan

INT25 17:00 **Progress update by the Quadripartite Joint Secretariat on setting up the panel and updating the GAP***Tba*

INT26 17:20 **Lessons from the Intergovernmental Panel on Climate Change***Abdalah Mokssit (Switzerland)*

ESCMID Global 2025 - Programme

| | | |
|-------|-------|---|
| INT27 | 17:40 | Q&A/Panel discussion, <i>Sabiha Essack (Durban, South Africa), Jomana Musmar (Washington Dc, United States)</i> |
| INT28 | 18:20 | Closing remarks and next steps |

Saturday, 12 April 2025

| | | |
|------|------------------|---------|
| 4699 | 08:30 - 10:30 | Hall 15 |
| | 2-hour Symposium | |

ANT

The quality of antibiotics used in the communities of LMICs

| | | |
|--------|--|--|
| Chairs | <i>Thi Thuy Nga Do (Ha Noi, Vietnam)</i> <i>Tba</i> | |
| 4699-1 | 08:30 | The quality of antibiotics and their potential impact on patient outcome and AMR <i>Paul Newton (Oxford, United Kingdom)</i> |
| 4699-2 | 09:00 | Quality of common antibiotics in two sub-Saharan countries <i>Tba</i> |
| 4699-3 | 09:30 | Encountered challenges and reflections on conducting multi-country medicine quality studies <i>Noudy Sengxeu (Vientiane Capital, Lao People's democratic republic)</i> |
| 4699-4 | 10:00 | Confusion in appearance of common used antibiotics in LMICs <i>Heiman Wertheim (Nijmegen, Netherlands)</i> |

| | | |
|------|------------------|--------|
| 4573 | 08:30 - 10:30 | Hall 6 |
| | 2-hour Symposium | |

CLN VAX

To screen or not to screen prior to transplant?

| | | |
|--------|---|---|
| Chairs | <i>Laura Alicia Barcan (Buenos Aires, Argentina)</i> <i>Oscar Len (Barcelona, Spain)</i> | |
| 4573-1 | 08:30 | HHV-8 Screening <i>Alessandra Mularoni (Palermo, Italy)</i> |
| 4573-2 | 09:00 | TB screening and prevention in endemic regions <i>Rubina Naqvi (Karachi, Pakistan)</i> |
| 4573-3 | 09:30 | Screening for and prevention of chagas in immunocompromised hosts <i>Marcelo Victor Radisic (Buenos Aires, Argentina)</i> |
| 4573-4 | 10:00 | Screening of lung donors for Mollicutes <i>Michael G Ison (Derwood, United States)</i> |

| | | |
|------|------------------|---------|
| 4326 | 08:30 - 10:30 | Hall 10 |
| | 2-hour Symposium | |

IPC

Endoscopy: infection risks and mitigation

| | | |
|--------|-------|---|
| 4326-1 | 08:30 | Should we be concerned about infection from contaminated endoscopes? <i>Claire Aumeran (Clermont-Ferrand, France)</i> |
| 4326-2 | 09:00 | Microbial surveillance of endoscopes; any standardisation to be expected? <i>Margreet C. Vos (Rotterdam, Netherlands)</i> |
| 4326-3 | 09:30 | Understanding the causes of medical device contamination: It is all biofilm! <i>Roberto Rusconi (Milan, Italy)</i> |
| 4326-4 | 10:00 | Does the European medical Device Regulation bring us safer duodenoscopes? <i>Markus Hell (Salzburg, Austria)</i> |

Co-organised with: ESCMID Study Group for Biofilms (ESGB), ESCMID Study Group for Nosocomial Infections (ESONI)

| | | |
|-------|---------------------|---------|
| OS002 | 08:30 - 10:30 | Hall 11 |
| | 2-hour Oral Session | |

DX

Translating metagenomics into clinical practice

| | | |
|-------|--|--|
| 00011 | Nanopore metagenomic sequencing for rapid bloodstream infection diagnostics evaluated in a prospective observational study <i>M. Albertsen* (Aalborg, Denmark), M.E. Nielsen, C. Thygesen, K.K. Søgaard, A.B. Sørensen, S.M. Karst, A.L. Krarup, H.L. Nielsen</i> | |
| 00012 | Interpretative Criteria for Adjudicating Clinical Significance to Next-Generation Sequencing Results from Bronchial-alveolar Lavage and Bronchial Wash. <i>J. Alexander* (Orlando, United States), A. Charles</i> | |
| 00013 | Implementing same-day respiratory metagenomic diagnostics in paediatric intensive care <i>R. Hammond* (London, United Kingdom), A. Kopec, J. Brown, J. Hatcher, A. Alcolea-Medina, R. Batra, D. Ward, L.B. Snell, J. Breuer</i> | |
| 00014 | Detection of pathogenic microorganisms using metagenomic next-generation sequencing in ICU patients with ongoing antibiotic therapy <i>T. Schroeder* (Nuertingen, Germany), M. Eliwi Alsaffan, A. Dervishi, P. Kawaletz, H. Stäudle</i> | |
| 00015 | Analysis of metagenomic pathogen detection compared to conventional diagnostics: clinical usage and relevance for patient outcomes <i>E. Siegel* (Mainz, Germany), V. Bianco-Wilhelmi, S. Koch, C. Seckert, C. Hamm, D. Teschner, O. Kriege, D. Grimm, I. Sagoschen, D. Schreiner, M. Bodenstein, G. Cakas, S. Hagge, S. Vieira-Silva, T. Sparwasser</i> | |
| 00016 | Same-day pan-microbial metagenomics for personalized therapy and pathogen surveillance on the intensive care unit: a single-centre prospective study <i>L.B. Snell* (London, United Kingdom), A. Alcolea-Medina, G. Humayun, N. Al-Yaakoubi, D. Ward, C. Alder, V. Patel, F. Vivian, C. Meadows, W. Duncan, R. Paul, N. Barrett, R. Batra, J. Edgeworth, J. Whitehorn, G. Nebbia</i> | |
| 00017 | Evaluation of the diagnostic efficacy of targeted next-generation sequencing in the detection of pathogens in bronchoalveolar lavage fluid from patients with lower respiratory tract infections in ICU <i>B. Ran* (Taiyuan, China), Y. Liu, X. Wu, X. Lin, X. Li, Q. Zhan, C. Wang, L. Huang, T. Zhai, Y. Cai, Y. Song, Q. Zhang, C. Zhang, J. Hao, L. Jin, Z. Huang</i> | |
| 00018 | Prognostic and diagnostic value of Next-generation sequencing in female reproductive tract infection and HPV persistence <i>P. Chunyan* (Shiyang, China), S. Qi, C. Jiachang, W. Peng, W. Taiquan, X. Xianru, Y. Jianying, Y. Qirong, Z. Pengyuan, L. Jun</i> | |
| 00019 | A promising approach to rapid, non-culture diagnosis of invasive fungal infections (IFIs) by targeted next-generation sequencing (tNGS) <i>M.H. Nguyen* (Pittsburgh, United States), H. Badrane, B. Stevens, S. Cheng, G. Guigon, E. Santiago, M. Rambaud, B. Hao, E. Driscoll, W. Maynard, C. Clancy</i> | |
| 00020 | Implementation of Clinical Metagenomics in France: Insights from a Five-Years Study <i>M. Dutkiewicz* (Paris, France), T. Ghelfenstein-Ferreira, L. Feghoul, S. Mercier-Delarue, A. Senhaji, A.L. Munier, F. Caméléna, J. Le Goff, M. Salmona</i> | |

| | | |
|------|------------------|---------|
| 4512 | 08:30 - 10:30 | Hall 12 |
| | 2-hour Symposium | |

PHEI

Barriers to TB/HIV elimination in low- and high-incidence settings

| | | |
|--------|--|--|
| Chair | <i>Daria Podlekareva (Copenhagen, Denmark)</i> | |
| 4512-1 | 08:30 | HIV and TB epidemic: the storm hasn't subsided yet <i>Tetiana Koval (Poltava, Ukraine)</i> |
| 4512-2 | 09:00 | Approaches for latent and active TB screening in people living with HIV <i>Raimonda Matulionyte (Vilnius, Lithuania)</i> |
| 4512-3 | 09:30 | Integration of HIV and TB care to improve patient outcome in resource-limited settings <i>Tba</i> |
| 4512-4 | 10:00 | How researchers can influence policy and practice in |

ESCMID Global 2025 - Programme

HIV/TB care *Jens D. Lundgren (Copenhagen, Denmark)*

Co-organised with: ESCMID Study Group for Mycobacterial Infections (ESGMYC), Euroguidelines in Central and Eastern Europe Network Group

4654 **08:30 - 10:30** **Hall 13**

CLN DX VAX

2-hour Educational Session

RSV infections: diagnosis, surveillance and treatment in the advent of vaccines

4654-1 **08:30** **Costs of RSV infection, compared to other respiratory viruses** *Barbara Rath (Besançon, France)*

4654-2 **08:50** **Virology and host interactions of RSV** *Richard Sugrue (Singapore, Singapore)*

4654-3 **09:10** **RSV surveillance in the EU/EEA in the vaccine era** *Eva Broberg (Solna, Sweden)*

4654-4 **09:30** **RSV fusion inhibitors and monoclonals: current status and future developments** *Peter Openshaw (London, United Kingdom)*

Co-organised with: ESCMID Study Group for Respiratory Viruses (ESGREV), International Society for Influenza and other Respiratory Viruses (ISIRV)

4690 **08:30 - 10:30** **Hall 14**

CLN

2-hour Educational Session

Traumatic wound infections: diagnosis and treatment options

Chair Veroniek Saegeman (Sint-Niklaas, Belgium)

4690-1 **08:30** **Multidrug-resistant infections after trauma in warzone** *Shehan Hettiaratchy (Hampton, United Kingdom)*

4690-2 **08:50** **Fungal infections during natural disasters** *Anuradha Chowdhary (New Delhi, India)*

4690-3 **09:10** **Bacteriophage therapy for multidrug-resistant wound infections in trauma** *Tristan Ferry (Lyon, France)*

4690-4 **09:30** **Infection of burn wounds** *Nur Benzonana (Istanbul, Türkiye)*

Co-organised with: ESCMID Study Group for Forensic and Postmortem Microbiology (ESGFOR), ESCMID Study Group for Non-traditional Antibacterial Therapy (ESGNTA), SEIMC (Sociedad Española Enfermedades Infecciosas Microbiología Clínica), International Society of Antimicrobial Chemotherapy (ISAC)

4263 **08:30 - 10:30** **Hall 16**

CLN DX

2-hour Symposium

Unveiling the challenges: nosocomial infections in ECMO-supported patients

Chairs Antonios Katsounas (Bochum, Germany) Jordi Riera (Barcelona, Spain)

4263-1 **08:30** **Source of infection and pathogens** *Christian Eckmann (Hannover, Germany)*

4263-2 **09:00** **Prophylaxis and empiric treatment** *Giacomo Grasselli (Besana In Brianza, Italy)*

4263-3 **09:30** **Diagnostic criteria and definitions** *Graeme Maclaren (Singapore, Singapore)*

4263-4 **10:00** **Microbial films** *Marta Hernández-Meneses (Barcelona, Spain)*

Co-organised with: European Extracorporeal Life Support Organization (EuroELSO)

4621 **08:30 - 10:30** **Hall 2**

CLN DX

2-hour Educational Session

Are urinary tract infections still the same?

Chairs Agnes Maria Sonnevend (Pécs, Hungary)

Tba

4621-1 **08:30** **Pathogenesis of UTI in males and females** *Tba*

4621-2 **08:50** **Diagnosis and treatment of UTI in the era of antimicrobial resistance** *Jennifer Kranz (Aachen, Germany)*

4621-3 **09:10** **Can UTI be prevented?** *Chris Harding (Newcastle Upon Tyne, United Kingdom)*

4621-4 **09:30** **Fungal and parasitic infections of the urinary tract** *Gladys Mwanji (Mwanza, Tanzania, United republic of)*

4323 **08:30 - 10:30** **Hall 3**

CLN ANT

2-hour Educational Session

OPAT: from aged wine to new vintage

Chairs Birgit Koch (Rotterdam, Netherlands) Sonia Luque (Barcelona, Spain)

4323-1 **08:30** **OPAT: principles, practice and checklists** *Charlotte Quintens (Leuven, Belgium)*

4323-2 **08:50** **COPAT: complex outpatient parenteral antimicrobial therapy** *Ronald Andrew Seaton (Glasgow, United Kingdom)*

4323-3 **09:10** **Antimicrobial stability and other challenges for OPAT practice?** *Mark Gilchrist (London, United Kingdom)*

4323-4 **09:30** **New OPAT safety and efficacy data to guide practice** *Matthew Rawlins (Murdoch, Australia)*

Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG), Society of Infectious Diseases Pharmacists (SIDP)

4496 **08:30 - 11:30** **Hall 4**

DX AMR

3-hour Educational Session

EUCAST Educational Workshop

Chairs Marlene Amara (Le Chesnay Cedex, France) Alasdair P. Macgowan (Bristol, United Kingdom)

4496-1 **08:30** **EUCAST update** *Sören G. Gatermann (Bochum, Germany)*

4496-2 **08:50** **Setting clinical breakpoints, assessing evidence** *Anouk Edwina Muller (The Hague, Netherlands)*

4496-3 **09:10** **Benzylicillin susceptibility testing of *S. pneumoniae* by disk diffusion** *Gunnar Kahlmeter (Tävelsås, Sweden)*

4496-4 **09:30** **What to do when there are no breakpoints** *Barbara Juliane Holzknacht (Copenhagen, Denmark)*

4496-5 **09:50** **Detection of resistance mechanisms** *Christian Giske (Stockholm, Sweden)*

Co-organised with: EUCAST Steering Committee

OS001 **08:30 - 10:30** **Hall 5**

TRN AMR PHEI

2-hour Oral Session

One Health means resistance everywhere

O0001 **Decoding the role of *bla*_{CPE} carrying plasmids on wings: A holistic view using the One Health approach** *S.A. Martínez-Álvarez* (Logrono, Spain), P. Châtre, T. Cardona-Cabrera, P. François, U. Höfle, M. Zarazaga, J.Y. Madec, M. Haenni, C. Torres*

O0002 **A novel isolation room model leveraging culture-independent HI-C metagenomics for tracking antimicrobial resistance transmission between patients and hospital environmental reservoirs** *V. Koh* (Singapore, Singapore), R. Cabrera, J. Chua,*

ESCMID Global 2025 - Programme

| | | | |
|-------|--|--|--|
| 00003 | | <i>J.S. Lee, N.S.B. Haidi Fitri, Z.X. Tan, X. Huan, N.M. Thevasagayam, T.K.B. Lee, K. Marimuthu, O.T. Ng</i> | |
| | | Deciphering the pathogenic potentials and epidemiological identities of <i>Staphylococcus pseudintermedius</i> colonizing companion dogs in Sao Paulo. <i>I.B. Moses* (Sao Paulo, Brazil), L. Sartori, D.A. Henriques, M.M. Marini, F.M. Lima, R.X. Espinosa, I. Orlandino Da Silva, F.F. Santos, L. Gonzaga, A.T. Ribeiro De Vasconcelos, A.C. Gales</i> | |
| 00004 | | Recent progress towards integrated surveillance of antimicrobial resistance in France. <i>L. Collineau* (Lyon, France), S. Bareille, G. Birgand, L. Lacmago, B. Lange, O. Lemenand, C. Chauvin</i> | |
| 00005 | | Exploring the plasmidome of 3rd generation cephalosporin-resistant Enterobacterales in wild birds: Insights into horizontal gene transfer and AMR dissemination. <i>B. Timmer* (Debrecen, Hungary), L. Miló, B. Koleszár, C. Freytag, Á. Lovas-Kiss, L. Laczkó, G. Kardos</i> | |
| 00006 | | Emergence of mobile colistin resistance in <i>Klebsiella</i> at human-animal-environment interface in Bangladesh. <i>S. Rahman* (Oxford, United Kingdom), A. Pondit, J. Parkhill, S. Saha, S.M.R. Islam, P.I. Disha, S.A. Nasreen, M.A.K. Azad, T.R. Walsh, R. Farzana</i> | |
| 00007 | | Unveiling the invisible: antimicrobial resistance genes and pathogenic microbial diversity in sewage of North India's largest industrial hub, A metagenomic perspective. <i>I. Singh* (Chandigarh, India), R. Sharma, A. Arora, B. Mohan, N. Taneja</i> | |
| 00008 | | Culturomics as a tool for ONE HEALTH approach: Unveiling the role of unknown microorganisms as antibiotic resistance carriers in wastewater samples. <i>E. Ouranou* (Heraklion, Greece), A. Psaroulaki, D. Chochlakis, M. Malliarou, K. Tryfinopoulou, A. Ntoula, E. Intze, I. Lagouvardos</i> | |
| 00009 | | One Health intervention impacts on antibiotic resistance in Denmark, England and Senegal: A mathematical model comparison. <i>G. Knight* (London, United Kingdom), R. Booton, J. Robotham, K. Aluzaitė, D. Belay, J. Guitian, M. Dione, E. Ernes</i> | |
| 00010 | | Clinically important sequence types and resistance genes in <i>Enterobacteriaceae</i> from coastal environments and gulls. <i>V. Silva* (Lisbon, Portugal), M. Quintelas, M. Caniça, R. Rivière, P. Poeta, G. Igrejas</i> | |

| | | | |
|------|---------------|------------------|--------|
| 4330 | 08:30 - 10:30 | | Hall 7 |
| | | 2-hour Symposium | |

New insights into *Candida* pathogenesis

| | |
|---------------|--|
| <i>Chairs</i> | <i>Aleksandra Barac (Belgrade, Serbia)</i> <i>Joshua Nosanchuk (Bronx, United States)</i> |
|---------------|--|

| | | | |
|--------|-------|--|--|
| 4330-1 | 08:30 | Insights into the evolution of <i>Candida</i> under antifungal pressure. <i>Attila Gacser (Szeged, Hungary)</i> | |
| 4330-2 | 09:00 | How do <i>Candida</i> extracellular vesicles modify virulence during disease? <i>Leonardo Nimrichter (Rio De Janeiro, Brazil)</i> | |
| 4330-3 | 09:30 | The commensal to pathogen transition: kind to killer. <i>Ilse D. Jacobsen (Jena, Germany)</i> | |
| 4330-4 | 10:00 | Fungal-bacterial interactions: who wins? <i>Rebecca Hall (Canterbury, United Kingdom)</i> | |

| | | | |
|------|---------------|------------------|--------|
| 4523 | 08:30 - 10:30 | | Hall 8 |
| | | 2-hour Symposium | |

Single-cell approaches to dissect cellular phenotypic heterogeneity of bacterial pathogen populations.

| | |
|---------------|--|
| <i>Chairs</i> | <i>Christian Stephan Lentz (Tromsø, Norway)</i> <i>Annelies Zinkernagel (Zurich, Switzerland)</i> |
|---------------|--|

| | | | |
|--------|-------|---|--|
| 4523-1 | 08:30 | Adaptive evolution and phenotypic heterogeneity of bacterial pathogens during infections. <i>Christoph Ernst</i> | |
|--------|-------|---|--|

(Cologne, Germany)

| | | | |
|--------|-------|--|--|
| 4523-2 | 09:00 | Single-cell imaging and heterogeneity in antimicrobial resistance. <i>Stefano Pagliara (Exeter, United Kingdom)</i> | |
| 4523-3 | 09:30 | Single-cell RNAseq and heterogeneity in bacterial transcription. <i>Anna Kuchina (Seattle, United States)</i> | |
| 4523-4 | 10:00 | Dissecting the function of individual bacteria in their spatial context. <i>Knut Drescher (Basel, Switzerland)</i> | |

| | | | |
|------|---------------|-----------------|-------------------------------------|
| 4769 | 08:30 - 12:00 | | Krieau 1 + 2 room (Courtyard hotel) |
| | | Special Session | |

TAE Day: morning round

| | | | |
|------|---------------|------------------|--------|
| 4761 | 09:30 - 10:30 | | Hall 1 |
| | | 1-hour Symposium | |

Year in Infection Control

| | |
|---------------|--|
| <i>Chairs</i> | <i>Nico Tom Muters (Bonn, Germany)</i> <i>Ermira Tartari (Msida, Malta)</i> |
|---------------|--|

| | | | |
|--------|-------|--|--|
| 4761-1 | 09:30 | <i>Andrew James Stewardson (Victoria, Australia)</i> | |
| 4761-2 | 10:00 | <i>Kalisvar Marimuthu (Singapore, Singapore)</i> | |

| | | | |
|------|---------------|-----------------|--------|
| 4765 | 11:00 - 12:00 | | Hall 3 |
| | | Special Session | |

Young Investigator Award Session

| | | | |
|------|-------|--|--|
| INT2 | 11:00 | Deciphering the pathogenic traits and epidemiological identities of <i>Staphylococcus pseudintermedius</i>: an emerging and underestimated zoonotic pathogen. <i>Ikechukwu Benjamin Moses (Abakaliki, Brazil)</i> | |
| INT3 | 11:12 | Drugs for Vector-borne Infections: Facts and Fibrillations. <i>Xin Hui Chan (Oxford, United Kingdom)</i> | |
| INT4 | 11:24 | Duke criteria for the diagnosis of infective endocarditis in clinical practice: are we there yet? <i>Matthaios Papadimitriou Olivgeris (Sion, Switzerland)</i> | |
| INT5 | 11:36 | Finding a place for observational studies in infectious diseases research. <i>Anthony Bai (Kingston, Canada)</i> | |
| INT6 | 11:48 | Clearing fungal fog in viral storms: deciphering influenza- and COVID-19-associated pulmonary aspergillosis. <i>Simon Feys (Leuven, Belgium)</i> | |

| | | | |
|------|---------------|------------|---------|
| 4549 | 11:00 - 12:00 | | Arena 1 |
| | | Open Forum | |

HIV: a global ethical Conundrum

| | | | |
|--------------|------------------------------------|---|--|
| <i>Chair</i> | <i>Seif Al-Abri (Muscat, Oman)</i> | | |
| 4549-1 | 11:00 | HIV, from key population to general population: a Pandora's Box. <i>Syed Faisal Mahmood (Karachi, Pakistan)</i> | |
| 4549-2 | 11:10 | Ethical considerations in preventing mother-to-child HIV transmission. <i>Glory Alexander (Bangalore, India)</i> | |
| 4549-3 | 11:20 | HIV drug trials in Africa: ethical concerns. <i>Shah Reena (Nairobi, Kenya)</i> | |
| 4549-4 | 11:30 | HIV-related stigma and discrimination in the healthcare setting. <i>Teymur Noori (Stockholm, Sweden)</i> | |

Co-organised with: ESCMID Ethics Advisory Committee (EEAC)

| | | | |
|------|---------------|--|--------|
| 4351 | 11:00 - 12:00 | | Hall 1 |
|------|---------------|--|--------|

ESCMID Global 2025 - Programme

Keynote Lecture

AMR PHEI

Asia: An AMR Hot Zone

Chairs *Giulia De Angelis (Rome, Italy)*
Robert Leo Skov (Copenhagen, Denmark)

4351-1 11:00 *David Paterson (Singapore, Singapore)*

OS010 11:00 – 12:00 Hall 10

1-hour Case Session

CLN

Antimicrobial drugs in action

00072 *In vivo* cefiderocol resistance due to *cirA* modification during treatment *E. Carretto* (Reggio Emilia, Italy), P. Pini, R. Farzana, C. Bedogni, R. Marrolo, P. Nardini, M. Bardaro, N.C. Facciolongo, S. Mezzadri, T.R. Walsh*

00073 Long-term outcomes in dalbavancin-treated patients with vascular graft infection. *A. Specklin* (Reims, France), T. Noël, M. Bonnet, A. Duprey, M. Hentzien*

00074 Aztreonam, ceftazidime/avibactam, and tigecycline combination for the management of multi-drug resistant *E. coli* on peritonitis in a pediatric liver transplant recipient. *R. Morales Junior* (Cincinnati, United States), V. Juodinis, C. Donini, J. Sampaio*

00075 Early oral antibiotic treatment in patients with post-neurosurgical brain abscesses caused by *Cutibacterium acnes* – a case series. *M. Karolyi* (Vienna, Austria), D. Stahl, E. Pawelka, S. Omid, A. Kuran, M. Naegeli, A. Zoufaly, C. Well, S. Fiscoeder, M. Ortler, C. Wenisch*

00076 Meropenem-vaborbactam as intrathecal-sparing therapy for the treatment of carbapenem-resistant *K. pneumoniae* shunt-related ventriculitis: two case reports. *G. Giuliano* (Siena, Italy), M. Sambo, P. Castellani, S. Benedetti, F. Tarantino, M. Tumbarello*

4291 11:00 – 12:00 Hall 11

1-hour Symposium

IPC

How long should contact isolation precautions be continued?

Chairs *Cansu Cimen (Oldenburg, Germany)*
Kyriaki Tryfinopoulou (Heraklion, Greece)

4291-1 11:00 Contact isolation in patients with MDR organisms: Why, when, where? *Gabriel Birgand (Nantes, France)*

4291-2 11:30 Is discontinuation of contact precautions associated with an increase in infections? *Daniel Diekema (Harpswell, United States)*

Co-organised with: ESCMID Study Group for Nosocomial Infections (ESGNI), EUCIC Steering Committee, Multidisciplinary Joint Committee Infection Control UEMS

4254 11:00 – 12:00 Hall 12

Meet-the-Expert

DX

Cut a long story short: choosing NGS platforms

4254-1 11:00 *Etienne Ruppe (Paris, France)*

4254-2 11:12 *Stefan Green (Chicago, United States)*

OS011 11:00 – 12:00 Hall 13

1-hour Oral Session

TRN ANT

Around the lab in 80 ways: a journey through innovative therapeutics

00077

In vivo expression of an mRNA encoded multi-mechanistic mAb combination against *Staphylococcus aureus* and protection in a disease model. *S. Bret* (Gaithersburg, United States), C. Tkaczyk, N. Michael, P. Mun Mun, T. George, S. Martin, G. Adam, M. Andal, D. Julie, S. Oleg, B. Elin, Y. Haitao, E. Mark, L. Ashley, D. Antonio*

00078

Hijacking intrinsic resistance in *Mycobacterium abscessus*. *G. Phelps* (Memphis, United States), S. Kurt, A. Jenner, S. Anderson, T. Jayasinghe, E. Griffith, C. Thompson, L. Yang, B. Wicki, F. Bright, L. Boeck, V. Loudon, R. Lee, A. Wright, W. Wright, O. Grant-Chapman, J. Ochoado, D. Conner, B. Troyer, A. Iverson, J. Rosch, B. Schulthess, P. Geeleher, S. Hobbie, B. Meibohm, A. Obregon-Henao, P. Sander, R. Lee*

00079

Tripartite bacteriophage-based strategy to combat human clinical pathogens. *P. Kalatzis* (Copenhagen, Denmark), R. Ibarra-Chávez, H. Sampson, S. Michniewski, A. Shen, M. Ford, B. Petersen, P. Worning, P. Klement, H.P. Calum, U.M. Singh, A. Millard, M.R.J. Clokie, T. Sicheritz-Pontén*

00080

Eosin Y and Ceragenin combinations for enhanced antimicrobial photodynamic therapy. *Y. Tekintas* (Cigli, Türkiye), P.B. Savage, M. Ucuncu*

00081

Identification of compounds capable of removing established bacterial biofilms. *T. Inzana* (Brookville, United States), A. Gates, W. Weng, J. Cusumano, Y.J. Lee, N. Vogelaar*

4504

11:00 – 12:00

Hall 14

Meet-the-Expert

PRO

How to perform clinical trials in mycoses?

4504-1 11:00 *Monica Slavin (Melbourne, Australia)*

4504-2 11:12 *Nkechi Azie (Jersey City, United States)*

Co-organised with: ESCMID Fungal Infection Study Group (EFISG)

OS012

11:00 – 12:00

Hall 15

1-hour Oral Session

PHEI

Climate Impact and One Health Approaches Against Infectious Diseases

00082

Airborne Threats: Pollution, Climate, and Respiratory Infections in a Pyrenean setting: The Andorran hospital based respiratory perspective. *C. Royo-Cebrecos* (Andorra, Andorra), N. Duran Torralbo, D. Vilanova Gonzalez, M. Clusas Antolin, L. Trapero*

00083

Effects of climate change on *Aedes aegypti* abundance and dengue transmission. *L. Geng* (Singapore, Singapore)*

00084

Impact of climate variables on Crimean-Congo hemorrhagic fever in Iran, Iraq, Kazakhstan, and Russia. *M. Fereidouni* (Jahrom, Iran, Islamic Republic of), D. Bisanzio, I. Lizinfeld, N. Pshenichnaya, G. Abuova, M.R. Shirzadi, H. Abdulghafoor Khaleel, R. Alhilfi, M. Keshkar-Jahromi*

00085

Successful public health and one health response to a high pathogenicity avian influenza outbreak in poultry farms in Victoria, Australia: implications for future planning. *E. Athan* (Geelong, Australia), A. Hussain, K. Blaney, L. Cardamone, N. Clarke, M. Hayes, M. Muleme, B. Mchamara, E. Jalil, S. Holwill, C.K. Lim, H. O'Brien, E. Layton, A. Fidao, S. Salmon, R. Kinnear*

00086

Turning disease surveillance into reality: Using metagenomic sequencing with piggyback wastewater. *M. Muralidhar* (St Lucia, Australia), L. Omaleki, M.N. Naseem, J.R.B. Mesa, C. Turni*

OS013

11:00 – 12:00

Hall 16

ESCMID Global 2025 - Programme

1-hour Oral Session

CLN DX

Viral challenges in organ transplantation

- 00087 **Evaluation of an individualized CMV prevention strategy guided by post-transplant CMV-specific cell-mediated immunity in intermediate-risk kidney transplant recipients.** *J.M. Caso* (Madrid, Spain), M. Fernández-Ruiz, E. González, N. Polanco, N. Redondo, T. Ruiz-Merlo, R. San-Juan, L.M. Allende, E. Paz-Artal, A. Andrés, F. López-Medrano, J.M. Aguado, I. Rodríguez-Goncer*
- 00088 **Real-world Use of Letermovir Prophylaxis for Cytomegalovirus (CMV) Prevention in Non-kidney Transplant Recipients.** *A. Mughrabi* (Rochester, Minnesota, United States), B. Bisono-Garcia, S. Chesdachai, N. Ranganath, R. Razonable*
- 00089 **Real-world administration of maribavir beyond the eight weeks established in the clinical trial.** *D. Martínez-Simón* (Barcelona, Spain), C. Ribera-Puig, M. Bodro, D. Company, J. Esperalba, I. Los Arcos, P. Clèries-Rovira, A. Padullés-Zamora, N. Sabé, M. Tuset, O. Len*
- 00090 **Prediction of BK Polyomavirus nephropathy in kidney transplantation by measuring neutralizing responses in a large cohort of donor and recipients.** *M. Solís* (Strasbourg, France), W. Fardi, I. Benotmane, F. Gallais, S. Caillard, S. Fafi-Kremer*
- 00091 **Dengue in solid organ transplant recipients.** *S.I. Galian* (Buenos Aires, Argentina), N. Pujato, N.S. Nolis, R. Del Grosso, P. Lopez, G. Aballay, M. Agustín, G. Werber*

4502 11:00 – 12:00 Hall 2

1-hour Symposium

CLN

What happens following TB infection?

*Chairs Catherine Ong (Singapore, Singapore)
Sean Wasserman (London, United Kingdom)*

4502-1 11:00 **Post-TB disease: burden and treatment strategies.** *Deborah Chong (London, United Kingdom)*

4502-2 11:30 **TB sequelae and fungal infection.** *Helmut Salzer (Linz, Austria)*

Co-organised with: ESCMID Study Group for Mycobacterial Infections (ESGMYC), CPAnet

4737 11:00 – 12:00 Hall 5

1-hour Symposium

TRN VAX

New frontiers in bacterial pathogenesis

*Chairs Silvio Daniel Brugger (Zurich, Switzerland)
Abdou Hachani (Melbourne, Australia)*

4737-1 11:00 **Bacterial infections and cellular immunity.** *Charlotte Odendall (London, United Kingdom)*

4737-2 11:20 **Immuno-metabolism in bacterial diseases.** *Tania Wong (New York, United States)*

OS007 11:00 – 12:00 Hall 6

1-hour Oral Session

CLN ANT VAX

New developments in prophylaxis and treatment of COVID-19

- 00057 **Ensirelvir for the prevention of COVID-19 among household contacts: key subgroup analyses of a randomized, double-blinded, placebo controlled post-exposure prophylaxis study, SCORPIO-PEPF.** *Hayden* (Charlottesville, United States), N. Ohmagari, T.W. Clark, M. Shinkai, A.F.*

Luetkemeyer, P. Sax, W.P. Hanage, K.A. Gebo, H. Ikematsu, K. Izumikawa, C.C. Butler, A. Fukushi, S. Kezbor, H. Sakaguchi, S. Lacey, G. Ichihashi, T. Uehara

00058 **Efficacy of nirmatrelvir/ritonavir on overall COVID-19 related symptoms in immunocompromised adult participants from the EPIC-IC trial.** *R. Mokgokong* (Tadworth, United Kingdom), P. Cislo, E. Tudone, E. Weinstein, J. Cappelleri*

00059 **COVID-19 patients benefitting from remdesivir for improved survival: a neural network-based approach.** *T.F. Aiello* (Barcelona, Spain), C. Teijón-Lumbreras, C. Garcia-Vidal, M. Chumbita, M. Rosario, A. Mateu Subirà, O. Peyrony, P. Monzó-Gallo, A. Gallardo-Pizarro, A. Martínez-Urrea, R. Méndez, E. Calbo, M. Ballester-Tellez, G. Cuesta-Chasco, M. Marcos, A. Soriano*

00060 **Efficacy and safety of sotrovimab vs oral antivirals in omicron waves: a retrospective analysis.** *C. Cacace* (Napoli, Italy), A. Russo, M. Pisaturo, P. Grimaldi, F. Ambrisi, G. Granata, F.G. Numis, N. Coppola*

00061 **Pharmacokinetics and immunogenicity of AZD7442 (Tixagevimab/Cilgavimab) in hospitalised COVID-19 patients: results from the DisCoVeRy trial.** *C. Massonnaud* (Paris, France), M. Hites, N. Peiffer-Smadja, T.H.L. Han, G. Carcelain, F. Mentré, F. Ader, On Behalf Of The Discovery Study Group*

OS008 11:00 – 12:00 Hall 7

1-hour Oral Session

CLN TRN

Advancing Malaria Research: From Molecular Insights to Clinical Challenges

00062 **Influence of second blood meals on *Plasmodium vivax* development and infectivity in mosquitoes.** *S. Bantuchai* (Bangkok, Thailand), W. Nguitraoool, J. Sattabongkot, C. Kumpitak*

00063 **Human hepatocytic infection and mosquito infectivity of *Plasmodium vivax* are linked with genomic architecture of Circumsporozoite Surface Protein.** *P. Tapaopong* (Bangkok, Thailand), G. Da Silva, A. Holzschuh, L. Cui, C. Koepfli, W. Roobsoong, J. Sattabongkot, W. Nguitraoool*

00064 **Severe imported *Plasmodium falciparum* malaria with hyperparasitaemia: evaluation of predictors for critical disease.** *T. Lingscheid* (Berlin, Germany), J. Jochum, P. Tober-Lau, J. Schöllgen, T. Zoller, L.E. Sander, M. Ramharther, F. Kurth*

00065 **The current status of *Plasmodium falciparum* chloroquine resistance transporter gene (K76T) and *Plasmodium falciparum* multi-drug resistance gene 1 (NB6Y) in Cameroon.** *M. Fru* (Buea, Cameroon)*

00066 **SOFA score vs WHO severity criteria to guide antimalarial treatment - 10 years of imported malaria cases in a UK tertiary centre reviewed.** *E. Savory* (Cambridge, United Kingdom), M. Routledge, B. Warne, E. Moore, D. Sparkes*

OS009 11:00 – 12:00 Hall 8

1-hour Case Session

CLN

Osteoarticular uninvited guests

00067 **Antibiotic-refractory oligoarthritis in an adolescent caused by *Borrelia bavariensis* in Croatia.** *N. Krajcar* (Zagreb, Croatia), L. Stemberger Marić, M. Vrdoljak Pažur, S. Roglić, R. Beck, G. Tešović*

00068 **Progression of vertebral echinococcosis despite radiotherapy treatment.** *M. González-Sanz* (Madrid, Spain), O. Martín, A. Romero-Alegria, M. Belhassen, S. Chamorro Tojeiro, D. Gayoso Cantero, F. Norman, B. Monge Maillo, C. Crespillo-Andújar, M.D. Corbacho Loarte, S. De La Fuente-Herranz, J. Cobo Soriano, J. Urbano, M. Martín Martín, J.A. Pérez-*

ESCMID Global 2025 - Programme

Molina

| | |
|-------|--|
| 00069 | Two cases of septic osteoarthritis of <i>Cutibacterium acnes</i> detected by 16S rRNA gene sequencing in immunocompetent adolescents <i>H. Okuno*</i> (Osaka, Japan), <i>K. Shiota, K. Amo</i> |
| 00070 | A UK case of Melioidosis with osteomyelitis two years after geographical exposure <i>C. Darlow*</i> (Liverpool, United Kingdom), <i>L. Swithenbank, R. Taggart, V. Owen, N. Wong, S. Woolley, W.D. Harrison, L. Ratcliffe, J. Lewis</i> |
| 00071 | When Infection Masquerades as Malignancy: A Case of Disseminated <i>Mycobacterium fortuitum</i> complex infection with Mixed Osteoblastic and Osteolytic Lesions and Lymphadenopathy in Anti-IFN-γ Immunodeficiency Syndrome <i>N. Hiranburana*</i> (Bangkok, Thailand), <i>S. Khahakaew, K. Meesilpavikkaj, M. Satja, G. Suwanpimolkul</i> |

| | | |
|------|------------------|--------|
| 4760 | 13:30 – 14:30 | Hall 1 |
| | 1-hour Symposium | |

CLN

Year in Infectious diseases

Chairs Nur Benzonana (Istanbul, Türkiye)
Evelina Tacconelli (Verona, Italy)

| | | |
|--------|-------|--------------------------------------|
| 4760-1 | 13:30 | Yoav Keynan (Winnipeg, Canada) |
| 4760-2 | 14:00 | Elisa Cordero Matia (Seville, Spain) |

| | | |
|------|------------------|---------|
| 4281 | 13:30 – 14:30 | Hall 16 |
| | 1-hour Symposium | |

PRO

Developing guidelines with AI tools: are they ready for prime time?

| | | |
|--------|-------|--|
| 4281-1 | 13:30 | The PROs and CONs of using AI tools for developing guidelines <i>Holger Schünemann</i> (Hamilton, Canada) |
| 4281-2 | 14:00 | AI in action: validated tools for speeding up your systematic reviews and how to use them <i>Sara Fernandez</i> (Oslo, Norway) |

Co-organised with: ESCMID Guidelines Subcommittee

| | | |
|------|------------------|--------|
| 4594 | 13:30 – 14:30 | Hall 2 |
| | 1-hour Symposium | |

IPC PHEI

Exploring children's role in infection spread

Chairs Sanjay Patel (Winchester, United Kingdom)
Tba

| | | |
|--------|-------|---|
| 4594-1 | 13:30 | Are children really super-spreaders of respiratory viruses? <i>Emmanuel André</i> (Leuven, Belgium) |
| 4594-2 | 14:00 | Should schools be closed at the start of the next pandemic? <i>Vittoria Colizza</i> (Paris, France) |

Co-organised with: European Society of Paediatric Infectious Diseases (ESPID)

| | | |
|-------|---------------------|---------|
| OS018 | 13:30 – 14:30 | Hall 11 |
| | 1-hour Oral Session | |

IPC ANT

Battling the Spore: *C. difficile* epidemiology and management

| | |
|-------|---|
| 00124 | Molecular epidemiology and antimicrobial resistome of <i>Clostridioides difficile</i> from private and public healthcare settings in three provinces in South Africa <i>H. Shirinda*</i> (Pretoria, South Africa), <i>A.M. Smith, B. Prinsloo, M. Kock, M. Moodley, M. Said, M. Ehlers</i> |
|-------|---|

| | |
|-------|---|
| 00125 | Screening for <i>Clostridioides difficile</i> colonization at admission and during hospitalization <i>N. Khanafer*</i> |
|-------|---|

(Lyon, France), *S. Bennia, G. Martin-Gaujard, L. Juillard, T. Rimmelé, L. Argaud, P. Cassier, O. Martin, P. Vanhems*

| | |
|-------|---|
| 00126 | Revolutionizing CDI treatment: Are shorter antibiotic regimens the future <i>M. Duricek*</i> (Prague, Czech Republic), <i>J. Benes, K. Halmova</i> |
|-------|---|

| | |
|-------|---|
| 00127 | Extended-pulsed fidaxomicin versus conventional dosing in patients at high risk of recurrence of <i>Clostridioides difficile</i> infection <i>E. Rubio-Martín*</i> (Seville, Spain), <i>R. Escudero-Sánchez, Á. Gutiérrez Liarte, A. Ibañez Zurriaga, C. Saez Bejar, B. Díaz Pollán, C. Marcelo Calvo, G. Ruiz Carrasco, G. Pérez Caballero, A.M. Rodríguez Benavente, S. De La Villa, J.D. Ruiz-Mesa, L.F. Caballero Martínez, I. Márquez Gómez, E. Calabuig, M. Tacias, R. Blanes, M.A. López Zúñiga, J. Rodríguez Granger, P. Merino Amador, A. Salinas, D. Rodríguez-Pardo, M. Villamarín Merlo, G. Maestro De La Calle, J. Mateo Flores, J.B. Pérez Gilaberte, R.M. Martínez Álvarez, F. Martínez García, N. Cobos-Trigueros, J. Llenas-García, M. Solivella-Rodríguez, L. Ramos Merino, B. Castelo López, M.M. Montero, D. Echeverría-Esnal, J. López-Contreras, P. Duch Llorach, M.R. Oltra-Sempere, C. Pinto-Pla, Í. Pineda, J.L. Del Pozo, J. Rodríguez-Baño, A. Halperin, A. Muriel García, S. Moreno Guillén, J. Cobo</i> |
|-------|---|

| | |
|-------|--|
| 00128 | Gut phageome profiling in <i>Clostridioides difficile</i> infection and faecal microbiota transplantation <i>C. Chen*</i> (Lausanne, Switzerland), <i>T. Pillonel, J. Schaefer, G. Greub, G. Resch, B. Guery, C. Bertelli, T. Galperine</i> |
|-------|--|

| | | |
|-------|---------------------|---------|
| OS019 | 13:30 – 14:30 | Hall 12 |
| | 1-hour Oral Session | |

TRN

Microbiome Dynamics and Health: From Pathogenesis to Therapeutic Potential

| | |
|-------|--|
| 00129 | Multi-omics integrated analysis revealed the key role of <i>Fusobacterium periodonticum</i> in colorectal tumorigenesis by decanoic acid promoting neutrophil chemotaxis <i>X. Chu*</i> (Beijing, China), <i>Y.1.C. Yangqiwen81@vip.163.Com</i> |
|-------|--|

| | |
|-------|--|
| 00130 | Exploring the respiratory microbiome in COPD patients: The role of <i>Haemophilus</i> spp. in disease pathogenesis <i>P. Camps-Massa*</i> (Barcelona, Spain), <i>L. Saiz-Escobedo, J. Guerrero, E. Cuevas, D. Guevara-Nuñez, F. Tubau, J. Burgos, M. Lopez, A. González-Díaz, C. Ardanuy, M. Domínguez, S. Santos, S. Martí</i> |
|-------|--|

| | |
|-------|--|
| 00131 | Using the in vitro MiGut system to simulate the ulcerative colitis microbiome and post-antibiotic recovery supported by a pre-defined consortium of microbes <i>I. Moura*</i> (Leeds, United Kingdom), <i>W. Davis Birch, N. Beauchemin, M. Vulic, K. Bentley, P. Culmer, M. Mayol, C. Ford, M. Henn, E. Halvorsen, M. Wilcox, N. Kapur, A. Buckley</i> |
|-------|--|

| | |
|-------|---|
| 00132 | Functional characterization of the Brazilian Yanomami microbiome along an urbanization gradient: Insights into the impacts of Westernization on human health <i>C. Callewaert*</i> (Gent, Belgium), <i>M. Thorp, B. De Pessemer, D. Good, E. Allen-Vercoe, L. Paulino, L. Vereecke</i> |
|-------|---|

| | |
|-------|---|
| 00133 | Colonization resistance of the intestinal microbiota to multidrug-resistant bacteria? <i>K. Villageois-Tran*</i> (Bobigny, France), <i>C. Emavivie, H. Skerdi, E.N. Saad, M. Julie, S.G. Voyag-R, E. Ruppe</i> |
|-------|---|

| | | |
|------|-----------------|---------|
| 4233 | 13:30 – 14:30 | Hall 14 |
| | Meet-the-Expert | |

CLN

Long acting injectables to treat and prevent infections: an example from HIV field

| | | |
|--------|-------|---|
| 4233-1 | 13:30 | Monica Gandhi (Salt Lake City, United States) |
| 4233-2 | 13:42 | <i>Tba</i> |

ESCMID Global 2025 - Programme

OS020 13:30 – 14:30 Hall 15
1-hour Oral Session

ANT

How to evaluate AMS programs

- 00134 **Preference-based instrumental variables for estimating the causal effects of antibiotic prescribing decisions in common infections: Assessing potential validity using CPRD data** *N. Nguyen** (Oxford, United Kingdom), *K. Pouwels, J. Robotham, S. Yu, S. Wordsworth*
- 00135 **Novel antibiotic spectrum metrics to quantify the impact of antimicrobial stewardship: a multicentre study** *B. Moshy** (London, United Kingdom), *R. Llewellyn, R. Lester, G. Pollara, T. Samuels, J. Sarah, B. Gemma, I. Balakrishnan*
- 00136 **Utilizing a weighted-incidence syndromic antibiogram to evaluate antimicrobial therapies and resistance trends in community-acquired infections in a community teaching hospital** *V. Huang** (Glendale, United States), *T. Pham, A. Vogler, H. Chhen, C. Vandenberg*
- 00137 **Capturing days of therapy per days of service as a stewardship tool to identify outliers in prescribing broad-spectrum antimicrobials in the hospital setting** *A. Farkas** (Livingston, United States), *S. Tamirisa, G. Severance, A. Yassin, E. Jaime, A. Hopkins*
- 00138 **Timing of Novel β -Lactams vs. Alternatives in Hospitalized Patients with Gram-Negative Infections: Line of Therapy (LoT) Analysis Preliminary findings** *Y. Yucel** (North Wales, United States), *J. Min, Y. Wang, M. Vendetti, Y. Emre, S. Ryan K.*

4485 13:30 – 14:30 Hall 3
Meet-the-Expert

TRN AMR

How antimicrobial tolerance impacts polymicrobial biofilm-associated infections

- 4485-1 13:30 *Hans Steenackers* (Leuven, Belgium)
- 4485-2 13:42 *Brian Conlon* (Chapel Hill, United States)

OS017 13:30 – 14:30 Hall 5
1-hour Case Session

CLN

Bad bacteria

- 00119 **Vancomycin Dependent Enterococci: An evolutionary dead end or the ultimate evolution of a superbug?** *R. Gupta** (London, Canada), *A. Cabrera, A. Kanyua, F. Almutawa, J. Delpont, K. Kavanoor Sridhar*
- 00120 **Whipple's disease: one of medicine's great imitators** *S. Kesevan** (Nottingham, United Kingdom), *F. Heard, E. Hart, V. Fleming, C. Santos, R. Thomson*
- 00121 **Phage Therapy as a Rescue Treatment for Recurrent *Pseudomonas aeruginosa* Bental Infection** *V. Eiferman** (Paris, France), *P.A. Vion, B. Rached, C. Granger, N. Hammoudi, A. Bleibtreu*
- 00122 **A clinical case of *Legionella longbeachae* pneumonia featuring unique epidemiological features in a major Italian hospital** *S. Guerriero** (Rome, Italy), *M. La Sorda, F. De Maio, S. Cardinali, M. Di Donato, P. Del Vecchio, C. Tarli, M. Fantoni, R. Murri, M. Sanguinetti, C. Torti*
- 00123 ***Francisella tularensis* – First autochthonous case in the UK** *G. Vanstone** (Truro, United Kingdom), *A. Belfield, L. Vincent, V. Perks, D. Wadham, B. Marques Silva, A. Evans, O. Lloyd, N.C. Gordon, C. Arumugam, A. Ainarozidou*

S11 13:30 – 17:00 Krievu 1 + 2 room (Courtyard hotel)
Special Session

TAE Day: afternoon round

4628 14:45 – 15:45 Arena 1
Open Forum

PRO

Science communication in a noisy world: podcasting and social media in ID/CM

- 4628-1 14:45 **The ID:IOTS guide to creating a successful CM/ID podcast** *Callum Mutch* (Edinburgh, United Kingdom)
- 4628-2 14:55 **Using social media for CM/ID education** *Tba*
- 4628-3 15:05 **Podcasting and social media for antimicrobial stewardship and pharmacy** *Erin McCreary* (Pittsburgh, United States)

Co-organised with: CMI Communications Board of Editors

4567 14:45 – 15:45 Hall 3
Meet-the-Expert

TRN PHEI

How to use large language models and machine learning for improving One Health

- 4567-1 14:45 *Javier Fernández* (Oviedo, Spain)
- 4567-2 14:57 *Nicolas Radomski* (Teramo, Italy)

Co-organised with: ESCMID Food- and Water-borne Infections Study Group (EFWISG), ESCMID Study Group for Epidemiological Markers (ESGEM), Portuguese Society of Microbiology (SPM)

4331 14:45 – 15:45 Hall 1
Keynote Lecture

PHEI

Defending against dengue: global epidemiology and strategies for prevention and control

4331-1 14:45 *Fernanda Boulos* (São Paulo, Brazil)

OS026 14:45 – 15:45 Hall 11
1-hour Oral Session

CLN ANT AMR

Carbapenem resistance Gram-negatives, what's new in treatment?

- 00180 **Ceftriaxone sulbactam disodium EDTA combination (CSE) as a treatment option for carbapenem resistant gram negative bacilli - to be or not to be?** *Y. Verma** (Hisar, India), *K. Narang, D. Bandlish, C. Sharma*
- 00181 **Sulbactam-durlobactam as an effective alternative option against NDM-producing *Escherichia coli* including cefiderocol and aztreonam-avibactam-resistant isolates in Switzerland** *C. Le Terrier** (Fribourg, Switzerland), *P. Nordmann, A. Delaval, L. Poirel*
- 00182 **Optimising Difficult-to-treat Gram-negative Bacterial Infection Outcomes with Personalised Fosfomycin-Based Combination Therapy Guided by *In vitro* Antibiotic Combination Testing** *T.P. Lim** (Singapore, Singapore), *J.Q.M. Teo, J.J.Y. Ho, T.G. Lee, L.J. Sin, K.K.K. Goh, N. Mohamed Yusoff, W.H.L. Lee, N.G.S. Chua, J.S. Chung, A.L.H. Kwa*
- 00183 **Management of infections caused by ST308 New Delhi metallo- β -lactamase-producing**

ESCMID Global 2025 - Programme

00184 *Pseudomonas aeruginosa* with *in vitro*-guided combination antibiotic therapy. *J.Q. Teo** (Singapore, Singapore), *J.H. Toh, H.Y. Chang, S.H. Tan, W. Lee, T.P. Lim, Y.E. Tan, S.J. Chung, A.L.H. Kwa*

In vitro activity of cefepime/enmetazobactam against clinical isolates of *Enterobacterales* in Portugal: A multicentre retrospective study. *H. Cruz** (Porto, Portugal), *C. Chaves, L. Carneiro*

OS027 **14:45 - 15:45** **Hall 12**

1-hour Oral Session

TRN AMR

Staphylococcus aureus: colonisation, virulence, and persistence

00185 **The nasal microbiome redefines and predicts Staphylococcus aureus nasal colonisation status.** *D. Aggarwal** (London, United Kingdom), *K.L. Bellis, B. Blane, M.C. De Goffau, J. Wagner, D.Y.K. Ng, K.E. Raven, P. Naydenova, S. Kaptoge, R. Henry, C. Perry, M.R. Walker, C. Churcher, S. Girgis, C.R. De Sousa, L. Sarkane, J. Brennan, S. Duthie, E. Johnson, M. Juhasz, S. Irvine, A. McMahon, A. Van Tonder, E. Di Angelantonio, A. Butterworth, J.A. Geoghegan, J. Danesh, J. Parkhill, S.J. Peacock, E. Harrison*

00186 **Development of a Staphylococcus aureus human nasal colonisation model.** *A. Hachani** (Melbourne, Australia), *B. Tran, E. Cho, R. Guerillot, B. Howden, T. Stinear, E. Vincan*

00187 **Selection-free, virulence gene promoter-controlled CRISPR interference system for in vivo pathogenesis study of Staphylococcus aureus - A proof of concept.** *R. Miah** (Tromsø, Norway), *M. Johannessen, M. Kjos, C. Lentz*

00188 **Placebo-controlled study of competitive exclusion using Lactococcus lactis to reduce transmission of LA-MRSA from pigs to humans.** *B. Duim** (Utrecht, Netherlands), *A. Vlasblom, A. Rittscher-Fogg, R. Rattigan, L. Wajda, D. Crespo-Piazuelo, M. Broekhuizen-Stins, L. Portengen, G. Van Eijden, C. Elend, S. Patel, L. Smit, M. Claesson, P. Lawlor, A. Zomer, J. Wagenaar*

00189 **Rifampicin-induced Staphylococcus aureus persister formation is driven by CodY and oxidative stress level.** *N. Pordone** (Lyon, France), *J. Guillemot, K. Rodriguez, N. Personnic, E. Botelho-Nevers, P. Verhoeven*

4329 **14:45 - 15:45** **Hall 13**

1-hour Symposium

IPC

Value-based syndromic diagnostics in medical microbiology: Pro / Con debate

Chairs *Hege Vangstein Aamot (Lørenskog, Norway)*
Eric Claas (Leiden, Netherlands)

4329-1 **14:45** **Pro: clinical benefit and potential for improved patient outcomes.** *Kirstine K. Søgaard (Aalborg, Denmark)*

4329-2 **15:15** **Con: limitations, costs, and possible overuse of syndromic panels.** *Gilbert Greub (Lausanne, Switzerland)*

Co-organised with: ESCMID Study Group for Genomic and Molecular Diagnostics (ESGMD), Société de Pathologie Infectieuse de Langue Française

4261 **14:45 - 15:45** **Hall 14**

1-hour Symposium

IPC

We need to talk about toilets...

Chairs *Stephanie J. Dancer (Glasgow, United Kingdom)*
Juliette Severin (Rotterdam, Netherlands)

4261-1 **14:45** **Infection risks from sanitation engineering.** *Davey*

Jones (Bangor, United Kingdom)

4261-2 **15:15** **Ventilation in toilets: how can we improve it?** *Michael Gormley (Edinburgh, United Kingdom)*

Co-organised with: ESCMID Food- and Water-borne Infections Study Group (EFWISG), ESCMID Study Group for Legionella Infections (ESGLI)

OS028 **14:45 - 15:45** **Hall 15**

1-hour Oral Session

DX

Unlocking the potential of the human microbiome for clinical diagnostics

00190 **Deep learning-enhanced wellness scores: Advancing gut microbiome-based health predictions.** *O.U. Nalbantoglu** (Kayseri, Türkiye), *A. Gundogdu, B.H. Ermis*

00191 **Comparison of Second-Generation and Third-Generation Sequencing technologies for 16S rRNA amplicon-based gut microbiome analysis.** *E. Rubio-Garcia** (Barcelona, Spain), *A. Pulgarin, R. Lopez-Aladid, L. Martinez-Priego, N. Palau, A. Mendoza, R. Isanta, A. Montalban, J.L. Villanueva-Cañas, M.M. Montero, M. Sanduzzi, M. Reig, C. Casals-Pascual*

00192 **Donor for fecal microbiota transplantation: a challenging research.** *B.S. Orena** (Milan, Italy), *M.F. Liporace, A. Maraschini, D. Girelli, D. Pizzotti, E. Petrillo, C. Alteri, C. Amoroso, F. Caprioli, A. Callegaro, L. Cariani*

00193 **Antibiotic resistance genes diversity and antimicrobial effects in the vaginal microbiome during pregnancy.** *N. Boutouchent** (Rouen, France), *S. Kennedy*

00194 **Distinct gut microbiota and metabolic profiles in brain tumor patients: Bridging microbial insights to CNS oncology.** *A. Gundogdu** (Kayseri, Türkiye), *O.U. Nalbantoglu, M. Ulgen, M.A. Sav, G. Ekinci, H.F. Kelestemur, U. Ture*

4376 **14:45 - 15:45** **Hall 16**

Meet-the-Expert

CLN ANT

Untangling the web: antimicrobial dose adjustments in renal impairment

4376-1 **14:45** *Claire Roger (Nimes, France)*

4376-2 **14:57** *Isabel Spriet (Leuven, Belgium)*

Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG), ESCMID Study Group for Critically Ill Patients (ESGCIP)

4445 **14:45 - 15:45** **Hall 2**

1-hour Symposium

CLN ANT

Macrolides in community-acquired pneumonia: therapeutic necessity or path to overuse?

Chairs *Marc J.M. Bonten (Utrecht, Netherlands)*
Karin Thursky (Carlton, Australia)

4445-1 **14:45** **Pro: maximising outcomes with evidence-based use.** *Evangelos Giamarellos-Bourboulis (Athens, Greece)*

4445-2 **15:15** **Con: the risks of routine (over)use.** *Aurélien Dinh (Garches, France)*

4566 **14:45 - 15:45** **Hall 4**

1-hour Symposium

VAX

Top papers in transplant ID

Chairs *Malgorzata Mikulska (Genoa, Italy)*
Nicolas Mueller (Zurich, Switzerland)

ESCMID Global 2025 - Programme

| | | |
|--------|-------|--|
| 4566-1 | 14:45 | Top 10 papers in infections in SOT <i>Patricia Munoz (Madrid, Spain)</i> |
| 4566-2 | 15:15 | Top 10 paper in infections in HCT and cellular therapy <i>Joshua Hill (Seattle, United States)</i> |

| | | |
|-------|---------------------|--------|
| OS025 | 14:45 – 15:45 | Hall 5 |
| | 1-hour Oral Session | |

DX IPC

Bacterial battles: a paediatric perspective on infections and interventions

| | |
|-------|--|
| 00175 | Strong Alignment Between National Standard Treatment Guidelines and WHO AWaRe Book Recommendations for Primary Care Paediatric Infections <i>D. Dona* (Padua, Italy), G. Brigadoi, A. Cantarutti, M. Masetti, G. Autore, S. Mathur, M. Sharland, S.M.R. Esposito</i> |
| 00176 | Correlation between antibiotic consumption and digestive colonization with multidrug-resistant <i>Enterobacteriales</i> in a paediatric haematology department <i>S. Frigui* (Tunis, Tunisia), N. Fitouri, Y. Chebbi, I. Fezaa, M. Ouederni, C. Drira, W. Achour</i> |
| 00177 | Interleukin-6 as a diagnostic biomarker for sepsis in neonates, children and pregnant women – a real-world cohort study <i>S.O. Whelan* (Dublin, Ireland), M. Eogan, N. McCallion, A. Walsh, F. Moriarty, M. Elsammak, R. Drew</i> |
| 00178 | Impact of rapid diagnostic stewardship interventions to reduce blood culture utilization in a pediatric medical center <i>E. Vaugon* (Los Angeles, United States), C. Costales, T. Barter, L. Posch, E. Orgel, J. Dien Bard</i> |
| 00179 | Infective endocarditis: A Decade of Experience at a Tertiary Pediatric Care Centre <i>M. De Luca* (Rome, Italy), R. Iacobelli, S. Samperi, S. Mercadante, L. Romani, L. Ragni, P. Bruno, G. Brancaccio, F.I. Calò Carducci, P. Bernaschi, A. Rizza, L. Lancella, L. Galletti</i> |

| | | |
|------|----------------------------|---------|
| 4206 | 16:15 – 18:15 | Hall 15 |
| | 2-hour Educational Session | |

PRO

The rare art of writing scientific articles: from conception to submission

Chairs *Marlieke De Kraker (Geneva, Switzerland)*
Mical Paul (Haifa, Israel)

| | | |
|--------|-------|--|
| 4206-1 | 16:15 | Expressing yourself correctly: writing tips <i>Angela Huttner (Geneva, Switzerland)</i> |
| 4206-2 | 16:35 | Constructing your manuscript for an original article <i>Jesús Rodríguez-Baño (Seville, Spain)</i> |
| 4206-3 | 16:55 | The use of artificial intelligence tools for writing articles: what to do and not to do <i>Erlangga Yusuf (Rotterdam, Netherlands)</i> |
| 4206-4 | 17:15 | Selecting the best journal for my manuscript <i>Andre Kalil (Omaha, United States)</i> |

Co-organised with: CMI Board of Editors

| | | |
|------|------------------|---------|
| 4733 | 16:15 – 18:15 | Hall 16 |
| | 2-hour Symposium | |

TRN

Controlled human infection models

Chairs *Frederick Hayden (Charlottesville, United States)*
Nikolai Siemens (Greifswald, Germany)

| | | |
|--------|-------|--|
| 4733-1 | 16:15 | Updates on the dengue human infection model <i>Kirsten Lyke (Baltimore, United States)</i> |
| 4733-2 | 16:45 | Controlled human infection models of streptococcal pharyngitis <i>Tba</i> |
| 4733-3 | 17:15 | Controlled human infection models of parasitic infections <i>Meta Roestenberg (Leiden, Netherlands)</i> |
| 4733-4 | 17:45 | Controlled human infection models of non-typhoidal <i>Salmonella</i> <i>Malick Gibani (London, United Kingdom)</i> |

Co-organised with: British Infection Association (BIA)

| | | |
|------|------------------|---------|
| 4630 | 16:15 – 18:15 | Hall 11 |
| | 2-hour Symposium | |

PHEI

STIs: an ongoing crisis

Chairs *Dagmar Heuer (Berlin, Germany)*
Tba

| | | |
|--------|-------|--|
| 4630-1 | 16:15 | STI treatment options are running out due to AMR <i>Magnus Unemo (Örebro, Sweden)</i> |
| 4630-2 | 16:45 | Genomic surveillance of <i>Neisseria gonorrhoeae</i> strains <i>Petra Wolffs (Maastricht, Netherlands)</i> |
| 4630-3 | 17:15 | Evolutionary insights into syphilis and <i>Treponema pallidum</i> <i>Mathew Beale (Cambridgeshire, United Kingdom)</i> |
| 4630-4 | 17:45 | Challenges in chlamydial STI infections <i>Cecile Bebear (Bordeaux, France)</i> |

Co-organised with: Deutsche Gesellschaft für Hygiene und Mikrobiologie

| | | |
|------|------------------|---------|
| 4416 | 16:15 – 18:15 | Hall 12 |
| | 2-hour Symposium | |

CLN DX VAX

Tick-borne encephalitis: contemporary diagnosis and management

Chairs *Joanna Maria Zajkowska (Białystok, Poland)*
Dace Zavadzka (Rīga, Latvia)

| | | |
|--------|-------|--|
| 4416-1 | 16:15 | Tick-borne encephalitis: immune response and clinical experience <i>Sara Gredmark Russ (Stockholm, Sweden)</i> |
| 4416-2 | 16:45 | TBE immune responses and vaccine effectiveness <i>Karin Stiasny (Vienna, Austria)</i> |
| 4416-3 | 17:15 | NS1 antibodies: diagnostics and screening of seroprevalence of TBE virus infection <i>Gerhard Dobler (Munich, Germany)</i> |
| 4416-4 | 17:45 | Treatment for TBE: where do we stand? <i>Daniel Ruzek (Brno, Czech Republic)</i> |

| | | |
|-------|---------------------|---------|
| OS032 | 16:15 – 18:15 | Hall 14 |
| | 2-hour Oral Session | |

CLN DX PHEI

Unraveling respiratory viruses, 2025

| | |
|-------|--|
| 00222 | Human metapneumovirus infections in hospitalized adults compared to respiratory syncytial virus and influenza infections over ten years in France <i>P. Loubet* (Nîmes, France), S. Guittou, R. Simon, L. Lefrancois, L.B. Luong Nguyen, P. Vanhems, F. Laine, F. Galtier, X. Duval, B. Lina, M. Valette, G. Lagathu, V. Foullogne, N. Houhou-Fidhou, A.S. L'honneur, F. Carrat, L. Meyer, C. Durier, O. Launay</i> |
| 00223 | Unveiling animal susceptibility to influenza viruses (H1N1(pdm09) and H5N1 HPAIV) using animal-derived respiratory organoids <i>F. Tarrés-Freixas* (Bellaterra, Spain), G. Ceada, N. Navarro, M. Pérez-Simó, N. Carmona-Vicente, L. Bonillo-Lopez, A. Moreno, C. López, J. Segalés, N. Majó, K. Kochanowski, J. Vergara-Alert</i> |
| 00224 | Exploring the impact of acute lung hypoxia on CD8 T cell phenotypes following severe influenza infection <i>B. Huckestein* (Memphis, United States), P. Thomas</i> |
| 00225 | Virological characterisation of RSV after Nirsevimab Breakthrough Infections in a Multicentre Observational Real-world Study in France <i>S. Fourati* (Créteil, France), A. Reslan, J. Bourret, Y. Rahou, L. Chollet, S. Pillet, P. Tremaux, N. Candace Dossou, E. Gault, M. Salmona, B.M. Imbert, A. Mirand, S. Larrat, A. Moisan, S. Marot, A. Schnuriger, N. Veyrenche, I. Engelmann, L. Handala, A. Henry, V. Stephan, S. Brichler, V. Avettand-</i> |

ESCMID Global 2025 - Programme

| | | | |
|-------|--|---|--|
| | | <i>Fenoel, N. Zemali, C. Lefeuvre, C. Pronier, L. Deroche, M.C. Jaffar, L. Mouna, C. François, A. Regueme, C. Hartard, S. Roger, F. Gallais, A. Ly, C. Rodríguez, G. Dos Santos, J. Buchrieser, O. Schwartz, J.M. Pawlotsky, F. Lemoine, E. Audureau, M.A. Rameix-Welti</i> | |
| 00226 | | Baseline immunity to highly pathogenic avian influenza viruses in a healthcare worker cohort. <i>C. Geurtsvankessel* (Rotterdam, Netherlands), M. Power, W. Rijnink, L. Gommers, T. Bestebroer, W. Soochit, W. Tan, B. Verstrepen, S. Bogers, G. Van Nierop, R. Sikkema, A. Grifoni, A. Sette, M. Koopmans, R. Fouchier, M. Richard, R. De Vries</i> | |
| 00227 | | Impact of reinfection on post-acute sequelae of COVID-19 over multi-organ systems. <i>J.Y.J. Tan* (Singapore, Singapore), J.T. Lim, L.E. Wee, C.J. Chiew, B. Ong, D.C.B. Lye</i> | |
| 00228 | | Clinical and economic burden of respiratory syncytial virus in adults with acute respiratory infections – a Danish nationwide cohort study. <i>S. Bratkovic* (Copenhagen, Denmark), Y. Çolak, M. Helleberg, M.J. Fonseca, S. Bratković, N. Vestergaard Dich, M. Pedersen, M. Kany, T. Pliakas, R. Reeves, A. Marijam</i> | |
| 00229 | | The burden of respiratory syncytial virus in children <3 years old presenting to primary, secondary and tertiary care in England: report from the STOP RSV prospective surveillance study. <i>E. Carter* (Liverpool, United Kingdom), H. Hill, D.M. Ferreira, A. Collins, C. Solórzano, L. Mclellan, L. Kerruish, F. Fyles, S. Drysdale, P. Gonzalez-Dias, G. Duncan, K. Davies, P. Crozier, P. Saunderson, R. Kramer, M. Bangert, N. Vassilouthis, S. Messahel, B. Caroline, S. Brearey, J. Bernatoniene, S. Bhowmik, J. Perry, P. Mottram, P. Mcnamara, D. Lewis, N. Van Kinnekan, A. Finn</i> | |
| 00230 | | Targeted metagenomic sequencing of influenza, RSV, and symptomatic respiratory infections from UK healthcare workers. <i>M. Knoll* (Hinxton, United Kingdom), L. Findlater, B. Katie, J. Wagner, T. Diego, D. Rajan, S. Frances Field, S. Thurston, A. Wong, B. Hyatt, N. Thesin, J. Robinson, R. Yeadon, A. Galvin, B. Blane, Y.L. Huang, K. Howe, M. Forbes, K. Figueroa, F. Schwach, S. Stott, A. Marhino, A. Frick-Kretschmer, B. Dave, T. Maddison, S. Hopkins, S. Foulkes, J. Islam, A. Atti, V. Hall, E. Harrison</i> | |
| 00231 | | Can changes in vital signs differentiate respiratory viruses in care home residents? <i>J. Rudolph* (Providence, United States), N. Bhaskar, F. Devone, K. Mcconeghy, C. Halladay, Y. Abul, S. Gravenstein</i> | |

| | | | |
|------|---------------|------------------|--------|
| 4562 | 16:15 – 18:15 | | Hall 2 |
| | | 2-hour Symposium | |

PK/PD to avoid emergence of resistance?

Chairs Anne-Grete Mårtson (Leiden, Netherlands)
Joseph Meletiadis (Athens, Greece)

| | | |
|--------|-------|--|
| 4562-1 | 16:15 | PK/PD and antibacterial therapy <i>Dolors Soy-Muner (Barcelona, Spain)</i> |
| 4562-2 | 16:45 | PK/PD and antifungal therapy <i>Roger Brüggemann (Nijmegen, Netherlands)</i> |
| 4562-3 | 17:15 | PK/PD and antiviral therapy <i>Joe Standing (London, United Kingdom)</i> |
| 4562-4 | 17:45 | PK/PD considerations in anthelmintic treatment <i>Jennifer Keiser (Allschwil, Switzerland)</i> |

| | | | |
|------|---------------|----------------------------|--------|
| 4520 | 16:15 – 18:15 | | Hall 3 |
| | | 2-hour Educational Session | |

Malaria: when the drugs don't work Management of treatment failure in non-endemic countries

Chairs Laura Nabarro (London, United Kingdom)
Tba

| | | |
|--------|-------|--|
| 4520-1 | 16:15 | Malaria in the non-endemic setting: who to treat as |
|--------|-------|--|

an outpatient and how to detect treatment failure
Emmanuel Bottieau (Antwerp, Belgium)

| | | |
|--------|-------|---|
| 4520-2 | 16:35 | Malaria resistance mutations in the non-endemic setting: role of genomic surveillance <i>Anna Rosanas Urgell (Antwerp, Belgium)</i> |
|--------|-------|---|

| | | |
|--------|-------|--|
| 4520-3 | 16:55 | How to manage <i>Plasmodium Knowlesi</i> infection <i>Giri Shan Rajahram (Kota Kinabalu, Malaysia)</i> |
|--------|-------|--|

| | | |
|--------|-------|---|
| 4520-4 | 17:15 | Epidemiology and control of <i>Plasmodium Knowlesi</i> <i>Kimberly Fornace (Singapore, Singapore)</i> |
|--------|-------|---|

Co-organised with: British Infection Association (BIA)

| | | | |
|------|---------------|------------------|--------|
| 4717 | 16:15 – 18:15 | | Hall 4 |
| | | 2-hour Symposium | |

Gram-positives, are they still going?

Chairs Diederik Bathoorn (Groningen, Netherlands)
Tba

| | | |
|--------|-------|---|
| 4717-1 | 16:15 | The vanco chronicles: enterococci's global journey <i>Guido Werner (Wernigerode, Germany)</i> |
|--------|-------|---|

| | | |
|--------|-------|---|
| 4717-2 | 16:45 | Pitfall in susceptibility testing of Gram-positives <i>Helena Zemlickova (Prague, Czech Republic)</i> |
|--------|-------|---|

| | | |
|--------|-------|---|
| 4717-3 | 17:15 | Drivers for daptomycin and linezolid resistance in Gram-positives <i>Glen Carter (Melbourne, Australia)</i> |
|--------|-------|---|

| | | |
|--------|-------|---|
| 4717-4 | 17:45 | What is new in treatment against MDR Gram-positives? <i>Alex Soriano (Barcelona, Spain)</i> |
|--------|-------|---|

| | | | |
|------|---------------|------------------|--------|
| 4363 | 16:15 – 18:15 | | Hall 5 |
| | | 2-hour Symposium | |

Biomarker testing to manage respiratory infections in primary care in low resource settings

Chairs Sonia Lewycka (Hanoi, Vietnam)
Heiman Wertheim (Nijmegen, Netherlands)

| | | |
|--------|-------|--|
| 4363-1 | 16:15 | The Vietnamese experience with CRP testing in the community setting <i>Thi Thuy Nga Do (Ha Noi, Vietnam)</i> |
|--------|-------|--|

| | | |
|--------|-------|--|
| 4363-2 | 16:45 | The Nigerian experience with CRP testing in the community setting <i>Augustine Onwunduba (Awka, Nigeria)</i> |
|--------|-------|--|

| | | |
|--------|-------|---|
| 4363-3 | 17:15 | CRP testing in diagnosing tuberculosis in Zambia and South Africa <i>Helen Ayles (Lusaka, Zambia)</i> |
|--------|-------|---|

| | | |
|--------|-------|---|
| 4363-4 | 17:45 | The health economics of CRP testing in LMICs <i>Yoel Lubell (Bangkok, Thailand)</i> |
|--------|-------|---|

Sunday, 13 April 2025

| | | | |
|------|---------------|------------------|---------|
| 4387 | 08:30 – 10:30 | | Hall 15 |
| | | 2-hour Symposium | |

Diphtheria: from re-emergence to vaccine strategies

Chairs Tba
Julie Toubiana (Paris, France)

| | | |
|--------|-------|---|
| 4387-1 | 08:30 | Diphtheria: from clinical picture to medical management <i>Regina Oladokun (Oyo, Nigeria)</i> |
|--------|-------|---|

| | | |
|--------|-------|--|
| 4387-2 | 09:00 | The epidemiology of diphtheria worldwide over the last half-century: more than one comeback <i>Andreas Hofer (Solna, Sweden)</i> |
|--------|-------|--|

| | | |
|--------|-------|---|
| 4387-3 | 09:30 | There's more than one toxigenic <i>Corynebacterium</i>: the current genomics landscape of diphtheria-associated strains <i>Sylvain Brisse (Paris, France)</i> |
|--------|-------|---|

| | | |
|--------|-------|---|
| 4387-4 | 10:00 | Diphtheria vaccination: a reappraisal <i>Gayatri Amirthalingam (London, United Kingdom)</i> |
|--------|-------|---|

Co-organised with: ESCMID Study Group for Epidemiological Markers (ESGEM), ESCMID Vaccine Study Group (EVASG)

ESCMID Global 2025 - Programme

4345 08:30 - 10:30 Hall 11

2-hour Educational Session

CLN DX

New guidelines for management of brain infections

Chairs Jacob Bodilsen (Aalborg, Denmark)
Kartika Maharani (Jakarta, Indonesia)

4345-1 08:30 Tuberculous meningitis: what can we learn from the first global guidelines? Joseph Donovan (Ho Chi Minh City, Vietnam)

4345-2 08:50 WHO guidelines on bacterial meningitis: change of clinical practice? Tba

4345-3 09:10 ESCMID encephalitis guidelines 2024: what's new? Tom Solomon (Liverpool, United Kingdom)

4345-4 09:30 WHO guidelines for cryptococcal meningitis: success stories and barriers to implementation Nelesh Govender (Johannesburg, South Africa)

Co-organised with: ESCMID Study Group for Infectious Diseases of the Brain (ESGIB)

4721 08:30 - 10:30 Hall 12

2-hour Symposium

ANT AMR

Proxy indicators: bridging the gap between surveillance and antimicrobial stewardship

Chairs Bhanu Sinha (Groningen, Netherlands)
Tba

4721-1 08:30 A broad spectrum of possibilities: spectrum scores as a unifying metric Céline Pulcini (Nancy, France)

4721-2 09:00 Proxy indicators to estimate appropriateness of antibiotic prescriptions Diane Ashiru-Oredope (London, United Kingdom)

4721-3 09:30 How to bridge the gap between surveillance and antimicrobial stewardship Mark G. J. De Boer (Leiden, Netherlands)

4721-4 10:00 Health economics, surveillance and antimicrobial stewardship Zhu Nina Jiayue (London, United Kingdom)

Co-organised with: Dutch Committee on Antimicrobial Policy, ESCMID Education Subcommittee, International Society for Infectious Diseases (ISID)

4728 08:30 - 10:30 Hall 13

2-hour Symposium

CLN IPC

Difficile to treat: advanced management strategies in difficult to treat CDI

Chairs Frédéric Barbut (Paris, France)
Kerrie Davies (Leeds, United Kingdom)

4728-1 08:30 Severe CDI: when standard protocols fail Hynek Bartos (Prague, Czech Republic)

4728-2 09:00 Therapies for complicated CDI Emma Jane Bishop (Melbourne, Australia)

4728-3 09:30 Recurrent CDI: Breaking the cycle Andrea Marino (Catania, Italy)

4728-4 10:00 Live biotherapeutic products for *Clostridioides difficile* infection Simon Goldenberg (London, United Kingdom)

Co-organised with: ESCMID Study Group for *Clostridioides difficile* (ESGCD)

OS038 08:30 - 10:30 Hall 14

2-hour Oral Session

DX AMR

Making fast for making better: AMR rapid diagnostics

00278 Point of care rapid lateral flow antibiotic resistance test to detect carbapenem resistance in lower respiratory tract infections S. Owen* (Bedford, United Kingdom), A. Gregg, Q. Liu, C. Chen, M. Edward, S. Jiang, W. Lu, L. Mynheer, W. Finch

00279 Evaluation of a new rapid Lateral flow immunoassay for the detection of DHA-producing Gram-negative bacteria C. Moguet* (Guipry, France), S. Oueslati, A. Vogel, S. Gelhaye, A. Chalin, H. Volland, T. Naas

00280 The NitroSpeed Taniborbactam NP test; easy detection of β -lactamase sensitivity to taniborbactam O. Raro* (Fribourg, Switzerland), S. Herrera-Espejo, M. Bouvier, A. Kerbol, L. Poirel, P. Nordmann

00281 Rapid detection of β -lactamase-mediated resistance to aminopenicillins from urines P. Nordmann* (Fribourg, Switzerland), N. Helsen, C. Duployez, L. Poirel, R. Dessein

00282 Rapid detection of antibiotic resistance in direct urine samples M. Bot* (Arnhem, Netherlands), J. Flipse, S. Bongers, J. Hoogerwerf, J. Ten Oever, H. Wertheim, M. Van Meer

00283 Next-Generation Utilizer Dipsticks for direct-from-sample phenotypic Antibiotic Susceptibility Testing in UTIs E. Iseri* (Stockholm, Sweden), W. Van Der Wijngaart, V. Özenci, R. Santini, A. Nakama, O. Ekelund, A. Van Belkum

00284 Screening for ceftriaxone-resistant *Neisseria gonorrhoeae* with the Urogenital and Resistance kit (AusDiagnostic) A. Braille* (Paris, France), M. Mainardis, F. Meunier, M. Mathar, M. Méricmèche, B. Condamine, F. Caméléna, B. Bercot

00285 Comparative evaluation of rapid antimicrobial susceptibility testing assays for Gram-negative bacteria from positive blood cultures D. Squitieri* (Rome, Italy), G. Menchinelli, C. Magri, T. D'inzeo, M. Cacaci, B. Posteraro, G. De Angelis, M. Sanguinetti

00286 Rapid detection of Carbapenemases directly from positive blood culture bottle: A tool for early shifting from empirical to targeted therapy K. Chaudhary* (Delhi, India), H. Gautam, P. Batra, S. Mohapatra, S. Sood, B. Dhawan, B. Das Kumar

00287 The impact of an updated rapid diagnostic platform on antimicrobial stewardship interventions K. Phe* (Houston, United States), R. Huynh-Phan, K. Le, Y. Xiao, T. Lasco, A. Zidar, V. Tam

4244 08:30 - 10:30 Hall 16

2-hour Symposium

AMR

AMR Surveillance in low resource countries: insights into clinical and policy translation

Chairs Kwame Ohene Buabeng (Ho, Ghana)
H. Rogier Van Doorn (Hanoi, Vietnam)

4244-1 08:30 New indicators in national monitoring and evaluation of AMR supported by improved data utilisation Direk Limmathurotsakul (Bangkok, Thailand)

4244-2 09:00 Interdisciplinary investigation of the drivers and burden of AMR in urinary tract infections Stephen Mshana (Mwanza, Tanzania, United republic of)

4244-3 09:30 A clinically-oriented AMR surveillance network: case-based surveillance and implementation Paul Turner (Siem Reap, Cambodia)

4244-4 10:00 National prescribing guidelines based on AMR surveillance data Vilada Chansamouth (Vientiane, Lao People's democratic republic)

Co-organised with: CAESAR network, ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS)

4731 08:30 - 10:30 Hall 2

2-hour Educational Session

CLN DX

New tools in acute bacterial infections and sepsis: from machine learning to precision medicine

Chairs Benjamin Mcfadden (Perth, Australia)

ESCMID Global 2025 - Programme

Rita Murri (Rome, Italy)

- 4731-1 08:30 Differentiating acute infection, sepsis and sepsis mimics in the ED? *Lisa Mellhammar (Lund, Sweden)*
- 4731-2 08:50 Machine learning for early recognition of sepsis *Karsten Borgwardt (Martinsried, Germany)*
- 4731-3 09:10 How to avoid common mistakes in randomised clinical study design *Mo Yin (Singapore, Singapore)*
- 4731-4 09:30 Improved clinical trials in community-acquired pneumonia using precision medicine *Lennie Derde (Utrecht, Netherlands)*

Co-organised with: ESCMID Scientific Affairs Subcommittee, European Clinical Research Alliance on Infectious Diseases (ECRAID), ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES), European Sepsis Alliance (ESA), ESCMID Study Group for Antimicro

4653 08:30 - 10:30 Hall 3

2-hour Symposium

VAX PHEI

Tackling the emergence of dengue and other *Aedes*-borne diseases in Europe

Chairs Martin P. Grobusch (Amsterdam, Netherlands)
Tba

- 4653-1 08:30 How dengue, chikungunya and zika virus disease became emerging threats to Europe *Celine Gossner (Solna, Sweden)*
- 4653-2 09:00 Surveillance of dengue in urbanised tropical regions *Vincent Junxiong Pang (Singapore, Singapore)*
- 4653-3 09:30 Mosquito surveillance and control: opportunities and challenges *Tba*
- 4653-4 10:00 Prospects for dengue, chikungunya and zika virus vaccines *Tba*

Co-organised with: European Centre for Disease Prevention and Control (ECDC)

4423 08:30 - 10:30 Hall 4

2-hour Educational Session

DX

Implementing metagenomics in my lab and mistakes to avoid

Chairs Hege Vangstein Aamot (Lørenskog, Norway)
Claudio Neidhöfer (Bonn, Germany)

- 4423-1 08:30 Is metagenomics right for my lab? *Paula Mölling (Örebro, Sweden)*
- 4423-2 08:50 Understanding the experimental and certification aspects of metagenomics *Mads Albertsen (Aalborg, Denmark)*
- 4423-3 09:10 Navigating tools, techniques, and procurement *Basil Britto Xavier (Groningen, Netherlands)*
- 4423-4 09:30 Setting realistic goals and outcomes for metagenomics integration *Claire Bertelli (Lausanne, Switzerland)*

Co-organised with: Danish Society for Clinical Microbiology, ESCMID Study Group for Genomic and Molecular Diagnostics (ESGMD), Trainee Association of ESCMID (TAE) Steering Committee

OS037 08:30 - 10:30 Hall 5

2-hour Oral Session

DX IPC

Whole genome sequencing: tracking transmission and reservoirs in outbreaks

- 00268 From outbreaks to outcomes: Harnessing WGS for IPC in a high-risk paediatric setting *N. Storey* (London, United Kingdom), E. Cloutman-Green, J. Hartley, H. Dunn, B. Brekle, M. Adil, S. Barua, J.*

Hatcher, J. Brown, J. Breuer

- 00269 Why do routine genome-oriented surveillance for *Pseudomonas aeruginosa*? *A. Rath* (Regensburg, Germany), L. Grancicova, B. Kieninger, A. Caplunik-Pratsch, J. Fritsch, A. Eichner, W. Schneider-Brachert*

- 00270 TreeTime estimation depicts transmission dynamics of clinical and environmental *Pseudomonas aeruginosa* from common reservoirs in healthcare environment through whole genome sequencing (WGS) *Ö. Yetis* (London, United Kingdom), Ö. Yetiş, F. Dyrkell, S. Ali, P. Wilson*

- 00271 Understanding *Serratia* transmission during a neonatal ICU outbreak: A combined genotyping and risk factor analysis *K. Jaakkola* (Lyon, France), C. Dananché, A. Fischer, J.C. Picaud, P. Cassier, M. Colomb-Cotinat, S. Hays, J.P. Rasigade*

- 00272 Genomic Insights into the Regional Transmission of KPC-Producing Bacteria: Clonal and Non-Clonal Plasmid Sharing *C. Shankar* (Ann Arbor, United States), A.M. Pirani, D.B. Narayanan, B. Brennan, S. Mcnamara, A. Miles-Jay, A. Bahr, E.S. Snitkin*

- 00273 Genome-oriented analysis of the first outbreaks involving the novel *Serratia sarumani* at a neonatal unit *A. Rath* (Regensburg, Germany), B. Kieninger, L.J. Klages, A. Eichner, A. Keller-Wackerbauer, S.M. Wellmann, A. Ambrosch, J. Fritsch, A. Caplunik-Pratsch, M. Kabesch, J. Kalinowski, W. Schneider-Brachert*

- 00274 Evaluating the Utility of Whole-Genome Sequencing to Optimise Infection Prevention and Control in a Hospital Setting: Findings from the GENOTIPE Study *I. Sey* (Brighton, United Kingdom), A. Yeoh, D. Wlazly, A. Davies, O. Mankanjuola, J. Leach, S. Mookerjee, M. Krutikov, J. Price*

- 00275 Outbreak of Carbapenem-Resistant *Acinetobacter seifertii* in a Neonatal Intensive Care Unit: Genomic Characterization and Surveillance *D. Pereira* (Porto Alegre, Brazil), P. Barth, L. Konkewicz, W. Latosinski, G. De Oliveira, L. Lutz, M. Mott, C. Constante, C. Wilhelm, L. Antochewis, R. Paiva, K. Tragnago, A. Barth, A. Martins*

- 00276 Unveiling the Clonal Dynamics and transmission mechanism of Carbapenem-Resistant *Klebsiella pneumoniae* in the ICU environment *X. Han* (Hangzhou, China), J. Zhou, Y. Jiang, Y. Yu*

- 00277 Survey of Infection Prevention staff perception of WGS integration into routine IPC practice *D. Ling* (Melbourne, Australia), B. Baral, V. Madigan*

4616 09:30 - 10:30 Hall 1

Keynote Lecture

VAX

Infections after Solid organ transplantation: past, present and future

Chairs Nina Khanna (Basel, Switzerland)
Priscilla Rupali (Vellore, India)

- 4616-1 09:30 Jay Fishman (Boston, United States)

4747 11:00 - 12:00 Arena 1

Open Forum

PRO

European CM/ID exam: going forward

Chair Siri Goepel (Tuebingen, Germany)

- 4747-1 11:00 View from medical microbiology *Maeve Doyle (Waterford, Ireland)*
- 4747-2 11:10 view from infectious diseases *Eoghan De Barra (Dublin, Ireland)*
- 4747-3 11:20 view from trainees (TAE) *Christian Kraef (Copenhagen, Denmark)*
- 4747-4 11:30 European exam - how to prepare? *Annelies Verbon (Bosch En Duin, Netherlands)*

Co-organised with: ESCMID Education Subcommittee, ESCMID Professional Affairs Subcommittee, UEMS Section of Medical Microbiology, UEMS Section

ESCMID Global 2025 - Programme

of Infectious Diseases

4223 11:00 – 12:00 Hall 6

1-hour Symposium

PHEI PRO

How to address anti-science in our community?

Chairs Tyra Grove Krause (Copenhagen, Denmark)
Tba

4223-1 11:00 **The rise of anti-science: lessons for the future scientist** Marion Koopmans (Rotterdam, Netherlands)

4223-2 11:30 **Open science for public trust** Lisa Hansen (Ottawa, Canada)

4210 11:00 – 12:00 Hall 1

Keynote Lecture

ANT AMR

The new frontiers in antimicrobial stewardship

Chairs Jose Ramon Pano-Pardo (Zaragoza, Spain)
Jeroen Schouten (Nijmegen, Netherlands)

4210-1 11:00 Karin Thursky (Carlton, Australia)

4589 11:00 – 12:00 Hall 10

1-hour Symposium

CLN

Sleeping sickness and Chagas: a tale of the two trypanosomes

Chairs Hanne Brekke (Oslo, Norway)
Irene Losada Galvan (Barcelona, Spain)

4589-1 11:00 **Human African Trypanosomiasis: recent diagnostic and medical practices** Jean-Mathieu Bart (Conakry, Guinea)

4589-2 11:30 **American Trypanosomiasis: Diagnosis, screening and management** Tba

Co-organised with: ESCMID Study Group for Clinical Parasitology (ESGCP)

OS047 11:00 – 12:00 Hall 11

1-hour Oral Session

CLN

Clinical studies in UTI

00344 **Short versus long antibiotic treatment for pyelonephritis and complicated UTIs: an updated systematic review and meta-analysis of RCTs.** Zahavi* (Haifa, Israel), D. Kunwar, J. Olchowski, H. Dallahseh, M. Paul

00345 **Antibiotic treatment duration of complicated urinary tract infection patients in Europe: results from the Ecrad POS-cUTI study** C.K.A.R. Kats* (Utrecht, Netherlands), J.M. Bravo-Ferrer, T.T. Doeschate, P.D. Van Der Linden, P. Martinez, O. Awwad, E. Rubio, P. Clevenbergh, A. Barac, A. Cano, E. Merino, P. Andrade, L. Jacquin, B. Koprivica, R. Espindola, P. Muñoz, T. Lafon, M. Mendris, J. Van Laethem, D. Vigliano, A. Ternhag, J. Rupp, A. Hernandez-Torres, D. Chadwick, B. Carevic, M.J.M. Bonten, E. Tacconelli, J. Rodriguez-Baño

00346 **Prevalence and impact of multidrug resistance in a cohort of patients admitted to emergency department for urinary tract infections: the UTILITY study, a prospective multicentre study** L. Onorato* (Naples, Italy), E. Allegorico, M. Macera, C. Monari, B. Migliaccio, F.G. Numis, C. Nasta, M.T. Florio, R. Sciorio, G. Guiotto, M. Giordano, R. Raucci, F. Dello Vicario, R. Nasti, A. Voza, N. Coppola

00347 **Weekly sequential antibioprophyllaxis for UTI in neurogenic bladder** R. Calin* (Paris, France), C.

Chesnel, C. Hentzen, M. Teng, F. Le Breton, V. Phe, F. Adda, C. Palacios, G. Amarenco, G. Pialoux

00348 **Evidence for the duration of antibiotic therapy for chronic bacterial prostatitis: a systematic review** L. Cordes* (Geneva, Switzerland), A. Huttner, R. Calin, K. Gupta, M. Lafaurie, M. Lambregts, V. Lavergne, B. Trautner

OS048 11:00 – 12:00 Hall 12

1-hour Oral Session

CLN AMR

Complexities of infections in solid organ transplantation

00349 **Solid Organ Transplants from donors with positive blood cultures: watch out for carbapenem-resistant Enterobacterales** A. Cona* (Palermo, Italy), C. Curatolo, P. Giordani, F. D'andrea, M. Campanella, E. Conoscenti, S. Caruso, G. Mulè, D. Lo Porto, F. Monaco, F. Cardinale, G. Di Martino, D. Di Carlo, N. Coppola, A. Mularoni

00350 **Risk factors for carbapenem-resistant Enterobacteriaceae infection after orthotopic liver transplant in a large cohort of pre-transplant CRE carriers** B. Miani* (Bologna, Italy), M. Rinaldi, M.P. Freire, E.S. Girao, D. Yahav, M. Valerio, L.M. Parra, L. Alagna, E. Franceschini, P. Burra, A. Mularoni, M. Halpern, L.F.A. Camargo, R. Romagnoli, E. Graziano, N. Caroccia, M. Di Chiara, P. Viale, M. Giannella

00351 **Serologic follow up of solid organ transplant recipients who receive organs from syphilis seropositive donors.** O. Fernandez Garcia* (Edmonton, Canada), D. You, J. Gratrix, A. Singh, K. Doucette

00352 **Prophylaxis strategies and risk of cytomegalovirus in solid organ transplant recipients** A.L. Dahl* (Copenhagen, Denmark), M. Koller, O.J. Manuel, K.S. Moestrup, J. Reekie, E. Tusch, C.G. Crone, M. Perch, F. Gustafsson, S.S. Sorensen, N. Schultz, K. Schonning, J. Lundgren, N. Mueller, M. Helleberg

00353 **Burden of non-microbiologically confirmed infections in solid organ transplant recipients** M. Zou* (Basel, Switzerland), M. Koller, O. Manuel, N. Mueller, K. Boggian, C. Hirtzel, C. Garzoni, N. Khanna, C. Van Delden, D. Neofytos

4614 11:00 – 12:00 Hall 13

1-hour Symposium

DX PHEI

Diagnosing the undiagnosed fraction: the final step towards viral hepatitis elimination

Chairs Mojca Maticic (Ljubljana, Slovenia)
Snjezana Zidovec Lepej (Zagreb, Croatia)

4614-1 11:00 **Role of reflex testing strategies in identifying patients with chronic viral hepatitis** Oana Sandulescu (Bucharest, Romania)

4614-2 11:30 **Management and elimination of hepatitis in hard-to-reach persons** Suda Tekin (Istanbul, Türkiye)

Co-organised with: ESCMID Study Group for Viral Hepatitis (ESGVH), Romanian Society for Infectious Diseases and HIV/AIDS

4413 11:00 – 12:00 Hall 14

1-hour Symposium

DX

Impact on including a measure of viability in molecular diagnostic tests

Chairs Fusun Can (Istanbul, Türkiye)
Denise O'sullivan (Teddington, United Kingdom)

4413-1 11:00 **Viability markers in support of development of *Chlamydia* screening recommendations** Petra Wolffs (Maastricht, Netherlands)

ESCMID Global 2025 - Programme

4413-2 11:30 Measuring viability to improve the correlation of AMR markers and clinical outcomes in *Neisseria gonorrhoeae* Tatum Mortimer (Athens, United States)

Co-organised with: ESCMID Study Group for Mycoplasma and Chlamydia Infections (ESGMAC)

Mansbridge, E. Fraser, I. Poles, J. Clarke

4394 11:00 - 12:00 Hall 15
Meet-the-Expert

PRO

How to teach Medical Mycology

4394-1 11:00 Katrien Lagrou (Leuven, Belgium)

4394-2 11:12 Mihai Mares (Iasi, Romania)

Co-organised with: European Confederation of Medical Mycology (ECMM)

4522 11:00 - 12:00 Hall 16
1-hour Symposium

TRN ANT

Innovating antimicrobial drug discovery and host-pathogen interaction studies using chemical biology

4522-1 11:00 Bacterial PROTACs: Do proteolysis-targeting degraders represent a viable strategy for new antimicrobials? Morreale Francesca Ester (London, United Kingdom)

4522-2 11:30 Activity-based protein profiling of bacterial pathogens: new enzymes and their functions at the host-microbe interface Christian Stephan Lentz (Tromsø, Norway)

4552 11:00 - 12:00 Hall 2
Meet-the-Expert

AMR

Global AMR Policy after UNGA: what do we do now!

4552-1 11:00 Gisela Robles Aguilar (Oxford, United Kingdom)

4552-2 11:12 Mike Sharland (London, United Kingdom)

OS043 11:00 - 12:00 Hall 3
1-hour Oral Session

IPC AMR

Navigating disinfection challenges: resistance, outbreaks, and efficacy

00324 Prolonged disinfectant exposure impacts the antimicrobial resistance of healthcare-associated microorganisms: a systematic review Á.R. Fernandes* (Porto, Portugal), A. Gonçalves Rodrigues, L. Cobrado

00325 Sink-associated outbreak of verona integron-encoded metallo-β-lactamase-producing carbapenem-resistant *Pseudomonas aeruginosa* in a Dutch intensive care unit M. Van Den Bos-Kromhout* (Zwolle, Netherlands), S. Debast, S. De Vries-Van Rossum, S. Abma-Blatter, B. Immeke, K. Zuur, M. Hijmering, J. Rossen

00326 Carbapenemase-producing Enterobacterales outbreak control by replacement of toilets or long-term disinfection? A real-life experience A.L. Engsbros* (Slagelse, Denmark), K.H. Hansen, M.F.J. Larsen, N. Kling, H.T. Larsen, R. Kjølsen, B. Hansen, L.K. Vejrum, A.L. Laugesen, M. Kemp

00327 Tolerance of *Klebsiella pneumoniae* biofilms to disinfection with peracetic acid M. Arvand* (Berlin, Germany), A. Richter, D. Csertő, K. Konrat

00328 Bringing balance to the formulation: disinfection efficacy and material compatibility J. Jennings* (Halifax, United Kingdom), T. Langford, H.

OS044 11:00 - 12:00 Hall 5
1-hour Case Session

CLN

Unusual presentations of unusual parasites

00329 Atypical neonatal cutaneous myiasis: a diagnostic challenge mimicking pustular rash in a resource-limited setting D. Ekwem* (Gulu, Uganda), E. Namara, E. Ssenuni, A. Amuge, V. Omona, R. Okidi, R. Olum

00330 An itchy awakening due to *Dermanyssus* infestation J. Sevestre* (Marseille, France), A.Z. Diarra, J.P. Dales, J.M. Bérenegr, S. Ranque

00331 Uterine Myiasis: A Rare Case of External Genitourinary Myiasis R.L. Johnson* (Birmingham, United States), J.C.F. Nakazaki, P. Legua

00332 Neurognathostomiasis Presenting with Cerebral Venous Sinus Thrombosis: A case report of rare clinical manifestation C. Norsungnerm* (Bangkok, Thailand), J. Vinichanan, L. Paitoonpong

00333 If at first, you don't succeed... Treatment-resistant Fascioliasis: case report W. Garr* (Leeds, United Kingdom), K. Woods, L. Nabarro

4344 11:00 - 12:00 Hall 7
1-hour Symposium

CLN DX

Lyme neuroborreliosis: challenges in diagnosis and treatment

Chairs Alexandra Mailles (Paris, France)
Joanna Maria Zajkowska (Białystok, Poland)

4344-1 11:00 Challenges in diagnosis of Lyme neuroborreliosis Rick Dersch (Freiburg, Germany)

4344-2 11:30 Challenges in treatment of Lyme neuroborreliosis Anne Marit Solheim (Kristiansand, Norway)

Co-organised with: ESCMID Study Group for Infectious Diseases of the Brain (ESGIB), ESCMID Study Group for Lyme Borreliosis (ESGBOR)

OS045 11:00 - 12:00 Hall 8
1-hour Oral Session

AMR

Social behavioural dynamics of antibiotic use and AMR

00334 Investigating the Knowledge, Attitudes, and Practices around Antimicrobial Resistance and Stewardship Among Syrian Healthcare Professionals: A Cross-Sectional Survey A. Abbara* (London, United Kingdom), H. Alhosni, F. Alahdab

00335 Gamified Intervention to Enhance Antimicrobial Stewardship: Improving Knowledge and Practices on the Rational Use of Antimicrobials Among Medicines and Therapeutics Committee Members ??? S. Mahadevaiah* (Mysore, India), C. Es, K. Anil, Y. Maheshwarappa, S.S. Sc, S. Srinivas, V. Swamy Gs, K. Gautam

00336 Healthcare providers' perspectives on antibiotic use and resistance in pregnancy, childbirth, and children under five years of age across four levels of hospitals in Lao PDR, 2024 S. Vantava* (Vientiane Capital, Lao People's democratic republic), K. Thilakoun, D. Sypaseuth, C. Khamla, I. Bounxou, P. Vanpheng, B. Phetsamone, S. Bangthong, K. Sengchanh, S. Latsamy, S. Vanphanom, L. Annick, S. Somphou

00337 High gender gap in female labour force participation and reduced gender inequality linked to high antibiotic consumption: Evidence from a global analysis D. Samria* (Bangalore, India), D. Batheja, A. Nandi

00338 Gender gaps in knowledge of antibiotics and

ESCMID Global 2025 - Programme

antimicrobial resistance: Evidence from India.
Deepshikha (Bengaluru, India), S.R. Umenthala, S. Goel, D. Samria, R. Bhagawati*

OS046 11:00 – 12:00 Hall 9
 1-hour Oral Session

VAX PHEI

Vaccines and prophylaxis against respiratory viral infections

00339 **Public health impact of universal prophylaxis with nirsevimab for prevention of infant hospitalizations due to respiratory syncytial virus. Full 2023-24 season analysis of the NIRSE-GAL study** (www.nirsegal.es/en)
F. Martín-Torres (Santiago De Compostela, Spain), N. Mallah, J. Pardo-Seco, O. Pérez-Martínez, M.I. Santiago-Pérez, M.T. Otero-Barrós, N. Suárez-Gaiche, R. Kramer, J. Jing, L. Platero-Alonso, R.M. Álvarez-Gil, O.M. Ces-Ozores, V. Nartallo-Penas, S. Mirás-Carballal, M. Piñeiro-Sotelo, J.M. González-Pérez, C. Rodríguez-Tenreiro-Sánchez, I. Rivero-Calle, Á. Manzanares-Casteleiro*

00340 **Relative effectiveness of high-dose versus standard-dose quadrivalent influenza vaccine against hospitalizations and mortality according to Charlson Comorbidity Index: A post-hoc analysis of the DANFLU-1 randomized trial**
K. Feldballe Bernholm (Copenhagen, Denmark), N. Dyrby Johansen, C. Espersen, D. Modin, K. Hyldekær Janstrup, J. Nealon, S. Samson, M. Loiacono, R.C. Harris, C. Schade Larsen, A.M. Reimer Jensen, N.E. Landler, S. Tellerup Nielsen, L. Russell, T. Skovsgaard Itenov, B.L. Claggett, S.D. Solomon, M.J. Landray, G.H. Gislason, L. Køber, P. Sivapalan, J.U. Stæhr Jensen, T. Biering-Sørensen*

00341 **Relative vaccine efficacy of a SARS-CoV-2 spike receptor-binding and N-terminal domain COVID-19 vaccine versus mRNA-1273: subgroup analyses**
C. Grassi (Cambridge, United States), S. Chalkias, P. Dennis, D. Petersen, K. Radhakrishnan, L. Vaughan, R. Handforth, N. Vicic, A. Rossi, R. Wahid, D. Edwards, J. Feng, W. Deng, H. Zhou, E. De Windt, V. Urdaneta, B. Girard, S. Faust, S. Walsh, C. Cosgrove, R. Das*

00342 **Effectiveness of RSV vaccine in lung transplant recipients: neutralizing antibody response against reference and seasonal strains**
N. Shirin (Ramat Gan, Israel), L. Levy, D. Yahav, M. Benzimra, Y. Bezalel, T. Hoffman, T. Sinai, M. Jurkowicz, O. Deri, N. Matalon, M. Saute, Y. Lustig, E. Nachum, M. Peled, I. Nemet, M. Mandelboim*

00343 **Novavax investigational COVID-19 Influenza Combination nanoparticle vaccine phase 2 study safety evaluation**
C. Bennett (Gaithersburg, United States), V. Shinde, S. Neal, J.S. Plested, T. Vincent, M. Zhu, S. Cloney-Clark, Z. Cai, B. Riviers, A. Ahmed, F. Mahkhou, A.M. Marchese, I. Cho, L. Fries, W. Woo*

4767 13:30 – 15:30 Hall 1
 Special Session

PRO

Selective Pressure

Chairs
Jacob Moran-Gilad (Beer Sheva, Israel)
Joshua Nosanchuk (Bronx, United States)
Jose Ramon Pano-Pardo (Zaragoza, Spain)
Jesús Rodríguez-Baño (Seville, Spain)
Anja Sterbenc (Ljubljana, Slovenia)
Suzanne Van Asten (Nijmegen, Netherlands)
David Van Duin (Chapel Hill, United States)

4315 13:30 – 14:30 Hall 11
 1-hour Symposium

TRN VAX

Immunosenescence and immune response to vaccination

Chairs
Petar Velikov (Sofia, Bulgaria)
Dafna Yahav (Ramat-Gan, Israel)

4315-1 13:30 **How immunosenescence impacts vaccine response**
Andrea Cossarizza (Modena, Italy)

4315-2 14:00 **Strategies to tackle immunosenescence and improve immune response to vaccination in the elderly**
Inna Ovsyannikova (Rochester, United States)

Co-organised with: ESCMID Study Group for Infections in the Elderly (ESGIE), ESCMID Vaccine Study Group (EVASG)

4732 13:30 – 15:30 Hall 15
 2-hour Educational Session

PRO

Tools for successful development as a medical educator

Chairs
Giorgia Caruana (Sion (Switzerland), Switzerland)
Tba

4732-1 13:30 **Developing your educator professional identity**
Tba

4732-2 13:50 **What do infection doctors need to learn to be prepared**
Simone Scheithauer (Göttingen, Germany)

4732-3 14:10 **Communities of practice: successful experience of a transformative collaboration and roadmap**
Erin Bonura (Portland, United States)

4732-4 14:30 **The critical need for ongoing innovations in medical education**
Clementine Schilte (France)

Co-organised with: Infectious Diseases Society of America (IDSA), ESCMID Professional Affairs Subcommittee, Trainee Association of ESCMID (TAE) Steering Committee, British Infection Association (BIA), Young Leader Circle of the American Society of Microbiology

4750 13:30 – 14:30 Arena 1
 Open Forum

DX

Essential diagnostics in Low-Resource Settings: why are we still talking?

Chair
Truls Michael Leegaard (Lørenskog, Norway)

4750-1 13:30 **Training skilled personnel in LMIC and brain drain: is the solution the problem?**
Sipho Kenneth Dlamini (Observatory, South Africa)

4750-2 13:40 **Leveraging surveillance networks to strengthen basic bacteriology**
Dissou Affolabi (Cotonou, Benin)

4750-3 13:50 **Microbial technologies to reverse societal inequalities and promote sustainability**
Tba

Co-organised with: ESCMID Professional Affairs Subcommittee, Dutch Society for Medical Microbiology (NVMM), ESCMID Parity Commission, Federation of European Microbiological Societies (FEMS), ESCMID Study Group for Antimicrobial stewardship (ESGAP), Société belge d'Infectiologie

4766 13:30 – 14:30 Arena 2
 Open Forum

PRO

Best of ID Week

4559 13:30 – 14:30 Hall 14
 1-hour Symposium

AMR PHEI

Farm to fork: food-borne antimicrobial resistance

Chairs
Beatriz Guerra Román (Parma, Spain)
Tba

4559-1 13:30 **Foodborne risk in meat and fishery products and impact on AMR**
Anders Dalsgaard (Frederiksberg C, Denmark)

4559-2 14:00 **Control challenges associated with food-borne**

ESCMID Global 2025 - Programme

multidrug resistance *Luisa Maria Vieira Peixe (Porto, Portugal)*

Co-organised with: ESCMID Food- and Water-borne Infections Study Group (EFWISG)

4346 13:30 – 14:30 Hall 16

CLN AMR

Meet-the-Expert

Local antimicrobials for deep infections

4346-1 13:30 *Karolina Akinosoglou (Patra, Greece)*

4346-2 13:42 *Pierre Tattevin (Rennes, France)*

Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG), ESCMID Study Group for Implant-associated Infections (ESGIAI), ESCMID Study Group for Infectious Diseases of the Brain (ESGIB)

OS052 13:30 – 14:30 Hall 2

CLN DX

1-hour Oral Session

AI in infectious diseases: the lab and beyond

00381 **Accurate strain typing of key bacterial pathogens through artificial intelligence analysis of MALDI-TOF mass spectra** *N. Macesic* (Melbourne, Australia), H.A. Nguyen, A.Y. Peleg, J. Song, J.A. Wisniewski, D.L. Dowe*

00382 **CarbaDetector: An Artificial Intelligence-Driven Prediction Model for Detecting Carbapenemase-Producing Enterobacteriales Using Disk-Diffusion** *L.K. Muhsal* (Oldenburg, Germany), C. Cimen, J. Sattler, O. Nolte, L. Dortet, R.A. Bonnin, A. Egli, A. Hamprecht*

00383 **AI-Driven Early Infectious Disease Detection in Dutch Primary Care: leveraging Bidirectional Encoder Representations from Transformers (BERT) and Early Recognition using Neural Information Encoding (ERNIE)** *G. Danae* (Groningen, Netherlands), M. Homburg, M.Y. Berger, T. Olde Hartman, A. Voss, A. Hamprecht, M. Brilman, L.L. Peters, M.S. Berends*

00384 **Predicting potentially infection-related findings in structured radiology reports** *J. Xu* (Oxford, United Kingdom), J.B. Delbrouck, J. Wei, A.S. Walker, C.P. Langlotz, D.W. Eyre*

00385 **Application of Artificial Intelligence in Assisting X-ray Diagnosis of Pediatric Pulmonary Infections** *H. Zhang* (Shanghai, China), X. Xu, J. Ai*

OS053 13:30 – 14:30 Hall 3

TRN

1-hour Oral Session

Immune evasion and intracellular survival strategies

00386 **Capsule-Dependent Modulation of Cell Death Pathways and Immune Evasion in *Acinetobacter baumannii*** *C. Jiang* (Beijing, China), H. Wang*

00387 **Intracellular lifestyle of *Acinetobacter baumannii*. Role of phospholipase A2 and transcriptional factor EB (TFEB)** *Y. Smani* (Seville, Spain), C. Atalaya Rey, I. Molina Panadero, A. Lora González, A. Hmadcha*

00388 **The role of peg344 of hypervirulent *Klebsiella pneumoniae* on suppressing autophagy responses of macrophages** *Z. Kuloglu* (Istanbul, Türkiye), Z.E. Kuloğlu, Ö. Albayrak, D. Güllü, G. Ekinci, F. Can*

00389 **c-Myc Inhibits Macrophage Antimycobacterial Response in Mycobacterium tuberculosis Infection** *C. Dollé* (Zurich, Switzerland), E. Sarti, R. Wolfensberger, K. Kusjeko, S. Bredl, R.A. Speck, M. Greter, J.H. Rueschoff, D. Mai, A. Diercks, P. Sander, G.S. Olson, J. Nemeth*

00390 **Targeting neutrophil extracellular traps (NETs) prevents tuberculosis immunopathology** *J.*

Kutschenreuter (London, United Kingdom), D.E. Kirwan, R. Cusman, K.H. Skolimowska, R.H. Gilman, J.S. Friedland, D.L.W. Chong*

4715 13:30 – 14:30 Hall 4

PHEI

1-hour Symposium

Emerging infectious diseases: staying informed and prepared in a globalised world

Chairs Nitin Gupta (Manipal, India) Pikka Jokelainen (Copenhagen, Denmark)

4715-1 13:30 **Lessons learnt from previous outbreaks** *Tba*

4715-2 14:00 **Disease X: preparedness for the next pandemic** *Yee Sin Leo (Singapore, Singapore)*

Co-organised with: ESCMID Emerging Infections Subcommittee, Deutsche Gesellschaft für Infektiologie, Deutsche Gesellschaft für Tropenmedizin, Reisemedizin und Globale Gesundheit e.V.

4247 13:30 – 14:30 Hall 5

CLN

1-hour Symposium

Sex differences in management and outcome of patients with serious bacterial infections

Chair Merel Lambregts (Leiden, Netherlands)

4247-1 13:30 **Sex impacts incidence, management, and outcome in bacteraemia** *Erik Solligard (Trondheim, Norway)*

4247-2 14:00 **The complex interplay between gender and sepsis** *Ines Lakbar (Montpellier, France)*

Co-organised with: ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES)

4748 14:45 – 15:45 Arena 1

PHEI

Open Forum

Navigating the future of pandemics across One Health

Chair Xavier Lescure (Paris, France)

4748-1 14:45 **Status of the One Health Joint Plan of Action by the Quadripartite** *Chadia Wannous (Paris, France)*

4748-2 14:55 **National surveillance responsibilities under the updated international health regulations** *Tba*

4748-3 15:05 **Long-term consequences of emerging viral diseases** *Alfonso J. Rodriguez-Morales (Pereira, Colombia)*

Co-organised with: ESCMID Emerging Infections Subcommittee, ESCMID Study Group for Public Health Microbiology (ESGPHM), Trainee Association of ESCMID (TAE) Steering Committee, Brazilian Society of Infectious Diseases (SBI), Latin American Society for Travel Medicine

4436 14:45 – 15:45 Hall 14

PRO

Meet-the-Expert

How to master conflict management and negotiation in healthcare

4436-1 14:45 *Esther Calbo (Terrassa, Barcelona, Spain)*

4436-2 14:57 *Jan A.J.W. Kluytmans (Utrecht, Netherlands)*

4500 14:45 – 15:45 Hall 12

TRN

1-hour Symposium

The challenge of a healthy microbiota in neonates

Chairs Maria Vehreschild (Frankfurt Am Main, Germany) Walter Zingg (Zurich, Switzerland)

ESCMID Global 2025 - Programme

N.D. Sari, D.S. Yildiz, H.D. Ozkaya, I.E. Yildiz, S. Kaya, O. Karabay, S. Alkan, F. Tabak

- 4500-1 14:45 Infant gut microbiome development *Debby Bogaert (Edinburgh, United Kingdom)*
- 4500-2 15:15 Metagenomic signatures and antibiotic disruption of the gut microbiome in neonates *Gautam Dantas (Saint Louis, United States)*

Co-organised with: ESCMID Study Group for Nosocomial Infections (ESGNI), European Society of Paediatric Infectious Diseases (ESPID)

- OS058 14:45 - 15:45 Hall 16
1-hour Case Session

CLN

In the field with fungi

- 00419 Fosmanogepix expanded access in patients with *Fusarium* infections *S. Dadwal* (Duarte, United States), A. Baluch, J. Dickter, J.R. Newman, M.H. Nguyen, R. Weihe, H. Schlamm, L. Ostrosky-Zeichner*
- 00420 Voriconazole's hidden toll: unravelling perostitis in a heart transplant recipient and a hematologic patient. *G. Motoa* (Boston, United States), A. Woolley, N. Issa*
- 00421 Unveiling the Uncommon: Managing Geotrichum candidum in Pancreatic Necrosis *L. Kriegl* (Graz, Austria), C. Geiger, I. Zollner-Schwetz, T. Valentin, H. Schlager, G. Zollner, K. Dichtl, R. Krause*
- 00422 Detection of siderophores as a superior non-invasive diagnostic tool in unravelling mixed fungal infections *V. Havlíček* (Prague, Czech Republic), R. Dobias, M. Navratil, R. Patil, D. Luptakova, D.A. Stevens*
- 00423 Efficacy of novel antifungal therapies in refractory *Candida* and *Aspergillus* infections: insights from compassionate use and clinical trials *S. Sedik* (Graz, Austria), R. Krause, C. Zurl, I. Zollner-Schwetz, M. Linhofer, C. Hoegenauer, G. Gorkiewicz, M. Hoenig, J. Prattes*

- OS056 14:45 - 15:45 Hall 2
1-hour Oral Session

PHEI

Emerging trends in viral hepatitis across Europe

- 00409 One of the largest outbreak of hepatitis A in the 21st century in Europe *I. Hockicková* (Kosice, Slovakia), J. Hockicko, D. Javorská, Š. Zamba, A. Vasilová, M. Ševčík, A. Cehelská, D. Hudáčková, P. Kristian*
- 00410 Higher prevalence of Cytomegalovirus and Epstein-Barr virus in acute-on-chronic liver failure – cause or consequence? *J. Sonnenberg* (Muenster, Germany), K. Thiagarajah, E. Görgülü, P. Lembeck, M. Glitscher, F. Uschner, M. Brol, W. Gu, R. Schierwagen, S. Klein, M. Schulz, T. Wiedemann, J. Reißing, J. Söhne, N. Kraus, M. Praktinjo, J. Fischer, H.P. Erasmus, J. Vasseur, S. Zeuzem, H. Storf, C. Welsch, J. Trebicka, S. Ciesek, J. Chang, T. Bruns, E. Hildt, K.H. Peiffer*
- 00411 Delta in Denmark: current prevalence of hepatitis delta virus infection *H. Watson* (Lyon, France), P. Jepsen, H. Vilstrup, H. Krarup*
- 00412 RathHEV as an aetiological agent of acute hepatitis in Europe: results from the ESGHV-RHEV Study *M. Casares* (Cordoba, Spain), B. Becerril, Á. Dencs, G. Gherlan, J. Caballero, L. Ríos, A.B. Pérez, A. Fuentes, C. Freyre, F. Franco-Álvarez De Luna, I. Viciana, M.D.C. Domínguez, M. Altindis, G. Özkaya, A. Rivero, A. Rivero-Juárez*
- 00413 Understanding the incidence and risk factors of low-level viremia in chronic hepatitis B: A propensity-matched comparison of tenofovir and entecavir. *Hasanoglu* (Ankara, Türkiye), R. Guner, E. Zerdali, A. Batirel, Y. Onlen, E. Parlak, B. Kurtaran, S. Tosun, I. Yilmaz Nakir, O. Gunal, N. Eser, H. Yağobbi, O. Tabki, T. Turunc, U. Balci, S. Komur, E. Tutuncu, L.N. Altunal,*

- OS057 14:45 - 15:45 Hall 3
1-hour Oral Session

ANT

Precision Medicine: from models to patient care

- 00414 Pharmacokinetics and pharmacodynamics of BPaLM, BPaLC and BPaL regimens for treatment of RR-TB. *F. Kloprogge* (London, United Kingdom), B.T. Nyang'wa, I. Motta, R. Moodliar, V. Solodovnikova, S. Rajaram, M. Rasool, Z. Huang, C. Berry, G. Davies, D. Moore*
- 00415 Physiologically Based Pharmacokinetic Modeling for Nemonoxacin in Predicting the Respiratory System Pharmacokinetic Profile: Based on Comprehensive Preclinical and Clinical Data *Y. Chen* (Shanghai, China), J. Zhao, J. Zhang*
- 00416 Context-specific genome-scale metabolic modelling reveals metabolic alterations in multidrug-resistant *Klebsiella pneumoniae* in response to polymyxin B/zidovudine combination *J. Zhao* (Melbourne, Australia), Y.W. Lin, J. Tao, Y. Zhu, T. Velkov, J. Li*
- 00417 Agent-based model predictions of polymyxin B activity on *Acinetobacter baumannii* *H. Soeorg* (London, United Kingdom), Y. Yuan, J. Readman, J. Standing*
- 00418 Monthly dalbavancin dosing for suppressive therapy: a case series and pharmacokinetic estimation analysis *C. Volk* (Madison, United States), W. Kufel, P. Hutson, R. Mahapatra, W. Rose*

- 4282 14:45 - 15:45 Hall 4
1-hour Symposium

IPC AMR

How innovations of AMR and HAI surveillance systems help the clinical practice

Chairs *Pascal Astagneau (Paris, France)
Mandy Wootton (Cardiff, United Kingdom)*

- 4282-1 14:45 The EUCAST system in surveillance of AMR *Sören G. Gatermann (Bochum, Germany)*
- 4282-2 15:15 Insights into developments in the surveillance of HAIs *Diamantis Plachouras (Solna, Sweden)*

Co-organised with: EUCAST Steering Committee, EUCIC Steering Committee, European Centre for Disease Prevention and Control (ECDC)

- 4688 16:15 - 17:15 Hall 15
1-hour Symposium

PHEI PRO

Communicating (your) ID science for policy and societal impact

Chairs *Leonard Leibovici (Petah-Tiqva, Israel)
Ines Steffens (Solna, Sweden)*

- 4688-1 16:15 Communicating to policy makers and for societal impact *Balázs Babarczy (Budapest, Hungary)*
- 4688-2 16:45 Influencing behaviour through the media and a multichannel communications strategy *Charlotte Hutchinson (London, United Kingdom)*

Co-organised with: CMI Board of Editors

- 4711 16:15 - 18:15 Hall 2
2-hour Educational Session

CLN VAX

Infections in cancer patients: tips for daily practice

Chairs *José Molina Gil-Bermejo (Sevilla, Spain)
Stefan Schwartz (Berlin, Germany)*

ESCMID Global 2025 - Programme

| | | |
|--------|-------|---|
| 4711-1 | 16:15 | Tailoring pharmacologic prophylaxis in patients with non-haematologic cancer: from viruses to fungi <i>Janne Vehreschild (Frankfurt, Germany)</i> |
| 4711-2 | 16:35 | Pneumonitis or pneumonia? A practical approach to lung infiltrates in patients with solid tumours <i>Tba</i> |
| 4711-3 | 16:55 | The diagnostic dilemmas and treatment challenges of mycobacteria in cancer patients <i>Şiran Keske (Istanbul, Türkiye)</i> |
| 4711-4 | 17:15 | HTLV-1 and T-cell lymphoma - predict & prevent <i>Lucy Cook (London, United Kingdom)</i> |

Co-organised with: ESCMID Study Group for Respiratory Viruses (ESGREV), International Immunocompromised Host Society (ICHS)

| | | |
|------|-----------------|--------|
| 4321 | 16:15 - 17:15 | Hall 1 |
| | Keynote Lecture | |

CLN

Tuberculosis: where are we now and where should we be

Chairs Jon S. Friedland (London, United Kingdom)
Delia Goletti (Rome, Italy)

| | | |
|--------|-------|---|
| 4321-1 | 16:15 | <i>Guy Thwaites (Ho Chi Minh City, Vietnam)</i> |
|--------|-------|---|

| | | |
|-------|---------------------|---------|
| OS063 | 16:15 - 17:15 | Hall 11 |
| | 1-hour Oral Session | |

DX

Improving blood culture diagnostics: rethinking the basics

| | |
|-------|---|
| 00461 | Blood culture volume, guideline adherence and pathogen yield of 35,433 paediatric blood cultures in Germany <i>J. Forstner* (Würzburg, Germany), A.L. Sieg, V. Rücker, H. Haefner, T. Bähr, S. Röbler, J. Held, V. Le Saout - Chapot, M. Hogardt, B. Spielberger, E.A. Idelevich, M. Christner, S. Zimmermann, S. Schneitler, M. Mauritz, C.S. Stingu, M. Gerlach, U. Von Both, S. Schoeler, L. Marr, J. Zens, E. Komini, M. Krone</i> |
| 00462 | Changing the paradigm: are two sets of blood cultures always needed? <i>R. Rosa* (Miami, United States), J. Somani, K. Manzanillo, H. Dinh, G. Rosello, L. Abbo</i> |
| 00463 | Evaluating clinical and economic impact of reducing blood culture incubation timings: Time to shift the paradigm? <i>R. Gupta* (London, Canada), J. Delpont, T. Mazzulli</i> |
| 00464 | Revolutionizing hospital workflows with blood culture-free ultra-rapid antimicrobial susceptibility testing: A clinical pilot study <i>K. Sunghoon* (Seoul, Korea, Republic of), K. Dong Young, J. Jisung, K. Tae Hyun, K. Junwon, J. Hyelyn, L. Gi Yoon, P. Wan Beom</i> |
| 00465 | Human <i>in vivo</i> footprints from blood plasma for improved diagnostics in sepsis <i>M. Sonntag* (Stuttgart, Germany), J. Mueller, A. Von Haeseler, Y. Vainshtein, S.O. Decker, T. Brenner, K. Sohn</i> |

| | | |
|------|-----------------|---------|
| 4334 | 16:15 - 17:15 | Hall 12 |
| | Meet-the-Expert | |

CLN

Navigating travel medicine: expert tips for safe international travel

| | | |
|--------|-------|---|
| 4334-1 | 16:15 | <i>Sophie Schneitler (Homburg, Germany)</i> |
| 4334-2 | 16:27 | <i>Andreas Neumayr (Basel, Switzerland)</i> |

| | | |
|-------|---------------------|---------|
| OS062 | 16:15 - 18:15 | Hall 13 |
| | 2-hour Oral Session | |

CLN

DX

TRN

Heterogeneity and complexity of sepsis

| | |
|-------|---|
| 00451 | A consensus immune dysregulation framework for sepsis: results of the SUBSPACE consortium <i>A. Moore* (Stanford, Ca, United States), T. Sweeney, A. Rogers, P. Khatri, H. Zheng, A. Ganesan, Y. Hasin-Brumshtein, M. Maddali, J. Levitt, T. Van Der Poll, B. Scicluna, E. Giamarellos-Bourboulis, A. Kotsaki, I. Martin-Loeches, A. Garduno, J. Sevransky, D. Wright, R. Rothman, M. Atreya, L. Moldawer, P. Efron, M. Kralovcova, T. Karvunidis, H. Giannini, N. Meyer</i> |
|-------|---|

| | |
|-------|---|
| 00452 | BLOODICU: Bloodstream infections and their outcomes in ICU patients - Insights from the PROSAFE Study <i>C. Genovese* (Milan, Italy), M. Offer, G. Tricella, G. Scaglione, E. Palomba, G. Montrucchio, F. Agostini, F. Dore, G. Monti, B. Viaggi, A. Gori, S. Finazzi, M. Colaneri</i> |
|-------|---|

| | |
|-------|---|
| 00453 | Deciphering the Dynamics of <i>Klebsiella pneumoniae</i> Colonization and Infection: Genomic Insights and Microbiome Interactions in ICU Patients <i>W. Yu* (Beijing, China)</i> |
|-------|---|

| | |
|-------|---|
| 00454 | Antibiotics with anti-anaerobe activity promote enteric pathobionts in ICU patients <i>S. Taylor* (Adelaide, Australia), S. Miller, E. Vasil, B. Reddi, L.A. Chapple, S. Bihari, M. Chapman, G. Rogers, L. Papanicolas</i> |
|-------|---|

| | |
|-------|--|
| 00455 | Association between blood culture time to positivity and 30-day bacteremia mortality differs for bacterial groups <i>M.H. Øvre* (Herlev And Gentofte, Denmark), J.B. Boel, J.G. Holler, S. Skovgaard, D.S. Hansen, T.S. Itenov, B.J. Holzknacht</i> |
|-------|--|

| | |
|-------|---|
| 00456 | Treatment patterns of patients with sepsis/SIRS/septic shock treated with ceftolozane/tazobactam - results from SPECTRA Y. <i>Yucel* (North Wales, United States), A. Soriano, F. Thalhammer, S. Kluge, P. Viale, M. Allen, B. Akrich, J. Levy, H. Yang, S. Kaul</i> |
|-------|---|

| | |
|-------|--|
| 00457 | Risk of myocardial infarction and stroke following bloodstream infection: a population-based self-controlled case series <i>J. Underwood* (Cardiff, United Kingdom), N. Reeve, V. Best, A. Akbari, H. Ahmed</i> |
|-------|--|

| | |
|-------|--|
| 00458 | Is transthoracic echocardiography required in all patients with <i>Staphylococcus aureus</i> bacteremia? Validating the VIRSTA and VIRSTA+ scores to define the population at low risk of endocarditis <i>D. Malano-Barletta* (Barcelona, Spain), M.A. Verdejo, G. Cuervo, C. Pitart, M. Hernández-Meneses, M. Bodro, S. Herrera, C. García-Vidal, P. Puerta, A. Del Río, M. Espasa, J.A. Martínez, L. Morata, Á. Soriano</i> |
|-------|--|

| | |
|-------|--|
| 00459 | DNA methylation changes in Sepsis: Potential use as biomarkers <i>I. López-Cruz* (Valencia, Spain), J.L. García-Giménez, L. Piles, M. Madrazo, G. Judit, M. López-Torres, A. Artero</i> |
|-------|--|

| | |
|-------|--|
| 00460 | Host response plasma biomarkers and transcriptomic alterations in critically ill patients with suspected aspiration pneumonia <i>D. Susanne* (Amsterdam, Netherlands), E. Michels, J. Butler, F. Uhel, O. Cremer, T. Van Der Poll</i> |
|-------|--|

| | | |
|------|------------------|---------|
| 4627 | 16:15 - 17:15 | Hall 14 |
| | 1-hour Symposium | |

TRN

AMR

Strain dynamics in determining gut microbial colonisation resistance

Chairs Silvio Daniel Brugger (Zurich, Switzerland)
Li Yang Hsu (Singapore, Singapore)

| | | |
|--------|-------|--|
| 4627-1 | 16:15 | Investigating <i>Escherichia coli</i> strain dynamics with metagenomics <i>Ashlee Earl (Cambridge, United States)</i> |
|--------|-------|--|

| | | |
|--------|-------|---|
| 4627-2 | 16:45 | Long-term colonisation dynamics of carbapenemase-producing Enterobacterales <i>Niranjan Nagarajan (Singapore, Singapore)</i> |
|--------|-------|---|

| | | |
|-------|---------------------|---------|
| OS064 | 16:15 - 17:15 | Hall 16 |
| | 1-hour Oral Session | |

DX

VAX

PHEI

ESCMID Global 2025 - Programme

Viral immune response - nature or nurture? Exploring the limits of immune response

- 00466** Orthopoxvirus-specific antibody dynamics up to two years after monkeypoxvirus infection or vaccination. *C. Van Dijck* (Antwerp, Belgium), N. Berens-Riha, L. Zaeck, I. Brosius, R. De Vries, J. Marien, L. Liesenborghs*
- 00467** DENG-VAC study: preliminary data on immunogenicity and reactogenicity of Qdenga vaccine versus natural infection. *A. D'abramo* (Rome, Italy), S. Vita, F. Colavita, E. Cimini, P. De Marco, E. Lalle, G. Maffongelli, L. Rosa, S. Cammisa, G. Delia, M. Fabrizio, N. Emanuele*
- 00468** Long-Lasting Immunity Followed by Natural CCHFV Infection. *H.N. Karakoç Parlayan* (Trabzon, Türkiye), A. Aslanabadi, D. Yapar, Q. Murphy, G. Kaplan, O. Akdoğan, A. Çelikbaş, A. Koroglu, F. Aksoy, E. Karaaslan, A. Abbasi, M. Karimi, M. Hojabri, G. Yilmaz, S.M. Ciupe, S.D. Pegan, E. Bergeron, G. Lewis, N. Baykam, M.M. Sajadi*
- 00469** Why does rabies virus not induce an anti-viral immune response: insights from experimental models and a human cohort. *C. Geurtsvankessel* (Rotterdam, Netherlands), C. Embregts, A. Gohar, B. Verstrepen, J. Aijaz, N. Salahuddin*
- 00470** Establishing a human challenge model for human metapneumovirus: disease characteristics and immune responses. *N. Noulin* (London, United Kingdom), A. Mann, N. Veselinski, J. Mori, B. Löndt, K. Bradley, M. Kalinova, S. Ascough, G. Boivin, C. Chiu, A. Catchpole*

- 4569** 16:15 - 17:15 Hall 3
1-hour Symposium

Targeted vs. standard perioperative prophylaxis in Solid Organ Transplant with MDR Gram-negative colonisation

- Chairs* *Tba*
David Van Duin (Chapel Hill, United States)
- 4569-1** 16:15 Standard prophylaxis. *Maddalena Giannella (Bologna, Italy)*
- 4569-2** 16:45 Targeted approaches. *Maristela P. Freire (Sao Paulo, Brazil)*
- Co-organised with: European Association for the study of the liver (EASL)

- 4714** 16:15 - 17:15 Hall 4
1-hour Symposium

Novel beta-lactams and beta-lactamase inhibitors: a diagnostic and therapeutic approach

- Chairs* *Robert A. Bonomo (Cleveland, United States)*
Arjana Tambic Andrasevic (Zagreb, Croatia)
- 4714-1** 16:15 Novel beta-lactams and beta-lactamase inhibitors: challenges for laboratory diagnostics. *Anna Sramkova (Pilsen, Czech Republic)*
- 4714-2** 16:45 Clinical perspectives of novel beta-lactams and beta-lactamase inhibitors. *Parikshit Prayag (Pune, India)*
- Co-organised with: EUCAST Steering Committee

- 4763** 17:30 - 17:30 Hall 1
1-hour Symposium

Year in public health

- Chairs* *Ziad A. Memish (Riyadh, Saudi Arabia)*
Catherine Moore (Cardiff, United Kingdom)
- 4763-1** 17:30 *Li Yang Hsu (Singapore, Singapore)*

- 4763-2** 18:00 *Rita Oladele (Lagos, Nigeria)*
-
- 4377** 17:30 - 18:30 Hall 11
1-hour Symposium

PK/PD in drug development: what's in it for me?

- Chairs* *Sandrine Marchand (Poitiers, France)*
Sebastian Wicha (Hamburg, Germany)
- 4377-1** 17:30 PK/PD from the EUCAST/regulatory perspective: what tools do we need? *Joseph Meletiadis (Athens, Greece)*
- 4377-2** 18:00 PK/PD for new anti-TB drugs. *Elin Svensson (Uppsala, Sweden)*
- Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG)

- OS070** 17:30 - 18:30 Hall 12
1-hour Oral Session

What's new in antifungal guidelines and management

- 00512** Global guideline for the diagnosis and management of candidiasis: an initiative of the ECMM in cooperation with ISHAM and ASMR. *Sprute* (Cologne, Germany), O.A. Cornely, M.B.I. Bassetti, C. Sharon, A. Groll, O. Kurzai, C. Lass-Flörl, L. Ostrosky-Zeichner, R. Rautemaa-Richardson, G. Revathi, M.E. Santolaya, L. White, L.P. Zhu*
- 00513** Impact of achieving early mycological eradication with rezafungin on all-cause mortality and ICU length of stay. *G.R. Thompson* (Davis, California, United Kingdom), A. Soriano, M. Bassetti, S. Dickerson, I. Bielicka, O.A. Cornely*
- 00514** An open-label study of ibrexafungerp in patients with refractory fungal infections (FURI). *O.A. Cornely* (Cologne, Germany), B.D. Alexander, P.G. Pappas, T.F. Patterson, M. Hoenigl, M.H. Miceli, P. Vergidis, A. Spec, G.R. Thompson III, L. Ostrosky-Zeichner, R.S. Siebert, M. Middle, E. McKie, F. Lewis, D. Angulo*
- 00515** Novel immunotherapy approach using pan-*Candida* monoclonal antibodies to treat life-threatening invasive candidiasis and tackle global AMR. *Y. Zhao* (Aberdeen, United Kingdom), C.A. Munro, S. Palliyil*
- 00516** Relative contribution of pharmacokinetics and immune signatures to clinical outcomes in patients with HIV-associated cryptococcal meningitis. *K. Stott* (Liverpool, United Kingdom), D. Tembo, C. Kajanga, A. Ahmadu, K.D. Ruwanthi, M. Moyo, D. Lawrence, T. Harrison, J. Jarvis, D. Namakhwa, D. Laloo, W. Hope, H. Mwandumba*

- OS071** 17:30 - 18:30 Hall 14
1-hour Oral Session

Intestinal parasitic uncovered: epidemiology and treatment success

- 00517** Giardia- Does the treatment work? The experience from a national tertiary referral centre. *A. Boté-Casamitjana* (London, United Kingdom), S. Eisen, L. Nabarro, N. Longley, G. Godbole*
- 00518** Giardiasis: Who gets it? Experience from a Central London Teaching Hospital. *A. Boté-Casamitjana* (London, United Kingdom), S. Eisen, L. Nabarro, N. Longley, G. Godbole*
- 00519** Assessing the Effect of Antimicrobial Treatment on the Accuracy of Serial Serum and Urine Testing for Detecting *E. histolytica* cfDNA. *P. Datta* (Chandigarh, India), D. Rattan, A. Duseja, N. Sharma, N. Kalra, S. Khurana*
- 00520** Longitudinal observation of *Blastocystis* sp. and *Dientamoeba fragilis* in children: a very rare

ESCMID Global 2025 - Programme

| | | |
|--------------|--|--|
| | occurrence in chronic diseases with gut dysbiosis. <i>J. Hurych*</i> (Prague, Czech Republic), <i>J. Havlova, V. Neuman, K. Litosova, K. Hubackova, L. Hlinakova, M. Kubat, O. Hradsky, J. Bronsky, K.L. Kolho, P. Saavalainen, H. Malcova, D. Cebecauerova, P. Drevinek, Z. Sumnik, O. Cinek</i> | |
| 00521 | High prevalence of the zoonotic <i>Angiostrongylus cantonensis</i> in rats in Spain. <i>J. Caballero-Gómez*</i> (Cordoba, Spain), <i>T. Fajardo-Alonso, I. García-Bocanegra, M. González, A. Beato-Benítez, R. Cuadrado-Matías, M.Á. Quevedo, R. Guerra, R. Martínez, A. Rivero-Juárez, J. Martínez, E. Martínez-Nevado, P. Soriano, D. Crailsheim, J. Lazpita, A. González, P. Foronda</i> | |

| | | |
|--------------|----------------------|----------------|
| OS072 | 17:30 – 18:30 | Hall 15 |
| | 1-hour Oral Session | |

PRO

Training models - a new model for training

| | |
|--------------|--|
| 00522 | Can ChatGPT4o help build Objective Structured Clinical Examination (OSCE) stations in infectious diseases ? <i>S. Villard*</i> (Paris, France), <i>Y. Guedj, L. Khider, L. Maisonobe, J. Mesnier, Y. Nguyen, B. Oules, M. Sanchez, S. Voicu, N. Burnichon, A. Faye, A. Mageau, T. Mirault, A. Pellat, C.A. Hobson, D. Bouzid, M. Thy, N. Peiffer-Smadja</i> |
|--------------|--|

| | |
|--------------|--|
| 00523 | Large language model in real-world clinical infectious diseases: are we there yet? <i>G. Carra*</i> (Switzerland, Switzerland), <i>M. Van Singer, A. Cancela Costa, P.A. Crisinel, L. Cobuccio, F. Desgranges, A. Filali, Y. Fougère, T. Galpérine, E. Gauthiez, B. Guery, M. Jaboyedoff, S. Meylan, A. Munting, E. Kampouri, M. Papadimitriou Olivgeris, M. Plebani, V. Suttels, P. Valladares, M.A. Hartley, J.L. Raisaro, D. Kaufmann, N. Boillat Blanco</i> |
|--------------|--|

| | |
|--------------|--|
| 00524 | Artificial Intelligence-Powered Transformation: Enhancing Public Health Education at Tampere University Towards Sustainable Development Goal 3. <i>S. Ahmad*</i> (Tampere, Finland) |
|--------------|--|

| | |
|--------------|--|
| 00525 | A Survey on Perceived Priorities for the Implementation of Artificial Intelligence in Developing ESCMID Guidelines. <i>J. Molina*</i> (Seville, Spain), <i>J.R. Paño-Pardo, B. Nagavci, M. Paul, T. Kostyanov, M.W. Langendam, J.P. Stahl, E. Tacconelli, S. Tschudin-Sutter, M. Zervos, L. Scudeller</i> |
|--------------|--|

| | |
|--------------|---|
| 00526 | Expect the unexpected: Longitudinally extensive transverse myelitis in a healthy young adult - a rare manifestation of tuberculosis. <i>S. Angirekula*</i> (Jodhpur, India), <i>R. Modi, R. Bora, R. Lohiya, S.K. Shrivastava, S. Jagannath, D. Kumar, S. Tiwari, G.K. Bohra</i> |
|--------------|---|

| | | |
|--------------|----------------------|----------------|
| OS073 | 17:30 – 18:30 | Hall 16 |
| | 1-hour Case Session | |

CLN

Still going viral

| | |
|--------------|---|
| 00527 | Clinical outcomes of adoptive cell therapy for EBV reactivation and EBV-PTLD in primary immunodeficiencies: prophylactic and therapeutic applications of post-allo-HSCT memory T cell infusions. <i>N. Maximova*</i> (Trieste, Italy), <i>S. Braidotti, M. Granzotto, R. Simeone</i> |
|--------------|---|

| | |
|--------------|--|
| 00528 | Histopathological proof of herpes simplex pneumonitis in a patient with severe COVID-19 pneumonia. <i>J. Heylen*</i> (Leuven, Belgium), <i>B. Lopuhaa, L. Maessen, S. Feys, L. Vanderbeke, G. De Vlieger, K. Lagrou, G. Hermans, M. Peetermans, E. Van Wijngaerden, P. Meersseman, A. Wilmer, G. De Hertogh, G. Verjans, J. Von Der Thüsen, J. Van Kampen, J. Wauters</i> |
|--------------|--|

| | |
|--------------|---|
| 00529 | Transmission of dengue virus from donors to recipient after solid organ transplantation. Case series in Argentina. <i>L. Barcán*</i> (Buenos Aires, Argentina), <i>S. Villamandos, R. Gago, M. Aguirre, A.</i> |
|--------------|---|

Martinoia, A. Patterer, M. Uranga, C. Sarkis, E. Temporiti, N. Pujato, S. Claudia, D. Calfunao, C. Nyveyro, M. Martinez, A. Smud, P. Giorgio

| | |
|--------------|---|
| 00530 | Rash without borders: waning immunity in a travelling physician. <i>R. Ville-Benavides*</i> (Mexico City, Mexico), <i>I. Avedaño-Gutiérrez</i> |
|--------------|---|

| | |
|--------------|---|
| 00531 | A handful of Orf: a case of successful management with cidofovir in a renal transplant recipient. <i>A. Kaya*</i> (Izmir, Türkiye), <i>G.S. İzgi, B. Yaman, Y. Tiftikçioğlu, I. Karaaslan, M. Taşbakan</i> |
|--------------|---|

| | | |
|-------------|----------------------|---------------|
| 4238 | 17:30 – 18:30 | Hall 3 |
| | 1-hour Symposium | |

VAX

Immune reconstitution syndrome in infectious diseases: Who. Are. You?

| | |
|---------------|--|
| <i>Chairs</i> | <i>Justyna Kowalska (Warsaw, Poland)</i> |
| | <i>Tba</i> |

| | | |
|---------------|--------------|--|
| 4238-1 | 17:30 | IRIS in HIV immunocompromised hosts: a failure of success. <i>Paola Maria Cinque (Milan, Italy)</i> |
|---------------|--------------|--|

| | | |
|---------------|--------------|---|
| 4238-2 | 18:00 | IRIS in non-HIV immunocompromised hosts: It is all about balance. <i>Tba</i> |
|---------------|--------------|---|

| | | |
|--------------|----------------------|---------------|
| OS069 | 17:30 – 18:30 | Hall 4 |
| | 1-hour Oral Session | |

ANT AMR

Determining new and revising old breakpoints

| | |
|--------------|--|
| 00507 | EUCAST disk diffusion testing of ten additional species of anaerobic bacteria. <i>J. Ahman*</i> (Växjö, Sweden), <i>J. Åhman, E. Matuschek, B.J. Holzkecht, P.C. Lindemann, H. Marchandin, S. Copley-Mawer, T. Morris, G. Kahlmeter</i> |
|--------------|--|

| | |
|--------------|--|
| 00508 | Standardised antimicrobial susceptibility testing protocol for <i>Legionella pneumophila</i> validated across ten European reference laboratories. <i>M. Sewell*</i> (Cardiff, United Kingdom), <i>C. Farley, A.V. Krøvel, M. Golob, D. Kese, U. Roisin, D. Lindsay, S. Nadarajah, B. Afshar, V. Gaia, S. Paukner, C. Michel, E. Fedoua, J.M. González-Rubio, F. González-Camacho, M. Petzold, M. Scaturro, C. Ginevra, G. Descours, S. Jarraud, L. Jones, O.B. Spiller</i> |
|--------------|--|

| | |
|--------------|---|
| 00509 | Antimicrobial susceptibility testing of the combination of aztreonam and avibactam in carbapenem-resistant Enterobacterales: a practical evaluation using the CLSI and EUCAST methods. <i>L.M.W. Chan*</i> (New Territories, Hong-Kong SAR, China), <i>D.Y.L. Lok, R.C.W. Wong, A.L.H. Lee, I.Y.Y. Cheung, V.C.Y. Chow</i> |
|--------------|---|

| | |
|--------------|---|
| 00510 | Determination of optimal disk diffusion mass for zosurabalpin. <i>M. Castanheira*</i> (North Liberty, United States), <i>J. Maher, Y. Edah, A. Trauner</i> |
|--------------|---|

| | |
|--------------|---|
| 00511 | The clinical significance of aminoglycoside susceptibility breakpoints modification. <i>O. Henig*</i> (Tel Aviv, Israel), <i>M. Elbaz, N. Bishouty, Y. Yaakobi, R. Ben-Ami</i> |
|--------------|---|

Monday, 14 April 2025

| | | |
|-------------|----------------------|----------------|
| 4662 | 08:30 – 10:30 | Hall 15 |
| | 2-hour Symposium | |

PHEI

Climate Change: changing risks and adaptation strategies for a world on the move

| | |
|---------------|--|
| <i>Chairs</i> | <i>Rachel Lowe (Barcelona, Spain)</i> |
| | <i>Giacomo Stroffolini (Lausanne, Switzerland)</i> |

| | | |
|---------------|--------------|---|
| 4662-1 | 08:30 | Vector-borne diseases in Europe and clinical consequences. <i>Tuba Dal (Ankara, Türkiye)</i> |
|---------------|--------------|---|

ESCMID Global 2025 - Programme

| | | |
|--------|-------|---|
| 4662-2 | 09:00 | Rising temperatures and risks of fungal disease <i>Anuradha Chowdhary (New Delhi, India)</i> |
| 4662-3 | 09:30 | Strategies for climate prevention and adaptation in a moving world <i>Kristie Ebi (Seattle, United States)</i> |
| 4662-4 | 10:00 | AMR in climate change-affected countries <i>Esmita Charani (London, United Kingdom)</i> |

Co-organised with: ESCMID Study Group for Infections in Travellers and Migrants (ESGITM)

| | | |
|------|----------------------------|---------|
| 4693 | 08:30 - 10:30 | Hall 11 |
| | 2-hour Educational Session | |

DX AMR

This bacterium might harbour AmpC, what should I do?!

Chairs *Sören G. Gatermann (Bochum, Germany)*
Pranita Tamma (Ellicott City, United States)

| | | |
|--------|-------|---|
| 4693-1 | 08:30 | Laboratory identification of AmpC and its impact on />in vitro resistance <i>Ana Gales (Sao Paulo, Brazil)</i> |
| 4693-2 | 08:50 | Divergent levels of AmpC expression in Gram-negative pathogens <i>Antonio Oliver (Palma, Spain)</i> |
| 4693-3 | 09:10 | Rational choice of antimicrobial therapy against AmpC-producing pathogens <i>Patrick Harris (Herston, Australia)</i> |
| 4693-4 | 09:30 | Novel antimicrobials active against AmpC: what RCTs tell us in support of their use? <i>Amy Mathers (Charlottesville, United States)</i> |

| | | |
|----|------------------|---------|
| S2 | 08:30 - 10:30 | Hall 12 |
| | 2-hour Symposium | |

Progress and challenges in drug discovery and development

Chairs *Douglas Huseby (Uppsala, Sweden)*
Tba

| | | |
|-------|-------|--|
| INT29 | 08:30 | Antibacterial therapies in clinical development <i>Tba</i> |
| INT30 | 09:00 | Scientific challenges of finding new antibacterial drugs <i>Tba</i> |
| INT31 | 09:30 | Antifungal drugs in clinical development <i>Oliver A. Cornely (Cologne, Germany)</i> |
| INT32 | 10:00 | The pros and cons of pathogen-specific or individualised treatment in acute bacterial infections <i>Tba</i> |

| | | |
|------|------------------|---------|
| 4230 | 08:30 - 10:30 | Hall 13 |
| | 2-hour Symposium | |

CLN

Sepsis Global 2025

Chairs *Brigitte Lamy (Bobigny, France)*
Willem Joost Wiersinga (Amsterdam, Netherlands)

| | | |
|--------|-------|---|
| 4230-2 | 08:30 | The WHO Global Maternal Sepsis Study <i>Carolina Carvalho Ribeiro Do Valle (Sao Paulo, Brazil)</i> |
| 4230-3 | 09:00 | Sepsis: year in review <i>Sylvain Meylan (Lausanne, Switzerland)</i> |
| 4230-4 | 09:30 | How to design and implement a Sepsis National Action Plan (SNAP) <i>Erika Vlieghe (Antwerp, Belgium)</i> |

Co-organised with: ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES), International Sepsis Forum (ISF)

| | | |
|------|------------------|---------|
| 4317 | 08:30 - 10:30 | Hall 14 |
| | 2-hour Symposium | |

CLN DX

Challenges in infection management, prevention and antimicrobial stewardship in long-term care facilities

Chairs *Gaetan Gavazzi (Grenoble, France)*
Giusy Tiseo (Pisa, Italy)

| | | |
|--------|-------|---|
| 4317-1 | 08:30 | The burden of nosocomial infections in long-term facilities <i>Virginie Prendki (Geneva, Switzerland)</i> |
| 4317-2 | 09:00 | Pneumonia in the elderly: management and prevention <i>Restrepo Marocs I. (San Antonio, United States)</i> |
| 4317-3 | 09:30 | Challenges in the clinical diagnosis of infection in the elderly <i>Maheen Abidi (Denver, United States)</i> |
| 4317-4 | 10:00 | Challenges in implementing antimicrobial stewardship in long-term care facilities <i>Elena Carrara (Verona, Italy)</i> |

Co-organised with: ESCMID Study Group for Infections in the Elderly (ESGIE), ESCMID Study Group for Nosocomial Infections (ESGNI), EUCIC Steering Committee

| | | |
|------|------------------|---------|
| 4385 | 08:30 - 10:30 | Hall 16 |
| | 2-hour Symposium | |

CLN AMR

Survival of the parasites: is treatment failure due to antimicrobial resistance?

Chairs *Hanne Brekke (Oslo, Norway)*
Jaco J. Verweij (Tilburg, Netherlands)

| | | |
|--------|-------|---|
| 4385-1 | 08:30 | Nitroimidazole refractory <i>Giardia Intestinalis</i> Infection <i>Pavla Tumova (Prague, Czech Republic)</i> |
| 4385-2 | 09:00 | Treatment failure in scabies <i>Francisco Bravo (Lima, Peru)</i> |
| 4385-3 | 09:30 | Recurrent <i>Enterobius</i> infections <i>Sarah Eisen (London, United Kingdom)</i> |
| 4385-4 | 10:00 | Recent advances in the treatment of Visceral Leishmaniasis and PKDL <i>Shyam Sundar (Varanasi, India)</i> |

Co-organised with: ESCMID Study Group for Clinical Parasitology (ESGCP)

| | | |
|------|----------------------------|--------|
| 4288 | 08:30 - 10:30 | Hall 2 |
| | 2-hour Educational Session | |

DX IPC

How can we infer and track plasmid outbreaks?

Chairs *Alessandra Carattoli (Rome, Italy)*
Jacob Moran-Gilad (Beer Sheva, Israel)

| | | |
|--------|-------|--|
| 4288-1 | 08:30 | New typing schemes for plasmids <i>Anita Schürch (Utrecht, Netherlands)</i> |
| 4288-2 | 08:50 | How plasmids shape the emergence of nosocomial pathogens <i>Jukka Corander (Oslo, Norway)</i> |
| 4288-3 | 09:10 | Understanding the complexity of plasmid outbreaks using bioinformatics <i>Torsten Seemann (Melbourne VIC), Australia)</i> |
| 4288-4 | 09:30 | Plasmid transmission at the One Health interface <i>Nicole Stoesser (Oxford, United Kingdom)</i> |

Co-organised with: ESCMID Study Group for Epidemiological Markers (ESGEM), ESCMID Study Group for Veterinary Microbiology (ESGVM)

| | | |
|------|------------------|--------|
| 4558 | 08:30 - 10:30 | Hall 3 |
| | 2-hour Symposium | |

PHEI

Haemorrhagic viral infections

Chairs *Önder Ergönül (Istanbul, Türkiye)*
Tba

| | | |
|--------|-------|--|
| 4558-1 | 08:30 | Ebola and Marburg: success of evolving therapeutic strategies <i>Ian Crozier (Frederick, United States)</i> |
| 4558-2 | 09:00 | Jack in the box: Re-emergence of Kyasanur Forest Disease in India <i>Kavitha Saravu (Manipal, India)</i> |
| 4558-3 | 09:30 | Crimean Congo Haemorrhagic Fever: Newer insights into pathogenesis leading to new vaccines and therapeutics <i>Ali Mirazimi (Stockholm, Sweden)</i> |
| 4558-4 | 10:00 | Venezuelan Equine Encephalitis: Impact of newer strategies for vector control <i>Carlos Seas (Lima, Peru)</i> |

ESCMID Global 2025 - Programme

OS078 08:30 - 10:30 Hall 5
2-hour Oral Session

CLN DX TRN

Trending topics in tuberculosis

- 00568 **Lineage-specific immune responses to *Mycobacterium tuberculosis*. Insights into L4 and L6 pathogenesis** M. Silva* (Porto, Portugal), J. Couto, M. Cardoso, B. Cá, M. Saraiva
- 00569 **Deciphering the functional role of distinctive *Mycobacterium tuberculosis* peptidoglycan modifications in modulating antibiotic resistance and the immune response** C. Silveiro* (Lisbon, Portugal), F. Olivença, M. Mandal, D. Pires, E. Anes, M.J. Catalão
- 00570 **Increased innate immune and neutrophil blood transcriptomic signatures associate with poor outcome in HIV-1 tuberculous meningitis** J.R. Barnacle* (London, United Kingdom), A.G. Davis, R.J. Wilkinson, K. Wilkinson, C. Stek, M. Maxebengula, N. Bangani, G. Kelly, M. Rodriguez-Lopez, R. Lai, S. Wasserman, G. Meintjes, A. O' Garra
- 00571 **Subpopulations in clinical samples of *Mycobacterium tuberculosis* can give rise to rifampicin resistance and shed light on how resistance is acquired** V. Brunner* (Oxford, United Kingdom), P. Fowler
- 00572 **A systematic comparison of automated *Mycobacterium tuberculosis* complex whole genome sequencing analysis pipelines** R. Spies* (Ho Chi Minh City, Vietnam), D. Crook, T. Peto, P. Fowler, R. Turner, H. Thai, J. Watson, T. Walker
- 00573 **Lung ultrasound for the detection of pulmonary tuberculosis using expert and AI-guided interpretation** V. Suttels* (Lausanne, Switzerland), T. Brokowski, J. Wolleb, P. Wachinou, A. Hada, G. Makpemikpa, E. Garcia, T. Brahier, O. Opota, D. Affolabi, M.A. Hartley, N. Boillat-Blanco
- 00574 **Nanomotion Technology for Rapid Antimicrobial Susceptibility Testing of *Mycobacterium tuberculosis*: Evaluating Novel Benzothiazinone Derivatives** A. Vocat* (Lausanne, Switzerland), A. Luraschi-Eggemann, C. Antoni, G. Cathomen, D. Cichočka, G. Greub, O. Riabova, V. Makarov, O. Opota, A. Mendoza, S. Cole, A. Sturm
- 00575 **Rapid drug susceptibility testing of *Mycobacterium tuberculosis* directly from clinical samples using targeted next-generation sequencing** E. Rosendal* (Lisbon, Portugal), J. Isidro, S. Carneiro, R. Macedo
- 00576 **Enhancing cerebral tuberculosis therapy with an innovative particulate nose-to-Brain drug delivery system: Insights from pharmacokinetic and pharmacodynamic studies** K. Jadhav* (Mohali, India), A.K. Singh, R.K. Verma
- 00577 **Multi-drug resistant tuberculosis among migrants in Europe** S.E. Hayward* (London, United Kingdom), K. Rustage, L.B. Nellums, J.S. Friedland, S. Hargreaves

4762 09:30 - 10:30 Hall 1
1-hour Symposium

DX

Year in clinical microbiology

Chairs Maurizio Sanguinetti (Rome, Italy)
Tba

4762-1 09:30 Mario Ramirez (Lisbon, Portugal)

4762-2 10:00 Anna Papa-Konidari (Thessaloniki, Greece)

4625 11:00 - 12:00 Arena 1
Open Forum

PRO

Predatory journals in CM/ID: from symptoms to cure

Chair Emily McDonald (Montreal, Canada)

4625-1 11:00 **The genesis of predatory journals: symptoms and root problems** Leonard Leibovici (Petah-Tiqva, Israel)

4625-2 11:10 **The role of editors and publishers of 'reputable journals': what can they do to stop predatory journals?** Tba

4625-3 11:20 **The roles of authors and academic institutions: towards governance and regulation** Tba

Co-organised with: CMI Communications Board of Editors

4678 11:00 - 12:00 Hall 1
Keynote Lecture

PHEI

HIV: from needle parks to injectables

Chairs Mary Horgan (Dublin, Ireland)
Gülsen Özkaya Sahin (Lund, Sweden)

4678-1 11:00 Huldrych Günthard (Zürich, Switzerland)

OS085 11:00 - 12:00 Hall 10
1-hour Oral Session

CLN PHEI

Planes, Pains, and Pathogens: The Perils of Travel Medicine

00620 **Fever in returning travelers from tropical regions: what not to miss in an evolving epidemiology** S. Caronni* (Milan, Italy), M. Pieruzzi, A. Rizzo, A.H. Behring, A. Poloni, A. Giacomelli, F. Salari, S. Grosso, A. Mancon, D. Mileto, S. Antinori

00621 **Tracing the Itch: A spatiotemporal analysis of scabies rates and its risk factors using the Global Burden of Disease data** S. Gupta* (Auckland, New Zealand), S. Thornley, G. Sundborn, C. Grant

00622 **Molecular epidemiological characterization of enterotoxigenic and enteroaggregative *Escherichia coli* causing traveller's diarrhoea and their relationship with clinical features** P. Oliveras* (Barcelona, Spain), E. Riera, L. Horvath, R.M. Albarracín, M.E. Valls, M.J. Alvarez-Martinez, M. Alguacil, E. Guiral, M. Espasa, D. Camprubi, J. Vila

00623 **Bites and bytes – can digital surveillance of travellers' illness predict outbreaks?** N. Hedrich* (Zürich, Switzerland), T. Lovey, P. Schlagenhaut

00624 **Travel-associated infections and diseases: a retrospective cross-sectional study** M. Trojanek* (Prague, Czech Republic), V. Grebenyuk, V. Jegorova, P. Hubacek, A. Briksi, J. Havlova, K. Dundrova, L. Kolarik, I. Zicklerova, L. Richterova, O. Beranek, T. Ernestova, L. Kohout, G. Meseznikov, A. Nycova, B. Pisova, R. Sindlerova, M. Tulach, Z. Uhrikova, M. Vidlicka, M. Stefan, F. Stejskal

OS086 11:00 - 12:00 Hall 11
1-hour Oral Session

DX TRN

Marker based diagnostics: forget the pathogen

00625 **A 29-mRNA molecular host response test demonstrates enhanced accuracy compared to a protein-based host response test for the diagnosis of bacterial and viral infections** N. Whitfield* (Sunnyvale, United States), C. Lu, O. Liesenfeld

00626 **Diagnostic accuracy of a bacterial versus viral host-protein test for pediatric inpatients with acute infection** B.P. Muller* (Basel, Switzerland), L. Bont, A. Klein, M. Stein, M. Mor, I. Srugo, R. Navon, T.M. Gottlieb, E. Eden

00627 **Diagnostic accuracy of combined urine lipocalin 2**

ESCMID Global 2025 - Programme

| | | |
|-------|--|---|
| | | and copper test in acute pyelonephritis or cystitis V. Havlíček* (Prague, Czech Republic), J. Hrbáček, T. Pluháček, J. Houst, A. Palyzova, D. Luptakova, D.A. Stevens, J. Novak, R. Dobias, R. Zchoval |
| 00628 | | Diagnostic Performance of Whole-Blood RNA Signatures for Tuberculosis Diagnosis in a Cohort of Patients with Non-Tuberculous Mycobacterial Lung Disease P. Escalante* (Rochester, Mn, United States), B. Piatkowski, B. Pathakumari, V. Van Keulen, N. Fadra, P. Arias-Sanchez, L. Gutierrez, S. Karnakoti, T. Peikert |
| 00629 | | Diagnostic utility of MxA and MxA/CRP ratio in differentiating viral and bacterial infections: a prospective cohort study O. Beranek* (Prague, Czech Republic), R. Prusa, M. Trojanek, Z. Uhríkova, J. Illner, P. Lehnert, P. Bukovska, M. Stefan, V. Jegorova, T. Ernestova, L. Kohout, G. Meseznikov, A. Nycova, R. Sindlerova, M. Tulach, M. Vidlicka, V. Grebenyuk |

| | | |
|-----|------------------|---------|
| S10 | 11:00 – 12:00 | Hall 12 |
| | Panel Discussion | |

AMR and vaccines

Chair Tba

| | | |
|-------|-------|---|
| INT37 | 11:00 | Overview of the current evidence of the impact of vaccines on AMR Adam Cunningham (Birmingham, United Kingdom) |
| INT38 | 11:20 | Panel discussion: gaps, needs, and opportunities to leverage vaccines against AMR, Adam Cunningham (Birmingham, United Kingdom), Erin Duffy, Mateusz Hasso-Agopsowicz (Geneva, Switzerland) |

| | | |
|------|------------------|---------|
| 4501 | 11:00 – 12:00 | Hall 13 |
| | 1-hour Symposium | |

Why is the concept of complicated UTI so complicated?

Chairs Gernot Bonkat (Basel, Switzerland) Maeve Doyle (Waterford, Ireland)

| | | |
|--------|-------|--|
| 4501-1 | 11:00 | The concept of complicated UTI: underlying conditions matter Suzanne Geerlings (Amsterdam, Netherlands) |
| 4501-2 | 11:30 | The concept of complicated UTI: the site of infection matters most Jesús Rodríguez-Baño (Seville, Spain) |

Co-organised with: ESCMID Education Subcommittee

| | | |
|------|-----------------|---------|
| 4744 | 11:00 – 12:00 | Hall 14 |
| | Meet-the-Expert | |

How to apply organoid models to study infectious disease

| | | |
|--------|-------|--|
| 4744-1 | 11:00 | Jennifer Rohn (London, United Kingdom) |
| 4744-2 | 11:12 | Tba |

| | | |
|-------|---------------------|---------|
| OS087 | 11:00 – 12:00 | Hall 15 |
| | 1-hour Oral Session | |

Antimicrobial resistance around birth

| | | |
|-------|--|---|
| 00630 | | Prevalence and risk factors of antibiotic resistance genes in breastmilk and neonatal oral cavity of preterm mother-infant pairs A. Sharma* (Chandigarh, India), S. Dutta, M. Biswal, A. Chakraborty, V. Suri, P. Ray |
| 00631 | | Effect of maternal peripartum antibiotic exposure on the microbial diversity, relative abundance of taxa, and resistome in breastmilk A. Chakraborty* |

(Chandigarh, India), S. Dutta, P. Sikka, D. Puri, A. Kumar, P. Kumar, A. Pal, A. Arora

| | | |
|-------|--|--|
| 00632 | | Dynamics of gastrointestinal colonisation by antibiotic-resistant bacteria in high-risk infants in Swiss and Greek neonatal intensive care units A. Braspenning* (Antwerp, Belgium), L. Timbermont, L. Van Heirstraeten, M. Berkell, A. Cook, E. Sieswerda, C.H. Van Werkhoven, J.A. Bielicki, S. Malhotra-Kumar |
| 00633 | | Harnessing functional omics to decipher how probiotics reduce antibiotic resistance gene carriage in infants' gut V.K. Pettersen* (Tromsø, Norway), A. Bargheet, G.H. Bø, C. Klingenberg |
| 00634 | | Dynamics of gut resistome and mobilome in early life: A meta-analysis V. Pettersen* (Tromsø, Norway), A. Bargheet, H.T. Noordzij, A.J. Ponsero, C. Jian, K. Korpela, M. Valles-Colomer, J. Debelius, A. Kurilshikov |

| | | |
|-------|---------------------|---------|
| OS088 | 11:00 – 12:00 | Hall 16 |
| | 1-hour Oral Session | |

Advancing diagnostics and preventive measures in hemato-oncological patients

| | | |
|-------|--|---|
| 00635 | | Prediction of bacterial and fungal bloodstream infections using machine learning in patients undergoing chemotherapy M. P Freire* (Sao Paulo, Brazil), A. Villani Jr, F. Lazzar Neto, L.A. De Padua Covas Lages, M. Salaroli De Oliveira, E. Abdala, F. L S Nunes, A.S. S Levin |
| 00636 | | Viral metagenomics in patients with persistent unexplained neutropenic fever- some clues to the cause of fever? A. Douglas* (Melbourne, Australia), L. Caly, M. Slavin, I. Savic, J. Moselen, A. Aziz, G. Papadakis, G. Ng, J. Druce, K. Thursky |
| 00637 | | Results of Optifill study: 18F-FDG-PET/CT guided antifungal stewardship in invasive pulmonary aspergillosis F. Lanternier* (Paris, France), C. Maunoury, F. Montravers, F. Marquant, S. Poiree, C. Elie, C. Robin, A. Thiebaut, F. Ader, F. Suarez, E. Blanchard, O. Lortholary |
| 00638 | | Long-term immunogenicity and boostability of the 5-dose pneumococcal vaccination schedule following allogeneic hematopoietic stem cell transplantation: a prospective cohort study S. Haggenburg* (Amsterdam, Netherlands), J. Schnyder, H. Garcia Garrido, M. Schoordijk, A. Reiners, B. Meek, M. Hazenberg, A. Goorhuis |
| 00639 | | Humoral and cellular immune response to adjuvanted respiratory syncytial virus vaccine RSVPreF3 in adults after allogeneic hematopoietic cell transplantation J. Lötscher* (Basel, Switzerland), C.S. Walti, J. Halter, N. Khanna, S. Heller, S. Schmid, K. Leuzinger |

| | | |
|-------|---------------------|--------|
| OS082 | 11:00 – 12:00 | Hall 2 |
| | 1-hour Oral Session | |

New insights in bloodstream infections and endocarditis

| | | |
|-------|--|---|
| 00605 | | Different from the start – Sex differences in Staphylococcus aureus bacteremia mortality A.C. Westgeest* (Leiden, Netherlands), M.M.C. Lambregts, F. Ruffin, V.G. Fowler, J.T. Thaden |
| 00606 | | Tracking evolution in action during invasive Staphylococcus aureus infections: the BARISTA study S. Giulieri* (Melbourne, Australia), D. Daniel, M. Duarte Aguilera, D. Velasquez-Reyes, R. Guérillot, A. Gador-Whyte, F. James, E. Goodall, P. Fuge-Larsen, M. Henri, J. Trubiano, M. Leroi, K. Bond, T. Stinear, S. Tong, J. Kwong, B. Howden |
| 00607 | | Identifying heterogeneity of treatment effect for antibiotic duration in bloodstream infection – an exploratory post-hoc analysis of the BALANCE randomized clinical trial S. Ong* (Toronto, Canada), R. |

ESCMID Global 2025 - Programme

Pinto, A. Rishu, S. Tong, R. Commons, J. Conly, G. Evans, M. Fralick, C. Kandel, P. Lagacé-Wiens, T. Lee, S. Lothar, D. Macfadden, J. Marshall, V. Martel-Laferrère, M. Mayette, E. McDonald, J. Neary, J. Prazak, E. Raby, A. Regli, B. Rogers, S. Smith, L. Taggart, H.T. Wang, T. Wuerz, D. Yahav, P. Young, R. Fowler, N. Daneman

| | |
|-------|---|
| 00608 | Bloodstream infection pathogen diversity and clinical impact revealed through unbiased whole genome sequencing: a prospective genomic epidemiology study <i>N. Macesic* (Melbourne, Australia), J. Hawkey, J. Wisniewski, A. Peleg</i> |
| 00609 | Risk of infection of intracardiac devices in patients with valvular infective endocarditis who carry cardiovascular implanted electronic devices. Analysis on a national cohort <i>A. Blanco-Arevalo* (Terrassa, Barcelona, Spain), E. Calbo, P. Muñoz, D. Monzon, M. Valerio, M. Hernandez Meneses, J.M. Miró, M. Cobo Belastegui, A. De Alarcon, R. Rodriguez, I. Villanueva Benito, J.C. Lopez-Azor, L. Garcia-Alvarez, L. Boix</i> |

| | | |
|------|------------------|--------|
| 4307 | 11:00 – 12:00 | Hall 3 |
| | 1-hour Symposium | |

Chronic infections in the era of CFTR modulators: what is going on in cystic fibrosis lungs these days?

Chairs *Pavel Drevinek (Prague, Czech Republic)*
Helle Krogh Johansen (Copenhagen, Denmark)

| | | |
|--------|-------|--|
| 4307-1 | 11:00 | The lung microbiome of people with cystic fibrosis receiving modulator therapy <i>Sebastien Boutin (Lübeck, Germany)</i> |
| 4307-2 | 11:30 | Tackling chronic infections in people with cystic fibrosis receiving modulator therapy: is it still necessary? <i>Alessandra Bragonzi (Milano, Italy)</i> |

Co-organised with: ESCMID Study Group for Biofilms (ESGB), Czech Society for Medical Microbiology

| | | |
|------|------------------|--------|
| 4725 | 11:00 – 12:00 | Hall 4 |
| | 1-hour Symposium | |

Infection prevention and control and intensive care: challenges and solutions

Chairs *Antonios Katsounas (Bochum, Germany)*
Claire Roger (Nimes, France)

| | | |
|--------|-------|---|
| 4725-1 | 11:00 | Intensive care unit (ICU) and infection: two sides of a coin <i>Reto Schuepbach (Zurich, Switzerland)</i> |
| 4725-2 | 11:20 | Ventilator-associated pneumonia (VAP) and ICU environment: how can we improve practices? <i>Despoina Koulenti (London, United Kingdom)</i> |

Co-organised with: ESCMID Study Group for Critically Ill Patients (ESGCIPI), EUCIC Steering Committee

| | | |
|-------|---------------------|--------|
| OS083 | 11:00 – 12:00 | Hall 5 |
| | 1-hour Oral Session | |

Don't 'rash' it

| | |
|-------|---|
| 00610 | Current Prevalence of Parvovirus B 19 Infections: Ankara Bilkent City Hospital Experience 2019-2024 <i>B. Dinc* (Ankara, Türkiye), F.G. Aslan, F. Kırca, A. Toyran, S. Aydoğan, B. Dinç</i> |
| 00611 | Managing an outbreak of parvovirus B19 infection in pregnancy: clinical outcomes from a single-centre study <i>M. Melchio* (Genoa, Italy), E. Ricci, E. Cristina, E. Di Marco, P. Caligiuri, F. Prefumo, S. Mangini, A. Mesini, M. Mariani, C. Russo, C. Saffiotti</i> |
| 00612 | The dark side of the „fifth disease“ endemic: human parvovirus B19 infections transmitted through blood transfusions in adults with malignant hematological diseases <i>B.G. Szabo* (Budapest, Hungary), D.</i> |

| | |
|-------|---|
| 00613 | Key learnings from a measles outbreak with multiple hospital exposures in Ireland, May-July 2024 <i>A.M. Murray* (Dublin, Ireland), G. Larkin, D. Hickey</i> |
|-------|---|

| | |
|-------|---|
| 00614 | Measles virus in the context of subacute sclerosing panencephalitis (SSPE) <i>J. Dina* (Caen, France), S. Medragh, J. Adnet, T. Belveyre, C. Vauloup-Fellous</i> |
|-------|---|

| | | |
|------|------------------|--------|
| 4716 | 11:00 – 12:00 | Hall 6 |
| | 1-hour Symposium | |

Antimicrobial prescribing: myths or pearls?

| | | |
|--------|-------|--|
| 4716-1 | 11:00 | Why treat IV when PO is possible? Tba |
| 4716-2 | 11:30 | De-escalation of antibiotic therapy to narrow-spectrum IV drugs <i>Flaminia Olearo (Hamburg, Germany)</i> |

Co-organised with: CMI Communications Board of Editors, ESCMID AMR Action Subcommittee, ESCMID Study Group for Antimicrobial Stewardship (ESGAP), Trainee Association of ESCMID (TAE) Steering Committee, ESCMID Scientific Affairs Subcommittee

| | | |
|------|------------------|--------|
| 4499 | 11:00 – 12:00 | Hall 7 |
| | 1-hour Symposium | |

Cutting edge methods in mycology

Chairs *Tba*
Antonio Vena (Genova, Italy)

| | | |
|--------|-------|---|
| 4499-1 | 11:00 | Imaging for diagnosing mycoses: focus on 18F-FDG PET/CT <i>Ana Fernández-Cruz (Majadahonda (Madrid), Spain)</i> |
| 4499-2 | 11:30 | Exploring the intersection of fungal metagenomics and medical mycology <i>Marcus De Melo Teixeira (Brasília, Brazil)</i> |

Co-organised with: ESCMID Fungal Infection Study Group (EFISG), ESCMID Education Subcommittee, Medical Mycology Study Group (GEMICOMED) within the SEIMC (Spanish Society of Infectious Diseases and Clinical Microbiology), ESCMID Study Group for Critically Ill Patients (ESGCIPI), Società Italiana per la Terapia Antinfett

| | | |
|-------|---------------------|--------|
| OS084 | 11:00 – 12:00 | Hall 8 |
| | 1-hour Case Session | |

Weird and unusual infections

| | |
|-------|---|
| 00615 | Vertical Transmission of Clade Ib monkeypoxvirus during Pregnancy: Clinical and Histopathological description of 3 cases <i>E. Hasivirwe Vakaniaki* (Kinshasa, Congo, the Democratic Republic of the), N.R. Swar Kuispond, H. Yuichiro, S. Tadaki, R. Bulakali Chirimwami, L. Liesenborghs, P. Mbala-Kingebeni, E. Bangwen, I. Brosius, T. Wawina-Bolakonga, S. Sabiti Nundu</i> |
| 00616 | First case of Oropouche fever in the South of Spain <i>I.A. Pérez-Hernández* (Malaga, Spain), E. Basallote Leal, M.A. Sempere Alcocer, B. O'donell Cortés</i> |
| 00617 | Wild hippopotamus bite and <i>Aeromonas</i> spp. infection: a treatment challenge. First case report. <i>J. Alza-Arcila* (Rio Negro, Antioquia, Colombia), N.M. Daza Alarcon, M.V. Montoya Garcia, A. Múnere-Echeverri, F.F. Jiménez Quiroz</i> |
| 00618 | From the sea to the land: an emerging species <i>K. Rodríguez* (Santo Domingo, Dominican Republic), A. Fernández, K. Espallat, J. Cruz, T. Flores</i> |
| 00619 | The first findings of <i>Wohlfahrtiimonas chitiniclastica</i> and <i>Ignatzschineria</i> species bacteremia in two cases with maggot infested wounds in Scandinavia <i>C. Mortensen* (Nykoebing F, Denmark), R. Jul, W.</i> |

ESCMID Global 2025 - Programme

Cebula, A. Laugesen, J. Møller, M. Kemp, A. Engsbro

| | | |
|------|-----------------|--------|
| 4613 | 11:00 – 12:00 | Hall 9 |
| | Meet-the-Expert | |

DX **AMR**

EUCAST: What's new in susceptibility testing

4613-1 11:00 *Erika Matuschek (Växjö, Sweden)*

4613-2 11:12 *Rafael Canton (Madrid, Spain)*

Co-organised with: EUCAST Steering Committee

| | | |
|------|---------------|---------|
| 4749 | 13:30 – 14:30 | Arena 1 |
| | Open Forum | |

PRO

Diversity in CM and ID: gender gaps and policy traps

Chair *Andre Fuchs (Augsburg, Germany)*

4749-1 13:30 **How to avoid parity traps in ID/CM research?** *Muge Cevik (St Andrews, United Kingdom)*

4749-2 13:40 **Gender gaps in visibility at scientific conferences** *Sarah Delliere (Paris, France)*

4749-3 13:50 **Psychological determinants of empowerment at individual and societal level** *Tba*

Co-organised with: ESCMID Education Subcommittee, ESCMID Parity Commission

| | | |
|------|-----------------|--------|
| 4649 | 13:30 – 14:30 | Hall 1 |
| | Keynote Lecture | |

Infectious disease challenges in an ever-changing environment

Chairs *Jacob Moran-Gilad (Beer Sheva, Israel)*
Tba

4649-1 13:30 *Pamela Rendi Wagner (Stockholm, Sweden)*

| | | |
|------|-----------------|---------|
| 4284 | 13:30 – 14:30 | Hall 16 |
| | Meet-the-Expert | |

CLN **VAX**

The older solid organ transplant recipient: between frailty, immunosenescence and infection

4284-1 13:30 *Maheen Abidi (Denver, United States)*

4284-2 13:42 *Alaa Atamna (Petah-Tikva, Israel)*

Co-organised with: ESCMID Study Group for Infections in Compromised Hosts (ESGICH), ESCMID Study Group for Infections in the Elderly (ESGIE)

| | | |
|------|------------------|--------|
| 4355 | 13:30 – 14:30 | Hall 2 |
| | 1-hour Symposium | |

VAX **AMR** **PHEI**

Vaccines and antimicrobial resistance

Chairs *Iva Butic (Zagreb, Croatia)*
Zitta Barrella Harboe (Hillerød, Denmark)

4355-1 13:30 **The impact of current and future vaccines on AMR: from pneumococcal to COVID-19** *Mateusz Hasso-Agopsowicz (Geneva, Switzerland)*

4355-2 14:00 **Can vaccines against AMR be translated into policy?** *Tba*

Co-organised with: ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS), ESCMID Vaccine Study Group (EVASG)

| | | |
|------|---------------|--------|
| 4736 | 13:30 – 15:30 | Hall 3 |
|------|---------------|--------|

PRO

2-hour Educational Session

Transforming your research idea into an appropriate study design

Chairs *Cassandra Bulescu (Bucharest, Romania)*
Mary Horgan (Dublin, Ireland)

4736-1 13:30 **Designing high-quality research studies: methodological skills and knowledge** *Mical Paul (Haifa, Israel)*

4736-2 13:50 **How to design and run scientific studies using AI agents as research assistants** *Tba*

4736-3 14:10 **Designing your first study: how to construct a workable project when your work environment may not help** *Thomas Tängdén (Uppsala, Sweden)*

4736-4 14:30 **Bridging early-career professionals with partners and seniors** *Giorgia Caruana (Sion (Switzerland), Switzerland)*

Co-organised with: CMI Board of Editors, CMI Communications Board of Editors, Trainee Association of ESCMID (TAE) Steering Committee

| | | |
|----|---------------------|---------|
| S4 | 13:30 – 14:30 | Hall 12 |
| | Meet-the-Innovators | |

Future prospects of electronic clinical decision support systems in stewardship programs

INT33 13:30 **Opportunities for clinical decision support systems in infectious disease management** *Nathan Peiffer-Smadja (Paris, France)*

INT34 14:00 **CDSS and AMS programs: the Lumed example** *Louis Valiquette (Canada)*

| | | |
|------|------------------|---------|
| 4454 | 13:30 – 14:30 | Hall 13 |
| | 1-hour Symposium | |

DX **AMR**

Predicting antibiotic susceptibility profiles from whole genome sequences: state-of-the-art

Chairs *Werner Ruppitsch (Vienna, Austria)*
Balaji Veeraraghavan (Vellore, India)

4454-1 13:30 **Impact of the WHO's developed catalogue of mutations on rapid TB diagnosis and treatment** *Thomas Schön (Kalmar, Sweden)*

4454-2 14:00 **Antimicrobial resistance prediction using whole genome sequencing** *Patricia Simner (Rochester, United States)*

Co-organised with: ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS), ESCMID Study Group for Epidemiological Markers (ESGEM), EUCAST Steering Committee

| | | |
|-------|---------------------|---------|
| OS092 | 13:30 – 14:30 | Hall 14 |
| | 1-hour Case Session | |

CLN

Mycobacterial mayhem

O0663 **Limitations of the Xpert® MTB/RIF assay: A series of four clinical cases** *A. Haas* (Salt Lake City, United States), A. Ma, J. Pham, P. Verma, U. Malhotra, E.C. Church, M. Narita, V. Escuyer, S. Shakir*

O0664 **Pharmacokinetic analysis of blood and cerebrospinal fluid cotezolid concentrations in a patient with tuberculous meningoencephalitis** *W. Nie* (Beijing, China), N. Chu*

O0665 **Is this the first case of Mycobacterium stephanolepidis infection in humans?** *S. Pérez-Recio* (Barcelona, Spain), M.D. Grijota-Camino, A. Lérica, A. Bauer, L. Fernández-Delgado, M.J. Luque, N. Sabe, F. Alcaide, M. Santin*

O0666 **Diagnostic Aspects of a Bacillus Calmette-Guérin**

ESCMID Global 2025 - Programme

00667 **Infection Following Intravesical Treatment for Bladder Cancer** *K.J. Kim* (Seoul, Korea, Republic of), J.H. Cha, S.G. Yoon, M.H. Nam, G.I. Lee, Y. Cho*

Mycobacterium abscessus: Is Shorter Antibiotic Therapy Combined with Surgery Sufficient? *M.J. Lopes* (Amadora, Portugal), C. Paulo, D. Trigo, M. Caixeiro, M. Alves, R. Macedo, P. Pacheco*

4463 **13:30 - 14:30** **Hall 15**

1-hour Symposium

ANT

Probiotics in Infectious diseases: current state-of-play

Chairs *Nicolas Benech (Lyon, France)*
Silvia Corcione (Turin, Italy)

4463-1 **13:30** **Probiotics in infectious diseases: the perfect complement to antimicrobial therapies?** *Tba*

4463-2 **14:00** **The horizon of next generation probiotics for infectious diseases** *Cormac Gahan (Cork, Ireland)*

Co-organised with: ESCMID Study Group for Host and Microbiota Interaction (ESGHAMI)

OS091 **13:30 - 14:30** **Hall 5**

1-hour Oral Session

TRN AMR

Genomic and molecular drivers of bacterial virulence and resistance

00658 **Characterization of the virulence shaping and adaptability in the methicillin-resistant *Staphylococcus aureus* ST9 lineage.** *Y. Chen* (Hangzhou, China), L. Sun*

00659 **Elucidating molecular mechanisms of bacterial conjugation: towards an improved understanding of plasmid evolution and epidemiology.** *S. David* (Oxford, United Kingdom), C. Seddon, J. Wong, N. Ishimoto, S. He, J. Bradshaw, W.W. Low, D. Aanensen, G. Frankel, K. Beis*

00660 **Clinical carbapenem-resistant *Klebsiella pneumoniae* (CRKP) strains carrying a mutH mutation are hypermutators that have heightened virulence and readily develop β -lactam/ β -lactamase resistance.** *S. Cheng* (Pittsburgh, United States), C. Clancy, M.H. Nguyen, B. Hao, G. Liu*

00661 **Genomic insights into the new prophages of MDR *Pseudomonas aeruginosa*: an example of phage-host-phage interaction.** *A. Uskudar Guclu* (Ankara, Türkiye), S. Unlu*

00662 **Genome-wide association study (GWAS) reveals importance of vaginal epithelium associated genes in case of recurrent vaginitis.** *R. Mändar* (Tartu, Estonia), E. Mutli, K. Koort, A. Salumets, T. Laisk*

4393 **14:45 - 15:45** **Hall 1**

Keynote Lecture

TRN

Staphylococcus aureus host-microbe interaction: ecology, disease, and vaccine development

Chair *Annelies Zinkernagel (Zurich, Switzerland)*

4393-1 **14:45** *Juliane Bubeck Wardenburg (St. Louis, United States)*

4740 **14:45 - 15:45** **Hall 11**

Meet-the-Expert

DX TRN

Bioinformatic tools from start to finish

4740-1 **14:45** *Vitor Borges (Lisbon, Portugal)*

4740-2 **14:57** *Clare Sloggett (Melbourne, Australia)*

S5 **14:45 - 15:45** **Hall 12**

1-hour Symposium

Do we need new antibiotics?

Chair *Ursula Theuretzbacher (Vienna, Austria)*

INT35 **14:45** **Yes: antibacterial resistance threatens medical outcomes** *Evelina Tacconelli (Verona, Italy)*

INT36 **15:15** **No: the bang for buck lies elsewhere!** *Marc Mendelson (Cape Town, South Africa)*

4726 **14:45 - 15:45** **Hall 13**

Meet-the-Expert

CLN AMR

AI use in antimicrobial stewardship

4726-1 **14:45** *Shruti Gohil (Irvine, United States)*

4726-2 **14:57** *Jose Ramon Pano-Pardo (Zaragoza, Spain)*

OS097 **14:45 - 15:45** **Hall 14**

1-hour Oral Session

PHEI

Update on zoonotic and enteric infections

00696 **A large-scale epidemiological study of *Campylobacter* employing whole genome analysis reveals the evolution of highly virulent and multidrug-resistant clones in the UK.** *B.S. Lopes* (Middlesbrough, United Kingdom), A.S. Boaitery-Biko*

00697 **Population dynamics and evolution of multidrug resistant clones of *Shigella sonnei* in Metropolitan France.** *C. Silva Nodari* (Paris, France), I. Carle, M. Lejay-Collin, L. Philippot, C. Ruckly, L. Fabre, M. Pardos De La Gandara, F.X. Weill*

00698 **Shiga toxin-producing *Escherichia coli* O26 as an increasingly common cause of haemolytic uraemic syndrome in England: A fifteen-year analysis of national enhanced surveillance data.** *L. McGeoch* (London, United Kingdom), O. Quinn, C. Sawyer, A. Douglas, C. Jenkins, S. Balasegaram*

00699 **Incidence, clinical presentation, and outcomes of *Pasteurella* infections: a population-based Danish study.** *L.Ø. Larsen* (Aalborg, Denmark), H.L. Nielsen, K.K. Søgaard*

00700 **Natural history of latent brucellosis and efficacy evaluation of B-spot in active and latent cases: A 12-month prospective cohort study.** *H. Wang* (Shanghai, China), G. Yuan, D. Li, H. Liu, J. Ai, W. Zhang*

OS098 **14:45 - 15:45** **Hall 15**

1-hour Case Session

CLN

Opportunistic infections in the Immunocompromised

00701 **Dog scratch disease? A case of *Vibrio vulnificus* in a liver transplant patient.** *E. Kim* (Galveston, United States), A. Covington*

00702 **Mpox infection among solid organ transplant recipients: a single center experience at a U.S. Tertiary Care Facility.** *J. Bini* (Miami, United States)*

00703 **Histoplasmosis in Hansen's Disease: Thalidomide for TNF-alpha inhibition in ENL with a Risk of Opportunistic Infections.** *K.K. Vaitheeswaran* (Delhi, India), M. Soneja, N. Bhari, R. M. G. K. V., S. Agarwal, R. Kumar, Y. Dharmashaktu*

ESCMID Global 2025 - Programme

00704 **Nocardiosis in a kidney transplant recipient: pros & cons of tedizolid** *M. Pellegrino** (Modena, Italy), *V. Todisco, S. Generoso, L. Benassi, E. Franceschini, F. Damiano, G. Donati, C. Mussini, A. Cervo*

00705 **Mycobacterium genavense-Associated IRIS with Macrophage Activation Syndrome: A Case Report Highlighting Diagnostic Challenges** *M. Meroi** (Verona, Italy), *M. Morra, M.E. De Rui, E. Tacconelli, F. Soldani*

4724 **14:45 – 15:45** **Hall 16**

1-hour Symposium

CLN DX

How to manage bacterial meningitis in low resource settings

Chairs *Christina Obiero* (Killifi, Kenya)
Tba

4724-1 **14:45** **Bacterial meningitis diagnosis and surveillance** *Divya Deodhar* (Vellore, India)

4724-2 **15:05** **Clinical presentation and management of CNS infections** *Kartika Maharani* (Jakarta, Indonesia)

Co-organised with: ESCMID Study Group for Infectious Diseases of the Brain (ESGIB), ESCMID Study Group for Forensic and Postmortem Microbiology (ESGFOR), Spanish Society of Forensic Pathologists (SEPAF)

OS095 **14:45 – 15:45** **Hall 2**

1-hour Oral Session

CLN PHEI

Community respiratory tract infections: latest trends and approaches

00686 ***Mycoplasma pneumoniae* increase in 2023/24 causes disease in adults in Europe** *C. Prat Aymerich** (Utrecht, Netherlands), *B. Streng, C. Prat-Aymerich, L. Bont, P. Meyer Sauteur, M. Bonten, A. Van Rossum*

00687 **Serotype distribution of pneumococcal community-acquired pneumonia in hospitalized adults in Germany** *D. Karssen** (Utrecht, Netherlands), *L. Hessels, G. Barten-Neiner, W. Bauer, S. Franch, T. Fühner, C. Hassiepen, D.F. Heigener, B. Hullegie, R. Jahja, K.D. Johnson, J. Kremling, C. Roberts, G.G.U. Rohde, M. Ruggieri, J. Scheider, D. Stolz, T.D. Swarthout, T. Weiss, H. Van Werkhoven, M. Bonten, C. Prat-Aymerich*

00688 **Community-acquired pneumonia identification from electronic health records in the absence of a gold standard: a Bayesian latent class analysis** *J. Wei** (Oxford, United Kingdom), *K. Yuan, A. Luk, S. Walker, D. Eyre*

00689 **Causes of death and risk factors for 90-day mortality and readmission in community-acquired pneumonia** *F. Al-Zergani** (Hvidovre, Denmark), *C. Lundetoft Clausen, P. Ravn, M. Sebastian Roldgaard, L. Kolte, H. Sarac, M. Fally, S. Bastrup Israelsen, T. Benfield*

00690 **Oropharyngeal carriage of gut-derived Enterobacteriales increases RTI risk in long-term aged care residents** *S. Miller** (Adelaide, Australia), *F. Zhang, S. Taylor, A. Shoubridge, E. Vasil, R. Woodman, L. Papanicolas, G. Rogers*

4581 **14:45 – 15:45** **Hall 4**

1-hour Symposium

AMR

Global clones and evolving resistance mechanisms towards newer beta-lactams: Where are we heading?

Chairs *Yeşim Beşli* (Istanbul, Türkiye)
Spyros Pournaras (Athens, Greece)

4581-1 **14:45** **Carbapenemase-producing Enterobacteriales: the not so good, the bad and the ugly** *Arjana Tambic Andrasevic* (Zagreb, Croatia)

4581-2 **15:15** **The *P. aeruginosa* frightening cocktail: high-risk clones, horizontally-acquired resistance and evolving mutational resistance** *Katy Jeannot* (Besançon, France)

Co-organised with: ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS)

OS096 **14:45 – 15:45** **Hall 5**

1-hour Oral Session

AMR

Trends in antifungal resistance

00691 **Turning resistance into vulnerability: leveraging genetic insights to predict collateral sensitivity and synergism for effective multidrug therapies** *K. Schmidlin** (Tempe, United States), *K. Geller-Samerotte*

00692 **Role of the C2585G substitution in the *MRR1* gene in the development of azole resistance in *Candida parapsilosis sensu strictu.*** *I. Franconi** (Pisa, Italy), *P. Noemi, A. Tavanti, A. Lupetti, R. Cosmeri, L. Maltinti, M. Falcone*

00693 **Fungaemia in a tertiary Madrid hospital from 2007 to 2024: changes in species epidemiology, increase in echinocandin resistance and low patient-to-patient transmission in recent years** *J. Guinea** (Madrid), *P. Escribano, G. Jesús, M. Machado, A. Burillo, P. Muñoz*

00694 **A multicentre study for determination of epidemiological cutoff values for rezafungin and four comparators against *Candida auris* with EUCAST broth microdilution reference methodology** *J. Meletiadi** (Haidari, Greece), *J. Guinea, S. Arikant-Akdagli, E.F.J. Meijer, J. Meis, M. Arendrup*

00695 **Decoding *Candida auris* Resistance in Latin America: *Candida.app* vs. *Pathogenwatch*** *J.D. Acosta-España** (Quito, Ecuador), *P. Eduarda, A. Herrera-Yela*

4398 **16:15 – 17:15** **Hall 11**

1-hour Symposium

VAX

ESCMID guidelines for the vaccination of immunocompromised individuals: solid organ transplant recipients

Chairs *Elisa Cordero Matia* (Seville, Spain)
Zitta Barrella Harboe (Hillerød, Denmark)

4398-1 **16:15** **Vaccination against respiratory pathogens** *Albert Vollaard* (Bilthoven, Netherlands)

4398-2 **16:45** **Other vaccines** *Olivier Epaulard* (Grenoble, France)

Co-organised with: ESCMID Study Group for Infections in Compromised Hosts (ESGICH), ESCMID Vaccine Study Group (EVASG)

4664 **16:15 – 17:15** **Hall 14**

1-hour Symposium

VAX PHEI

What's the role of infant and maternal immunisation for paediatric RSV prevention?

Chairs *Joanne M. Langley* (Halifax, Canada)
Peter Openshaw (London, United Kingdom)

4664-1 **16:15** **Pros and cons of passive infant immunisation with mAb before their first RSV season** *Federico Martín-Torres* (Santiago De Compostela, Spain)

4664-2 **16:45** **Pros and cons of maternal vaccination in preventing severe RSV infections in infants** *Anne Vergison* (Luxembourg, Luxembourg)

4764 **16:15 – 17:30** **Hall 1**

Special Session

PRO

ESCMID Global 2025 - Programme

Excellence Award Lectures

| | | |
|------|-------|---|
| INT7 | 16:15 | TBA <i>Marion Koopmans (Rotterdam, Netherlands)</i> |
| INT8 | 16:50 | Can global warming bring new infectious diseases? <i>Arturo Casadevall (Baltimore, United States)</i> |

| | | |
|----|------------------|---------|
| S3 | 16:15 – 18:15 | Hall 12 |
| | 2-hour Symposium | |

Innovation in direct from blood detection of BSIs

| | | |
|-------|-------|--|
| INT40 | 16:15 | Quantamatrix uRAST <i>Tae Hyun Kim (Seoul, Korea, Democratic people's republic of)</i> |
| INT39 | 16:45 | Swedish Foundation for Strategic Research Project Ultrafast bacterial species identification and antibiotic susceptibility testing <i>Johan Elf (Sweden)</i> |
| INT41 | 17:15 | Deepull <i>Tba</i> |
| INT42 | 17:45 | Critical review <i>Tba</i> |

| | | |
|------|----------------------------|---------|
| 4694 | 16:15 – 18:15 | Hall 13 |
| | 2-hour Educational Session | |

How to detect, manage and communicate hospital outbreaks

| | |
|--------|---|
| Chairs | <i>Margaret Ip (Shatin, Hong-Kong SAR, China)</i> <i>Rossitza Vatcheva-Dobrevska (Sofia, Bulgaria)</i> |
|--------|---|

| | | |
|--------|-------|---|
| 4694-1 | 16:15 | How to detect hospital outbreaks <i>David Fisman (Toronto, Canada)</i> |
| 4694-2 | 16:35 | How to confirm hospital outbreaks using genomics <i>John W. A. Rossen (Groningen, Netherlands)</i> |
| 4694-3 | 16:55 | How to rapidly respond to an ongoing hospital outbreak <i>Ermira Tartari (Msida, Malta)</i> |
| 4694-4 | 17:15 | How to communicate hospital outbreaks via scientific publication <i>Ines Steffens (Solna, Sweden)</i> |

| | | |
|------|-----------------|---------|
| 4327 | 16:15 – 17:15 | Hall 15 |
| | Meet-the-Expert | |

CLN DX

Fungal meningitis: recognition and current status of management

| | | |
|--------|-------|---|
| 4327-1 | 16:15 | <i>Olivier Lortholary (Paris, France)</i> |
| 4327-2 | 16:27 | <i>Janis Blair (Phoenix, United States)</i> |

| | | |
|-------|---------------------|--------|
| OS102 | 16:15 – 17:15 | Hall 2 |
| | 1-hour Oral Session | |

DX AMR

AI tools empowering AMR prediction in WGS and MALDI-TOF

| | | |
|-------|--|--|
| 00733 | | A scalable machine learning approach to predict antimicrobial susceptibility from whole genome sequencing data <i>Y. Zhong* (Liverpool, United Kingdom), A. Gerada, A. Howard, P. Green, W. Hope</i> |
| 00734 | | Machine Learning-Based Antimicrobial Resistance Prediction of 11 antibiotics for <i>Klebsiella pneumoniae</i> from Clinical NGS Data <i>X. Jia* (Beijing, China), J. Zhang, J. Chen, Q. Yang</i> |
| 00735 | | AI-Powered Real-Time Plasmid Prediction Using Nanopore Sequencing <i>E. Sauerborn* (Munich, Germany), S. Atum, H. Urel, M. Peisker, N. Wantia, E. Foster-Nyarko, L. Urban</i> |
| 00736 | | MALDI-TOF Prediction model based on machine learning algorithm for the detection of ST23 high-virulence <i>K. pneumoniae</i> <i>L. Dortet* (Le Kremlin-</i> |

Bicêtre, France), L. Mancera Pascual, M.J. Arroyo

| | | |
|-------|--|--|
| 00737 | | Predicting rifampicin resistance in <i>Mycobacterium tuberculosis</i> complex with a machine learning based MALDI-TOF MS approach <i>Y.W. Sun* (Taichung, Taiwan, China), P. Huang, B. Tsou, S.C. Chang, C.W. Lu, C.C. Chen, J. Yu</i> |
|-------|--|--|

| | | |
|------|------------------|--------|
| 4481 | 16:15 – 18:15 | Hall 4 |
| | 2-hour Symposium | |

DX TRN

Precision genomics to improve infectious diseases management

| | |
|--------|---|
| Chairs | <i>Ruth Massey (Cork, Ireland)</i> <i>Jacob Moran-Gilad (Beer Sheva, Israel)</i> |
|--------|---|

| | | |
|--------|-------|---|
| 4481-1 | 16:15 | Human genomics approaches to infection immunity <i>Fergus Hamilton (Bristol, United Kingdom)</i> |
| 4481-2 | 16:45 | Applying bacterial GWAS to uncover new mechanisms of antibiotic resistance <i>Marco Galardini (Hannover, Germany)</i> |
| 4481-3 | 17:15 | Evolution in action: large-scale within-host evolution analyses of persistent bacterial infections <i>Stefano Giulieri (Melbourne, Australia)</i> |
| 4481-4 | 17:45 | Machine learning in bacterial genomics and metagenomics <i>Francesco Asnicar (Trento, Italy)</i> |

| | | |
|-------|---------------------|--------|
| OS103 | 16:15 – 17:15 | Hall 5 |
| | 1-hour Oral Session | |

TRN AMR

Polymicrobial interactions and competition

| | | |
|-------|--|--|
| 00738 | | The <i>Klebsiella pneumoniae</i> type VI secretion system effector Tle4 facilitates adaptation survival by damaging the cell membrane of competing bacteria <i>W. Li* (Shanghai, China), J. Zhang</i> |
| 00739 | | <i>Candida albicans</i> promotes TSST-1 production in <i>Staphylococcus aureus</i> by depleting glucose and lifting carbon catabolite repression <i>M. Carriou* (Lyon, France), C. Badiou, A. Souldard, K. Chikh, O. Vitalis, A. Frugier, K. Dufresne, G. Lina</i> |
| 00740 | | Understanding polymicrobial biofilm dynamics: focus on <i>Pseudomonas aeruginosa</i> and its molecular interactions <i>S. Kansal* (Chandigarh, India), U. Dutta, A. Angrup, P. Ray</i> |
| 00741 | | Intra- and interspecific antagonism inhibits growth of <i>Staphylococcus aureus</i> in human nasal microbial communities <i>L. Brüllsauer* (Zurich, Switzerland), M. Boumasmoud, S.D. Brugger, A.R. Hall</i> |
| 00742 | | Combination therapy against drug resistance biomimetic dual-species biofilm model of <i>Pseudomonas aeruginosa</i> and <i>Staphylococcus aureus</i> <i>P. Mojarrad* (Helsinki, Finland), P. Tammela, T. Laaksonen, Z. Gounani</i> |

| | | |
|------|------------------|---------|
| 4527 | 17:30 – 18:30 | Hall 11 |
| | 1-hour Symposium | |

PHEI

Avian influenza in mammals: jumps under the radar

| | |
|--------|--|
| Chairs | <i>Patricia Antunes (Porto, Portugal)</i> <i>Ana Vale (Dublin, Ireland)</i> |
|--------|--|

| | | |
|--------|-------|--|
| 4527-1 | 17:30 | Threat of highly pathogenic avian influenza to non-traditional hosts, including humans <i>Thijs Kuiken (Rotterdam, Netherlands)</i> |
| 4527-2 | 18:00 | Recent changes in the epidemiology of avian influenza in relation to human health risks <i>Ron Fouchier (Rotterdam, Netherlands)</i> |

Co-organised with: ESCMID Food- and Water-borne Infections Study Group (EFWISG), ESCMID Study Group for Veterinary Microbiology (ESGVM), ESCMID Study Group for Respiratory Viruses (ESGREV), European Scientific Working group on Influenza (ESWI)

ESCMID Global 2025 - Programme

4450 17:30 – 18:30 Hall 15
1-hour Symposium

CLN

Echinococcosis: neglected but expanding

Chairs Daniel Grupel (Jerusalem, Israel)
Francesca Tamarozzi (Negrar-Verona, Italy)

4450-1 17:30 Expansion and diversity of cystic echinococcosis Pedro Legua (Lima, Peru)

4450-2 18:00 Management of echinococcosis: evidence, eminence and new developments Beate Grüner (Ulm, Germany)

Co-organised with: Österreichische Gesellschaft für Antimikrobielle Chemotherapie (ÖGACH), Österreichische Gesellschaft für Hygiene, Mikrobiologie und Präventivmedizin (ÖGHMP), Österreichische Gesellschaft für Infektionskrankheiten und Tropenmedizin (OEGIT), ESCMID Study Group for Infections in Travellers and Migrants (ESGITM)

OS109 17:30 – 18:30 Hall 16
1-hour Oral Session

PRO

Training CM/ID - a global view

00780 Specialist training in infectious diseases in Europe. J. Salmanton-García* (Cologne, Germany), J. Salmanton-García, A. Guerra Maio, J.P. Stahl, E. De Barra, S. Jensen-Fangel, C. Torti, C. Kraef, J.M. Miró, A. Verbon, O.A. Cornely, N.J. Beeching

00781 Infectious Diseases Residency Training over the World P. Irkoren* (Istanbul, Türkiye), C. Cimen, S. Keske, O. Ergonul

00782 Five years of experience with the virtual International Postgraduate Diploma in Infection Prevention and Control from the Infection Control Africa Network. A. Tostmann* (Nijmegen, Netherlands), E. Schoeman, B. Du Toit Ludick, E. Ruizendaal, Y. Gouws, J. Hopman, C. Azzouz, S. Mehtar

00783 Combatting challenges in laboratory capacity through an innovative, longitudinal Gram stain training programme for blood culture specimens in Zimbabwe. T. Mwaturo* (Harare, Zimbabwe), D. Hettle, F. Makoga, A. Mudungwe, B. Sado, K. Kranzer

00784 Benefit of the implementation of Entrustable Professional Activities (EPA) as an assessment tool in the Laboratory of clinical bacteriology: a study focused on the improvement of residents' skills and feelings. H. Pailhories* (Angers, France), C. Zins, R. Chenouard, M. Kempf, M. Eveillard

4427 17:30 – 18:30 Hall 2
Meet-the-Expert

DX AMR

How to perform molecular surveillance of multidrug resistant bacteria

4427-1 17:30 Martina Lengerova (Brno, Czech Republic)

4427-2 17:42 Henrik Hasman (Copenhagen, Denmark)

OS107 17:30 – 18:30 Hall 3
1-hour Oral Session

VAX

Novel vaccines in clinical development

00770 Safety and immunogenicity of a seasonal booster dose of the 6-valent, OspA-based Lyme borreliosis vaccine candidate VLA15 in a healthy population aged 5-65 years M. Messier* (Lyon, France), L. Wagner, R. Hochreiter, J. Larcher-Senn, E. Lamberth, R. Simon, C. Clarkin, J. Stark, S. Eder-Lingelbach

00771 Safety and immunogenicity of mRNA mpo vaccine candidate mRNA-1769: Interim analysis results from a Phase 1/2 Trial H. Hiruy* (Cambridge, United States), R. Lazarus, K. Mccafferty, K. Cohen, R. Dhar, T. Rizk, A. Adeniji, X. Chang, L. Siquel, H. Bennett, B. Leav

00772 Development of a Rapid-Acting Oral Cholera Vaccine: Phase I Clinical Trial A. Hannaford* (Boston, United States), D. Leitner, M. Waldor, L. Baden, M. Desjardins, M. Suzuki, L. Carr, D. Slater, H. Levine, H. Kaul, J.B. Park Chang, A. Piermatti, N. Puri, B. Piantadosi, J. Harris, S. Piantadosi, A. Sherman, S. Walsh

00773 Safety and immunogenicity of a Group B Streptococcus vaccine in participants aged 55-75 years L. Oostvogels* (Frederiksberg, Denmark), A. Alhatemi, S. De Gussem, E. Englev, B. Jacobs, B. Johansson-Lindborn, G. Kitson, G. Waerlop, I. Leroux-Roels

00774 Aggregated summary of immunogenicity and safety for the chikungunya virus virus-like particle (VLP) vaccine development programme L. Tindale* (Toronto, Canada), J. Richardson, D. Anderson, J. Mendy, S. Muhammad, T. Loreth, V. Jenkins, P. Ajiboye, L. Bedell

OS108 17:30 – 18:30 Hall 5
1-hour Oral Session

CLN IPC

Novel approaches to preventing device-related infections

00775 Clinical and microbiological impact of antibiotic-impregnated catheters in ventriculoperitoneal shunt infections in adults. M. Sanz De Mena* (Barcelona, Spain), I. Pelegrín Senent, J. Gómez Junyent, J. Poblet Florentin, C. Iglesias, A. Siverio Parés, S. Gómez Zorrilla, L. Sorlí Redó, M. Montero, J.P. Horcajada Gallego

00776 Reducing drainage-associated meningitis by using an antiseptic dressing: A randomized controlled trial AntiRedMen S. Scheithauer* (Goettingen, Germany), O. Moerer, V. Rohde, N. Srivastava, T. Asendorf, K. Antweiler, D. Mielke, G. Uwe, N. Lennart, S. Friedrich, A. Beste, N. Kucheryava, M. Baehr

00777 Efficacy of antimicrobial envelopes in preventing cardiac implantable electronic device infections – systematic review and meta-analysis A. Mahajan* (Melbourne, Australia), C. Robson

00778 A bundled approach to reducing central line associated blood stream infections (CLABSI) in hemodialysis (HD) patients J. Guerrero* (Scarborough, Canada), A. Garga, S. Paramalingam, R. Lovinsky, F. Go

00779 Increased long-term mortality in patients with prosthetic joint infection after primary total hip arthroplasty – a cohort study with 89'709 patients N. Imhasly* (Lucerne, Switzerland), A. Widmer, C. Brand, V. Zdravkovic, A. Spoerri, K. Schmidlin, M. Wicki, M. Beck, R. Sommerstein

Tuesday, 15 April 2025

4353 08:30 – 10:30 Hall 12
2-hour Symposium

VAX PHEI

Out of the spotlight or out of reach? Vaccination of hard-to-reach groups

Chairs Olivier Epaulard (Grenoble, France)
Justyna Kowalska (Warsaw, Poland)

4353-1 08:30 Ukrainian war refugees and vaccination attitudes: experience from Poland Maria Ganczak (Zielona Gora, Poland)

4353-2 09:00 Vaccination in migrants in Latin America: The challenges of transit through Darien, Panama Alfonso

ESCMID Global 2025 - Programme

J. Rodríguez-Morales (Pereira, Colombia)

4353-3 09:30 **Are penitentiary systems ready for introducing vaccination programmes?** *Lara Tavoschi (Pisa, Italy)*

4353-4 10:00 **HPV and other essential vaccinations for sex workers** *Debora Konopnicki (Brussels, Belgium)*

Co-organised with: ESCMID Vaccine Study Group (EVASG)

4369 08:30 - 10:30 Hall 13

2-hour Symposium

CLN

Breaking new ground in febrile neutropoenia management

Chairs Murat Akova (Ankara, Türkiye) Tba

4369-1 08:30 **Do we need to redefine the concept of febrile neutropoenia in the era of immunotherapy?** *Manuela Aguilar-Guisado (Seville, Spain)*

4369-2 09:00 **Should some patients be empirically treated with combination therapy?** *Dina Averbuch (Jerusalem, Israel)*

4369-3 09:30 **Role of new antibiotics in febrile neutropoenia** *Malgorzata Mikulska (Genoa, Italy)*

4369-4 10:00 **Can treatment strategies be personalised using AI or new diagnostic tools?** *Carolina Garcia Vidal (Barcelona, Spain)*

Co-organised with: ESCMID Study Group for Infections in Compromised Hosts (ESGICH), European Conference on Infections in Leukemia (ECIL)

4739 08:30 - 10:30 Hall 5

2-hour Educational Session

PRO

The rules of the game: how to tackle the peer-review and publication process

Chairs Oana Sandulescu (Bucharest, Romania) Tba

4739-1 08:30 **Communicating with journals, editors and reviewers** *Angela Huttner (Geneva, Switzerland)*

4739-2 08:50 **Publishing from LMICs: overcoming disparities** *Mosepele Mosepele (Gaborone, Botswana)*

4739-3 09:10 **The Wild West of predatory journals** *Ursula Hofer (London, United Kingdom)*

4739-4 09:30 **Communicating your publications on social media**

Co-organised with: Deutsche Gesellschaft für Hygiene und Mikrobiologie, CMI Communications Board of Editors, ESCMID Parity Commission, CMI Board of Editors

4768 08:30 - 10:30 Hall 1

Special Session

CLN

Clinical Grand Round

Experts Nina Khanna (Basel, Switzerland) Dimitrios P. Kontoyiannis (Houston, United States) Lior Neshet (Beersheba, Israel) David Paterson (Singapore, Singapore) Priscilla Rupali (Vellore, India) Monica Slavin (Melbourne, Australia)

CGR01 **Case 1K. Malur*** (Mumbai, India), *U. Agrawal, N. Shah, A. Sunavala, S. Basu, C. Rodrigues*

CGR02 **Case 2C. Wong*** (Victoria, Australia), *M. Tang, C. Aboltins, L. Gardner, Y. Hersusianto*

CGR03 **Case 3F. Ferreira*** (Porto, Portugal), *F. Pinto Ferreira, F. Faria, D. Nogueira, M. Pinto Alves, S. Almeida, C. Miranda, I. Furtado, A. Ludgero Vasconcelos*

CGR04 **Case 4J.A. Lee*** (Taipei, Taiwan, China)

CGR05 **Case 5B. Lorenzo*** (Naples, Italy), *L. Bertolino, R. Gallo, A.M.C. Peluso, F. Patauner, O. Infante, F. Luciano, A. Vulcano, L. Panico, E. Durante Mangoni*

CGR06 **Case 6 Armani Hawes** (Baltimore, United States)

CGR07 **Case 7 Sima Sharara** (Baltimore, United States)

Co-organised with: Infectious Diseases Society of America (IDSA)

OS113 08:30 - 10:30 Hall 11

2-hour Oral Session

TRN ANT AMR

Knockin' on Science's Door: New Antimicrobial Solutions

O0812 **Chimerbactin: a hybrid antibiotic for persistent Gram-positive infections that overcomes resistance development** *R. Lee* (Memphis, United States), Y. Zhao, A. Arya, M. Laffeur, R. Conlin, G. Phelps, C. Dunn, E. Griffith, J. Portelinha, N. Chumbler, V. Loudon, I. Lister, S. Zia, K. Urish, K. Lewis*

O0813 **A Novel Klebicin Cocktail to Treat Lung Infection Caused by *Klebsiella pneumoniae*** *V.D. Paul* (Bangalore, India), A. Ambady, U. Chopra*

O0814 **Thiophene derivatives: A promising solution against MDR Gram-negative bacilli** *A. Rey Hidalgo* (Seville, Spain), I. Molina Panadero, M. Morales-Tenorio, A. Garcia-Rubia, T. Samernate, P. Nonejuie, A. Martínez, A. Hmadcha, A. De Alarcón, C. Gil, Y. Smani*

O0815 **Molecular insight into non-lytic polyproline peptide disruption of *Klebsiella pneumoniae* biofilms** *R. Fleeman* (Orlando, United States), R. Beckman Iv, B. Victoria, L. Suits, P. Eswara*

O0816 **Reverting cefotaxime resistance in CTX-M-15-producing *Escherichia coli* using Targeted-Antibacterial-Plasmids (TAPs): a CRISPR-Cas9 approach** *N. Roson-Calero* (Barcelona, Spain), E. Derollez, P. Rouze, A. Dediou-Berne, S. Bigot, C. Ballesté-Delpierre, J. Vila, P. Bogaerts, C. Lesterlin*

O0817 **Structural and functional characterization of LysSM5: An innovative endolysin from Salmonella Phage vB_SenA_SM5K** *Sharma* (Chandigarh, India), H. Kaur, N. Chaudhary, S. Prajapati, B. Mohan, N. Taneja*

O0818 **Rational step-by-step design of a two-phage cocktail against a contemporary *A. baumannii* strain recovered from a burned patient at CHUV** *G. Resch* (Lausanne, Switzerland), H. De Villiers De La Noue, G. Golliard, X. Vuattoux*

O0819 **A novel antibiotic class targeting the enolase of *Acinetobacter baumannii*** *Molina Panadero* (Seville, Spain), A. Moreno Rodriguez, A. Rey Hidalgo, L. Tomás Gallardo, M. De La Cruz, P. Sánchez, T. Samernate, A.J. Pérez Pulido, S. Glisic, O. Genilloud, P. Nonejuie, A. Hmadcha, Y. Smani*

O0820 **Reviving antibiotic potency: Pharmacological Assessment of JS238 a newly designed potentiator against *P. aeruginosa*** *P. Rasouli* (Brussels, Belgium), J.M. Brunel, J.H. Lorent, F. Van Bambeke*

O0821 **Advancements in combating tularemia: Novel therapeutic strategies targeting *Francisella tularensis*** *S. Guillier* (Brétigny-Sur-Orge, France), M. Gâchon, C. Lemoigne, C. Rougeaux, V. Lourde, C. Demeure, J. Pizarro Cerda, G. Guichard, G. Compain, D. Burnouf, O. Gorgé, J. Wagner*

4671 08:30 - 10:30 Hall 14

2-hour Symposium

AMR PHEI

Using mathematical and epidemiological models to identify the drivers of AMR

Chairs Marc J.M. Bonten (Utrecht, Netherlands) Sarah Tschudin Sutter (Basel, Switzerland)

4671-1 08:30 **Quantifying the drivers of antiviral resistance: what does it take to prevent resistance evolution?** *Roger Kouyos (Zürich, Switzerland)*

4671-2 09:00 **Inferring the determinants of AMR dynamics across bacterial pathogens** *Lulla Opatowski (Paris, France)*

ESCMID Global 2025 - Programme

| | | |
|--------|-------|---|
| 4671-3 | 09:30 | Expanding access to antibiotics with stewardship: a One Health perspective <i>Katariina Pärnänen (Helsinki, Finland)</i> |
| 4671-4 | 10:00 | Assessing the associations of microbiome and socio-demographic dynamics on AMR <i>Tba</i> |

4511 08:30 - 10:30 Hall 15

2-hour Educational Session

DX **PHEI**

Endemic mycoses and mycetoma: underdiagnosed and underreported fungal diseases

*Chairs Rita Oladele (Lagos, Nigeria)
Tba*

4511-1 08:30 **Advances and gaps in the diagnosis and treatment of histoplasmosis***Diego Rodrigues Falci (Porto Alegre, Brazil)*

4511-2 08:50 **Paracoccidioidomycosis: an update on diagnostic challenges***Beatriz L. Gomez (Bogota, Colombia)*

4511-3 09:10 **What is new in Talaromycosis***Brown Lottie (London, United Kingdom)*

4511-4 09:30 **Mycetoma: treatment challenges of a unique neglected tropical disease***Borna Nyaoke-Anoke (Nairobi, Kenya)*

4234 08:30 - 10:30 Hall 2

2-hour Educational Session

DX **PHEI**

An update on arboviral disease challenges

*Chairs Misa Korva (Ljubljana, Slovenia)
Anna Papa-Konidari (Thessaloniki, Greece)*

4234-1 08:30 **The global epidemiology of arboviral diseases***Chantal B.E.M. Reusken (Bilthoven, Netherlands)*

4234-2 08:50 **Arboviral diseases transmitted by mosquitoes***Luisa Barzon (Padua, Italy)*

4234-3 09:10 **Arboviral diseases transmitted by ticks***Joanna Maria Zajkowska (Białystok, Poland)*

4234-4 09:30 **Arboviral diseases transmitted by sandflies***Rémi Charrel (Marseille, France)*

Co-organised with: EURL-PH-VBV, Polish Association of Epidemiologists and Infectiologists

4437 08:30 - 10:30 Hall 3

2-hour Symposium

ANT

Faecal microbiota transplantation and live biotherapeutic products: scientific and regulatory challenges

*Chairs Lindsey Ann Edwards (London, United Kingdom)
Ed J. Kuijper (Leiden, Netherlands)*

4437-1 08:30 **How can we recognise and deal with adverse events of Faecal Microbiota Transplantation?***Serena Porcari (Rome, Italy)*

4437-2 09:00 **What to check? – An attempt at evidence-based donor screening***Elisabeth Terveer (Leiden, Netherlands)*

4437-3 09:30 **What are the right bugs – Developing LBPs out of FMTs***Lena Biehl (Cologne, Germany)*

4437-4 10:00 **What's up next? – Hot LBP candidates***Ilan Youngster (Beer Yaakov, Israel)*

Co-organised with: ESCMID Study Group for Host and Microbiota Interaction (ESGHAMI), The European Faecal Microbiota Transplantation Network of academics (EurFMT), European Helicobacter & Microbiota Study Group (EHMSG)

4729 08:30 - 10:30 Hall 4

CLN 2-hour Symposium

News in endocarditis care

*Chairs Michele Bartoletti (Milan, Italy)
Pilar Retamar Gentil (Seville, Spain)*

4729-1 08:30 **Endocarditis guidelines: what is new?***Siegbert Rieg (Freiburg, Germany)*

4729-2 09:00 **Oral therapy and outpatient care***Laura Escolà-Vergé (Barcelona, Spain)*

4729-3 09:30 **PK/PD aspects of endocarditis antibiotic therapy***Fekade Bruck Sime (Brisbane, Australia)*

4729-4 10:00 **The Endocarditis Team: there is no way to work alone***Barbara Hasse (Zurich, Switzerland)*

Co-organised with: ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES), ESCMID Study Group for Antimicrobial stewardship (ESGAP), Sociedad Espanola de Infecciones Cardiovasculares (SEICAV)

4256 11:00 - 12:00 Arena 1

Open Forum

VAX **PHEI**

Vaccine rollout in low resource settings

Chair Asma Nasim (Karachi, Pakistan)

4256-1 11:00 **Partially effective dengue vaccine: benefit versus potential harm***Tba*

4256-2 11:10 **Introduction of malaria vaccines to countries in sub-Saharan Africa: acceptance and barriers***Bernhards Ogotu (Nairobi, Kenya)*

4256-3 11:20 **The story of COVID-19 vaccines in LMIC***Paul Adepoju (Periton, United Kingdom)*

Co-organised with: ESCMID Ethics Advisory Committee (EEAC)

4687 11:00 - 12:00 Hall 12

Meet-the-Expert

PHEI

How to use citizen science for public health

4687-1 11:00 *Anna Noel-Storr (Leamington Spa, United Kingdom)*

4687-2 11:12 *Jani Sormunen (Turku, Finland)*

Co-organised with: European Centre for Disease Prevention and Control (ECDC)

4240 11:00 - 12:00 Hall 15

1-hour Symposium

CLN **VAX**

dsDNA virus infections in immunocompromised patients

4240-1 11:00 **Challenges of diagnosis: do we need to treat all patients with detectable dsDNA virus PCR?***Hans H. Hirsch (Basel, Switzerland)*

4240-2 11:30 **The role of CRISPR-Cas9-edited antiviral T cells against dsDNA virus infections***Tba*

4489 11:00 - 12:00 Hall 1

Keynote Lecture

TRN

What genomics brought to the knowledge of tuberculosis, leprosy and buruli ulcer

Chair Emmanuelle Cambau (Paris, France)

4489-1 11:00 *Stewart T. Cole (Paris, France)*

ESCMID Global 2025 - Programme

4465 11:00 – 12:00 Hall 11
1-hour Symposium

AMR

Antimicrobial stewardship across the lifespan from paediatrics to geriatrics

Chair *Priya Nori (New York, United States)*

4465-1 11:00 Antimicrobial Stewardship in paediatrics across different settings *Taylor Morrisette (Charleston, United States)*

4465-2 11:30 Stewardship in geriatrics: an exceedingly important target *Dafna Yahav (Ramat-Gan, Israel)*

4245 11:00 – 12:00 Hall 13
Meet-the-Expert

DX

Implementing AI in microbiological diagnostics: practical steps and quality control

4245-1 11:00 *Oliver Nolte (Zürich, Switzerland)*

4245-2 11:12 *Jennifer Dien Bard (Los Angeles, United States)*

Co-organised with: ESCMID Study Group for Genomic and Molecular Diagnostics (ESGMD), Swiss Society for Microbiology (SSM)

4551 11:00 – 12:00 Hall 14
1-hour Symposium

AMR

People-centred approach to strengthening the AMR response at primary care

Chairs *Benedikt Huttner (Geneva, Switzerland)*
Mirfin Mpundu (Lusaka, Zambia)

4551-1 11:00 Implementation of WHO's people-centred interventions *Nienke Van De sanDe Bruinsma (Geneva, Switzerland)*

4551-2 11:30 Opportunities for strengthening AMR interventions in primary healthcare *Sholpan Kaliyeva (Karaganda City, Kazakhstan)*

Co-organised with: World Health Organisation (WHO)

OS122 11:00 – 12:00 Hall 16
1-hour Oral Session

PRO

Serious games - a serious business

00878 The development process, impact and implementation of an educational VR-module in infection prevention and control for medical students and healthcare workers in The Netherlands. *A. Tostmann* (Nijmegen, Netherlands), O. Coenen-Bouwman, B. Schippers, F. Luk, M. Graner, F. Van Hoek, N. Stikkelbroeck, M. Dronkers*

00879 Impact of Professional Background on Performance in ToREIMC: A Gamified Medical Knowledge Platform. *A. Blanco-Di Matteo* (Pamplona, Spain), M. Morante Ruiz, M. Riesgo Magaña, M. Martín García*

00880 Serious games and storytelling to enhance adolescents' capabilities for decision-making regarding meningococcal vaccination: a monocenter study. *T. Morris* (Saint-Etienne, France), S. Essalim, K. Atroune, V. Ronat, M. Moulin, R. Eichel, E. Botelho-Nevers, A. Gagneux-Brunon*

00881 'The Sepsis Olympics': Raising awareness of the Sepsis 6 care bundle in an Irish Hospital through a clinical challenge game. *C. Uhomobhi* (Dublin, Ireland), K. Costelloe, J. Harte, N. Power, E. De Barra*

00882 Improvement of learners' confidence in antibiotic management by an interdisciplinary annual multi-centred webinar. *A. Friedrichs* (Kiel, Germany), E. Kramme, T. Koch, J. Jochum, A. Van Der Linde, H.*

Gerth, F. Jahn, A. Neubert

4494 11:00 – 12:00 Hall 2
1-hour Symposium

CLN TRN

Beat the cancer by beating the infections

Chairs *Daniela Maric (Novi Sad, Serbia)*
Mojca Maticic (Ljubljana, Slovenia)

4494-1 11:00 Prevention of infection-associated cancer: learning from each other *Catharina Alberts (Amsterdam, Netherlands)*

4494-2 11:30 Test and treat early to prevent cancer: hepatitis B and hepatitis C *Francesco Negro (Geneva, Switzerland)*

4293 11:00 – 12:00 Hall 4
1-hour Symposium

CLN IPC

Personalised patient management and infection prevention: Current evidence and future perspectives

Chairs *Agnes Hajdu (Budapest, Hungary)*
Iris K. Minichmayr (Vienna, Austria)

4293-1 11:00 The dosing perspective: towards individualised treatment strategies *Thomas Tängdén (Uppsala, Sweden)*

4293-2 11:30 The infection control perspective: advancing patient-centred approaches *Alessia Savoldi (Verona, Italy)*

4507 11:00 – 12:00 Hall 5
1-hour Symposium

CLN

Emerging fungal diseases in children: Global challenges and approach to management

Chairs *Andreas H. Groll (Münster, Germany)*
Tba

4507-1 11:00 Emerging fungal infections in immunocompromised and geographically exposed children *Laura Ferreras-Antolin (London, United Kingdom)*

4507-2 11:30 Best available treatments and options for children in resource-limited settings *Fabianne Carlesse (Sp, Brazil)*

Co-organised with: ESCMID Fungal Infection Study Group (EFISG), German-Speaking Mycological Society (DMyKG)

OS118 11:00 – 12:00 Hall 6
1-hour Oral Session

ANT AMR

Plasmids as a powerful tool of antibiotic resistance spread

00858 Co-anchorage of antibiotic resistance genes and mobile genetic elements on bacterial plasmids boosts horizontal gene transfer across sewage interfaces *M. Shafiq* (Shantou, China)*

00859 The emergence of *tet(X4)* and *mcr* co-harbored on the same plasmid and its clinical significance *N.N. Rakhi* (Oxford, United Kingdom), A. Lankapalli, T. Lanyon-Hogg, P. Niumsup, K. Thomson, K. Sands, T.R. Walsh*

00860 The plasmidome of a global collection of convergent *K. pneumoniae* and its impact on virulence *M. Martin* (Silver Spring, United States), A. Sapre, T. Luo, U. Carolino-Macdonald, E. Mills, B. Corey, R. Maybank, A. Ong, Y. Kwak, J. Bennett, T. Russo, P. Mc Gann, F. Lebreton*

00861 Factors that affect plasmid transfer in multispecies biofilms *H.Y. Liu* (Norwich, United Kingdom), M.*

ESCMID Global 2025 - Programme

Yasir, E. Trampari, G. Langridge, M. Webber

00862 Identification of the *czc* metal efflux operon on a new plasmid type in a *Pseudomonas aeruginosa* clinical isolate belonging to ST357 O11A. Valcek* (Brussels, Belgium), D.I. Costescu Strachinaru, P. Soentjens, A. Stoefs, C. Van Der Henst

OS119 11:00 – 12:00 Hall 7

1-hour Case Session

CLN

Looking inside endovascular infections

00863 A Case of Persistent *Legionella micdadei* Aortitis with Endocarditis: Diagnostic and Therapeutic Challenges V. Zwart* (Breda, Netherlands), E. Kayabasi, H. De Groot, R. Bentvelsen

00864 Management and Prognosis of Vascular Endograft Infections: Case Series N. Scarpulla* (Napoli, Italy), F. Patauner, L. Bertolino, R. Andini, A.M.C. Peluso, R. Gallo, E. Durante-Mangoni

00865 Fungal frenzy: handling an uncommon etiology in prosthetic valve endocarditis I. Cafarella* (Naples, Italy), R. Gallo, F. Patauner, F. Luciano, L. Bertolino, A.M.C. Peluso, F. Boccia, R. Zampino, E. Durante Mangoni

00866 Successful Use of Oritavancin as Consolidation Therapy for Infective Endocarditis Caused by *Enterococcus* spp.: Experience from Seven Cases in a Referral Center F. Frondizi* (Rome, Italy), G.M. Leanza, F. Catania, F. Sangiorgi, M. Chiuchiarelli, B. Andriolo, L. Vahedi, B. Liguoro, F. Giovannenze, E. Taddei, G. Scoppettuolo, C. Torti

00867 Clinical Features and Outcomes of Gram-Negative Bacterial Endocarditis: A Case Series from a University Hospital G. Oliva* (Rome, Italy), F. Giovannenze, G. Leanza, F. Frondizi, M. Chiuchiarelli, B. Liguoro, B. Andriolo, E. Tadde, G. Scoppettuolo, C. Torti

OS120 11:00 – 12:00 Hall 8

1-hour Oral Session

TRN AMR

Exploring Host-Pathogen Interactions and Immune Dynamics in Bacterial Virulence

00868 Bacteria and host responses in both mice and human lung organoid model revealed the role of a novel plasmid *pvirh1* in hypervirulent Carbapenem-resistant *Klebsiella pneumoniae* Y. Zhang* (Shanghai, China), W. Liu, K. Lin, L. Chen, J. Wu, N. Jiang

00869 Presence and role of hypervirulence-associated markers in *Klebsiella pneumoniae* groups based on LD50 value in mouse septic model A. Avdeeva* (Saint-Petersburg, Russian Federation), D. Kandina, E. Podvysotskaia, P. Chulkova, M. Velizhanina, J. Sopova, V. Lomonosova, V. Galushka, A. Afinogenova, V. Shapovalova, O. Sullian, I. Ageevets, V. Ageevets, S. Sidorenko

00870 Meta-transcriptomic Insights into Host-Pathogen Interactions in Necrotizing Soft Tissue Infections Using Differential Analysis T. Vashist* (Chandigarh, India), N. Rana, D. Nair, A. Angrup, V. Sharma, C. Tandup, P. Ray, A. Arora

00871 Unveiling the hidden virulence of *Acinetobacter baumannii*: how the lipooligosaccharide core modulates immune responses and enhances interferon- γ production Y.T. Lee* (Taipei, Taiwan, China), Y.C. Wang

00872 Platelets drive neutrophil-mediated neuroinflammation in tuberculous meningitis K. Skolimowska* (London, United Kingdom), R. Wilkinson, J. Friedland, D. Kirwan, T. Reid, D. De Swardt, D. Chong, J. Kutschenreuter, M. Saeed, A. Davis, S. Wasserman, R. Goliath, Q. Kakana, P. Renner, M. Panchoo, C. Stek, R. Johnson, M.

Maxebengula

OS121 11:00 – 12:00 Hall 9

1-hour Oral Session

IPC AMR

Shaping the future of IPC - digitalisation of surveillance

00873 PRAISE hospital-onset bacteraemia and fungaemia algorithm as novel automated surveillance indicator: results from four European university hospitals S.D. Van Der Werff* (Stockholm, Sweden), S.J.S. Aghdassi, M. Behnke, M.S.M. Van Mourik, G. Catho, M. Brekelmans, L.A. Peña Diaz, N. Buetti, F.D. Rüther, D. Dinis Teixeira, D. Sjöholm, P. Nauclér

00874 Transforming hospital-onset bacteremia and fungemia data to the OMOP common data model H. Düsseldorf* (Vienna, Austria), G. Duftschild, E. Presterl

00875 Prospective evaluation of a machine learning-based real-time multidrug-resistant organism prediction system V. Vasikasin* (Bangkok, Thailand), W. Nasomsong, A.H. Holmes, R.L. Peach, K. Bhangnanda, A.C. Myall, C.H. Yoon, D. Changpradub, S. Mookerjee, J. Price, B. Mauricio, T.M. Rawson

00876 Dutch Electronic Health Records in primary care: the Nivel general practitioners database F.F. Stelma* (Utrecht, Netherlands), J. Van Summeren, M. Hooiveld, C. Baliatsas, V. Sankatsing, J. Schmitz, S. Van Beusekom

00877 Local signs at catheter insertion sites: Insights from the multicenter DeepCath cohort study with 4,256 pictures N. Buetti* (Geneva, Switzerland), S. Ruckly, A. Byczko, L. Gallay, A. Nguyen, H. Slimani, J.R. Zahar, J.F. Timsit

OS129 13:30 – 14:30 Hall 10

1-hour Oral Session

TRN

Biofilm biology and control

00930 Influence of non-coding small RNA00203 in biofilm cells of *Acinetobacter baumannii*: Transcriptomic and phenotypic D. Gebrelibanos* (Hong Kong, China), P. Leung, A. Shenkutie, F. Chow

00931 Sub-MIC antibiotic effects on *Pseudomonas aeruginosa* biofilm streamer formation A. Di Claudio* (Pieve Emanuele, Italy), R. Rusconi, E. Secchi, G. Savorana

00932 Regulation of Novel Genes and Their Downstream Functions in the AI-2-Mediated Quorum Sensing System of *Klebsiella pneumoniae* X. Chu* (Beijing, China), Y.1.C. Yangqiwen81@vip.163.Com

00933 Exploring structural differences in biofilms of smooth and rough *Mycobacterium abscessus* clinical strains through confocal laser scanning microscopy M. Cano-Fernández* (Madrid, Spain), J. Esteban, P. López-Roa, A. Ruedas-López, M.C. Muñoz-Egea

00934 Antibacterial and biofilm eradication of mupirocin-loaded nano-emulsions Z. Najmi* (Novara, Italy), A.C. Scallia, A. Cochis, J. De Souza Nunes, J. Alkorta, L. Rimondini, D. Dupin

4712 13:30 – 15:30 Hall 11

2-hour Educational Session

CLN IPC

Best practices and emerging strategies in the management of ventilator- and healthcare-associated pneumonia

Chairs Fusun Can (Istanbul, Türkiye)
Jeroen Schouten (Nijmegen, Netherlands)

ESCMID Global 2025 - Programme

| | | |
|--------|-------|--|
| 4712-1 | 13:30 | Artificial Intelligence to predict VAP <i>Miia Jansson (Oulu, Finland)</i> |
| 4712-2 | 13:50 | Metagenomic approach to VAP diagnosis <i>Jacques Schrenzel (Geneva, Switzerland)</i> |
| 4712-3 | 14:10 | Viruses in VAP and HAP: should we worry about them? <i>Catia Cilloniz (Barcelona, Spain)</i> |
| 4712-4 | 14:30 | Optimising antibiotic therapy in VAP <i>Pinyo Rattanaumpawan (Bangkok, Thailand)</i> |

| | | |
|------|------------------|---------|
| 4308 | 13:30 – 15:30 | Hall 13 |
| | 2-hour Symposium | |

Novel strategies for eliminating the 'worst films ever'

| | |
|--------|--|
| Chairs | <i>Elisa Borghi (Milan, Italy)</i> <i>Markus Zeitlinger (Vienna, Austria)</i> |
|--------|--|

| | | |
|--------|-------|---|
| 4308-1 | 13:30 | What answers can biofilm PK/PD modelling provide? <i>Coen Van Hasselt (Leiden, Netherlands)</i> |
| 4308-2 | 14:00 | subMIC antibiotic effects to improve biofilm PK/PD parameters – still relevant? <i>Francoise Van Bambeke (Brussels, Belgium)</i> |
| 4308-3 | 14:30 | PK/PD-based optimisation of antibiotic treatments to suppress resistance in dynamic biofilm models <i>Maria Dolores Macia Romero (Palma, Spain)</i> |
| 4308-4 | 15:00 | Giving antibiotics an upper hand in the treatment of biofilm infections – antibiotic augmenting strategies <i>Claus Moser (Copenhagen, Denmark)</i> |

Co-organised with: ESCMID Study Group for Biofilms (ESGB), ESCMID Scientific Affairs Subcommittee

| | | |
|------|------------------|---------|
| 4691 | 13:30 – 15:30 | Hall 14 |
| | 2-hour Symposium | |

Enhancing efficiency and reducing cost in microbiological diagnostics using pool testing

| | | |
|--------|-------|--|
| 4691-1 | 13:30 | Congenital cytomegalovirus detection by pool testing in saliva <i>Giannina Izquierdo (Santiago, Chile)</i> |
| 4691-2 | 14:00 | Detection of blood-corne pathogens in asymptomatic blood donors by pool testing <i>Patricia Alvarez (Rio De Janeiro, Brazil)</i> |
| 4691-3 | 14:30 | Large-scale pooled testing to increase rapid molecular diagnostic test coverage for tuberculosis <i>Melissa Sander (Bamenda, Cameroon)</i> |
| 4691-4 | 15:00 | Pool testing for screening of bacterial sexually transmitted infections <i>Tba</i> |

| | | |
|-------|---------------------|---------|
| OS130 | 13:30 – 14:30 | Hall 16 |
| | 1-hour Oral Session | |

Advances in fungal diagnostics

| | | |
|-------|--|--|
| 00935 | | BAL galactomannan dynamics predict survival in critically ill patients with virus-associated pulmonary aspergillosis <i>V. Delanote* (Leuven, Belgium), J. Wauters, S. Feys, J. Heylen, H.M. Lauwers, C. Jacobs, L. Maessen, Y. Debaveye, P. Frederiks, G. Hermans, P. Meersseman, M. Peetermans, E. Van Wijngaerden, A. Wilmer, K. Lagrou</i> |
| 00936 | | Retrospective Assessment of a New Chemiluminescence Immunoassay for Serum (1, 3)- β -D-Glucan Levels in Patient with Invasive Fungal Infections <i>Z. Zhou* (Tianjin, China), K. Yuan, L. Ye, S. Liu, A. Huang, Z. Chen, W. Yan, S. Niu, K. Hua, Q. Wang, G. Zhang, H. Wang, Y. Zhao, G. Li</i> |
| 00937 | | Evaluation of a multiplex PCR assay using barcoded magnetic bead technology for detection of fungal pathogens in bronchoalveolar lavage fluid: a diagnostic aid for invasive fungal infections <i>S. Zhang* (Baltimore, United States)</i> |

| | | |
|-------|--|--|
| 00938 | | Combined use of (1,3)- β -D-glucan and PCR in oral wash for <i>Pneumocystis jirovecii</i> pneumonia diagnosis in non-HIV population <i>A. Falcó-Roget* (Barcelona, Spain), A. Albasanz-Puig, A. Pérez, S. Serradell, A. Guillén, E. Revilla, I. Los-Arcos, Ö. Len-Abad, I. Ruiz-Camps, M.T. Martín-Gomez</i> |
|-------|--|--|

| | | |
|-------|--|---|
| 00939 | | Iron levels in bronchoalveolar lavage fluid of hematological patients with suspected invasive pulmonary aspergillosis and their association with 12-week mortality: a retrospective cohort study <i>H. Lamberink* (Amsterdam, Netherlands), J. Heijmans, A. Wagemakers, K. Van Dijk</i> |
|-------|--|---|

| | | |
|------|------------------|--------|
| 4735 | 13:30 – 15:30 | Hall 2 |
| | 2-hour Symposium | |

Staphylococcus aureus: Its expansion dynamics and interactions with its pals

| | |
|--------|---|
| Chairs | <i>Barbara C. Kahl (Münster, Germany)</i> <i>Tba</i> |
|--------|---|

| | | |
|--------|-------|--|
| 4735-1 | 13:30 | <i>S. aureus</i> and its special relationship to <i>S. epidermidis</i> <i>Andreas Peschel (Tübingen, Germany)</i> |
| 4735-2 | 14:00 | The role of the <i>S. aureus</i> type VII secretion system in host-bacterial community interactions <i>Tba</i> |
| 4735-3 | 14:30 | Clonal population expansion of <i>S. aureus</i> occurs due to escape from a finite number of intraphagocyte niches <i>Simon Foster (Sheffield, United Kingdom)</i> |
| 4735-4 | 15:00 | How bacteriophages and pathogenicity islands drive the evolution of <i>S. aureus</i> <i>John Chen (Singapore, Singapore)</i> |

Co-organised with: ESCMID Study Group for Staphylococci and Staphylococcal Diseases (ESGS)

| | | |
|------|----------------------------|--------|
| 4719 | 13:30 – 15:30 | Hall 3 |
| | 2-hour Educational Session | |

Beyond the gift of life: viral infection during pregnancy

| | | |
|--------|-------|---|
| 4719-1 | 13:30 | Hepatitis B during pregnancy: diagnosis, management and outcome <i>Tba</i> |
| 4719-2 | 13:50 | RSV and Influenza during pregnancy: management and outcome <i>Monika Redlberger-Fritz (Austria)</i> |
| 4719-3 | 14:10 | Prenatal screening and prevention of congenital CMV: shifting concepts and consensus guideline <i>Marianne Leruez-Ville (Paris, France)</i> |
| 4719-4 | 14:30 | Novel methods of vaccine administration to newborns <i>Tba</i> |

Co-organised with: ESCMID Study Group for Viral Hepatitis (ESGVH), European Society for Infectious Diseases in Obstetrics and Gynaecology (ESIDOG), Society on Liver Diseases in Africa (SOLDA), Gastroenterology and Hepatology Association of SubSaharan Africa (GHASSA)

| | | |
|------|------------------|--------|
| 4556 | 13:30 – 15:30 | Hall 4 |
| | 2-hour Symposium | |

Molecular epidemiology, resistance mechanisms and management of Gram-negative bacteria

| | | |
|--------|--|--|
| Chairs | <i>Agnes Maria Sonnevend (Pécs, Hungary)</i> <i>Kyriaki Xanthopoulou (Cologne, Germany)</i> | |
| 4556-1 | 13:30 | Globally emerging resistance patterns of Enterobacterales <i>Sasheela Ponnampalanan (Kuala Lumpur, Malaysia)</i> |
| 4556-2 | 14:00 | Non-fermenters still important globally: a review of spread and resistance <i>Anupa Thampy (Vellore, India)</i> |
| 4556-3 | 14:30 | Innovative rapid diagnostic methodologies for Gram-negative pathogens <i>Laurent Dortet (Le Kremlin-Bicêtre, France)</i> |
| 4556-4 | 15:00 | Tailoring treatment to resistant Gram-negative bacteria: newer therapeutic approaches <i>Maria</i> |

ESCMID Global 2025 - Programme

Milagro Montero (Barcelona, Spain)

Co-organised with: ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS)

4348 13:30 - 15:30 Hall 5
2-hour Educational Session

CLN

Tropical dermatology: a case-based approach

Chairs Pedro Legua (Lima, Peru)
Tba

4348-1 13:30 Parasitic diseases Tba
4348-2 13:50 Madura foot and other Implantation mycoses M Ramam (New Delhi, India)
4348-3 14:10 Mycobacteria Francisco Bravo (Lima, Peru)
4348-4 14:30 Approach to rash in the returning traveller Frank O. D. Pettersen (Oslo, Norway)

OS127 13:30 - 14:30 Hall 6
1-hour Oral Session

PHEI

The good, the bad and the itchy: update on STIs

00920 High frequency of Nichols-like strains of *Treponema pallidum* subsp. *pallidum* circulating in Barcelona, Spain P. Nadal-Baron* (Barcelona, Spain), J. Trejo-Zahinos, M. Arando, A. Barberan-Masegosa, M. Bernat-Sole, A. Perez-Ugarte, M. Valverde Espinal, A. Canals Quintana, J.J. Gonzalez-Lopez, A. Anton, M. Alberny, O. Mitjà, M.N. Larrosa, Y. Hoyos-Mallecot
00921 Doxycycline post-exposure prophylaxis (doxy-PEP) use and outcomes in metropolitan Detroit C. Arena* (Detroit, United States), N. Everson, R. Kenney, I. Brar, S. Gudipati, N. Yared, S. Davis, M. Veve
00922 The Gonococcus Bacterial Load Measured by the Cycle Threshold (Ct) in Urinary Samples Correlates with Symptomatology G. Beraud* (Orleans, France), T. Prazuck, L. Barhoum, H. Meyjonnade, J. Effa, L. Hocqueloux, A. Seve, J. Guinard, K. Kochbati, E. Carbonelle, C. Guillaume
00923 STI pathogen interactions and viability in men who have sex with men (MSM) E. Rayo* (Zurich, Switzerland), D. Onorini, C. Leonard, H. Marti, T. Pesch, B. Hampel, N. Low, N. Borel
00924 Epidemiology of bacterial genitourinary infections among women with recurrent vulvovaginal Candidiasis (RVVC) in Nigeria S. Fayemiwo* (Ibadan, Nigeria), L. Novak-Frazer, I. Adewole, R. Rautemaa-Richardson

OS126 13:30 - 15:30 Hall 8
2-hour Oral Session

CLN DX PHEI

Emerging viruses, diverse threats

00910 Epidemiological and clinical features of mpox during the clade Ib outbreak in South-Kivu, Democratic Republic of the Congo: a prospective cohort study I. Brosius* (Antwerp, Belgium), E. Hasivirwe Vakaniaki, S. Sabiti Nundu, L. Liesenborghs, P. Mbala-Kingebeni, G. Mukari, P. Munganga, J.C. Tshomba, E. De Vos, E. Bangwen, Y. Mujula, A. Tsoumanis, C. Van Dijck, A. Alengo, L. Mutimba-Mambo, F. Mweshi Kumbana, J. Babingwa Muunga, D. Mazambi Mambo, J. Wakilongo Zangilwa, S. Bilembo Kitwanda, S. Houben, N. Hoff, J.C. Makangara-Cigolo, E. Kinganda-Lusamaki, M. Peeters, A. Rimoim, J. Kindrachuck, N. Low, P. Katoto, E. Bwenge Malembaka, J.H. Amuasi, O. Tshiani, R. Kojan, D. Muamba Kambaj, C. Kacita, D. Mukadi-Bamuleka,

S. Ahuka-Mundeke, K. Vercauteren, T. Wawina-Bokalanga, J.J. Muyembe-Tamfum

00911 Tracing the origin, spread and molecular evolution of Dengue type 1 cases occurred in Northern Italy in 2023 G. Romano* (Pavia, Italy), G. Ferrari, A.M.G. Pitrolo, F. Rovida, A. Piralla, F. Baldanti

00912 Dengue Country Risk Estimation: Vector Suitability and Imported Activity 2024 M. Torres Portillo* (Toronto, Canada), K. Williams, R. Lababidi, A. Thomas, K. Khan

00913 Rat HEV in humans in Germany: presence but low detection rate, a screening study 2022 - 2023 L.J. Mueller* (Berlin, Germany), M.L. Schmidt, T. Schwarz, T.D. Best, T. Bleicker, J. Panajotov, J. Jansen, J. Melchert, T. Mauno, C. Drosten, R. John, V.M. Corman

00914 Emergence of new enterovirus D68 lineage in Europe in 2023 associated with distinct amino acid substitutions in VP1 protein A. Hirvonen* (Vantaa, Finland), C.K. Johannesen, P. Simmonds, T.K. Fischer, H. Harvala, K.S.M. Benschop

00915 Health-economic impacts of chikungunya vaccination in 34 countries N. Salant* (Oxford, United Kingdom), D. Smith, D. Hollingsworth, K. Pouwels, J. Zhou, S. Radoykova, J. Lord, K. French

00916 Clinical importance of a new tick-borne flavivirus virus, Alongshan Virus: retrospective serologic and molecular study in Switzerland F. Tagini* (Lausanne, Switzerland), O. Opota, A. Eggermann, A. Coste, G. Greub

00917 From Trade Routes to Transmission Routes: Risk Assessment of Japanese Encephalitis Outbreak in Pakistan under China-Pakistan Economic Corridor Using One Health Approach S. Ahmad* (Tampere, Finland)

00918 Building a screening protocol for the detection of Orthobunyavirus oropoucheense infection G. Gagliardi* (Milan, Italy), D. Mileto, A. Mancon, L. Morelli, M. Cutrera, A. Cavallo, A. Rizzo, V. Micheli, A. Lombardi, A. Dolci

00919 Substantial viral diversity in bats and rodents from East Africa: insights into conservation, recombination, and co-circulation D. Wang* (Shenzhen, China)

OS128 13:30 - 14:30 Hall 9
1-hour Oral Session

CLN ANT

AI Aiding AMS

00925 Using natural language processing to understand free-text antibiotic prescriptions A. Martin* (Middlesbrough, United Kingdom), L. Christopher

00926 Enhancing Antimicrobial Stewardship Through Collaboration Between an Intelligent System and Infectious Disease Experts H.M. Wei* (Taichung, Taiwan, China), Y.L. Hsu, Y.W. Chang, I.C. Chen, K.P. Hwang

00927 Augmented Intelligence in Infectious Diseases (AI²D) as an antimicrobial stewardship tool for early antibiotic discontinuation in suspected lower respiratory tract infections J.L. Lim* (Singapore, Singapore), P.Z.B. Cherng, P.M. Chlebicki, L.S.C. Gan, S.Y. Thien, S.L.S. Tang, L.X.T. Lee, Y.C.D. Yii, P.Y. Zhou, Y. Wang, S.J. Chung, L.H.A. Kwa

00928 Virtual antimicrobial stewardship ward rounds: predicting antibiotic course stopping decisions in hospitals using machine learning K. Yuan* (Oxford, United Kingdom), J. Wei, C.H. Yoon, Q. Gu, W. Walker, T. Zhu, D. Eyre

00929 Prospective evaluation of a machine learning-based decision support system for intravenous-to-oral antibiotic switching W. Bolton* (London, United Kingdom), R. Wilson, P. Georgiou, A. Holmes, T. Rawson, M. Gilchrist